Methods of treating breast cancer using tetrahydronaphthalene derivatives as estrogen receptor degradation agents

By using a combination of tetrahydronaphthalene derivative compound and CDK4/6 inhibitor, the problem of limited treatment effect on ER+ and HER2-breast cancer patients in the prior art is solved, and significant tumor growth inhibition and survival prolongation are achieved.

CN118986983APending Publication Date: 2024-11-22ARVINAS OPERATIONS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411132121.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2020-05-11
Filing Date
2020-08-24
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing breast cancer treatment methods are limited in patients with ER+, HER2-metastatic or locally advanced breast cancer, especially in drug resistance and progressive diseases of endocrine therapy, and there is a lack of effective treatment options.

Method used

A compound containing tetrahydronaphthalene derivative (Formula (I)) is used as an estrogen receptor degrader, combined with CDK4/6 inhibitors, such as Pabocinib, for oral therapy, through controlled release of oral drugs Dosage forms and combinations are used to enhance efficacy.

Benefits of technology

It significantly inhibited ERα levels and breast cancer cell growth, improved progression-free survival and overall survival, and provided an effective treatment plan for drug-resistant diseases, which was better than the tumor growth inhibitory effect of a single drug.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118986983A_ABST
    Figure CN118986983A_ABST
Patent Text Reader

Abstract

The present application relates to the treatment and / or prevention of breast cancer, including locally advanced or metastatic ER +, HER2-breast cancer, in a subject in need thereof, comprising administering a compound of formula (I), (I), or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotope derivative, or prodrug thereof, where R1, R2, R3, R4, m, and n are defined herein. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of a Chinese invention patent application filed on August 24, 2020, with application number 202080074710.2, and invention name “Method for treating breast cancer using tetralin derivatives as estrogen receptor degraders”.

[0002] Citations of Related Applications

[0003] This application claims priority to and the benefit of U.S. Application No. 63 / 023,067, filed May 11, 2020, U.S. Application No. 62 / 942,663, filed December 2, 2019, U.S. Application No. 62 / 924,653, filed October 22, 2019, and U.S. Application No. 62 / 891,648, filed August 26, 2019, the entire contents of each of which are incorporated herein by reference. Technical Field

[0004] The present application relates to treating breast cancer, including locally advanced or metastatic ER+, HER2- breast cancer, comprising administering a compound of formula (I) to a subject in need of treatment. Background Art

[0005] In the United States (US), breast cancer is the second leading cause of cancer death in women, with an estimated 41,000 women dying from breast cancer in 2018. Although breast cancer is less common in men, men account for approximately 1% of all newly diagnosed cases, and nearly 500 men are expected to die from the disease in 2018 (Seigel RL et al., Cancer Statistics, CA Cancer J Clin. 2018, 68(1); 7-30.).

[0006] It is estimated that as of January 2017, approximately 155,000 women with metastatic breast cancer (mBC) live in the United States. It is also reported that the number of women with mBC is increasing, mainly due to improved treatment and the aging of the U.S. population. From 2000 to 2010, the estimated number of women with mBC increased by 17%, and is expected to increase by 31% from 2010 to 2020 (Mariotto AB et al., "Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States" Cancer Epidemiol. Biomarkers Prev. 2017, 26 (6): 809-815.).

[0007] Treatment options for advanced breast cancer, or mBC, depend on a variety of different factors, including whether the tumor expresses hormone receptors, i.e., estrogen receptors (ER) and / or progesterone receptors, or human epidermal growth factor receptor 2 (HER2). The standard of care for women with mBC is endocrine therapy, chemotherapy, and / or targeted therapy, alone or in combination. Patients with ER-positive (ER+) and HER2-negative (HER2-) mBC are treated with endocrine therapy, sometimes in combination with targeted drugs such as CDK4 / 6 inhibitors (CDKi). In patients with aggressive disease or disease that continues to progress on endocrine therapy, chemotherapy may be initiated.

[0008] The current standard of care for women with ER+, HER2-mBC is endocrine therapy + / - CDKi or mTOR inhibitors. Endocrine therapy includes ovarian ablation or suppression (for premenopausal women), tamoxifen (select ER modulators), aromatase inhibitors, and fulvestrant (SERDs). Metastatic breast cancer remains incurable, and sequencing of endocrine therapy is the recommended approach for treating ER+ breast cancer. Adding targeted agents, including CDKi and mTOR inhibitors, to the backbone of endocrine therapy further improves patient outcomes.

[0009] Fulvestrant is considered to be the cornerstone component of the endocrine regimen targeted by ER in the advanced disease environment, and works via an indirect mechanism of protein degradation, resulting in the instability of ER. Single-agent fulvestrant is administered with 500mgIM on the 1st, 15th and 29th days, and once a month thereafter. The efficacy of fulvestrant is established by comparing with the selective aromatase inhibitor anastrozole in 2 randomized controlled clinical trials in postmenopausal women with locally advanced or mBC (Astra Zeneca Faslodex Full Prescribing Information, revised in March 2019). In the adjuvant or advanced disease environment, all patients progressed after the previous treatment of breast cancer with anti-estrogen or progestin therapy. In both trials, eligible patients with measurable and / or evaluable disease were randomly grouped to receive monthly fulvestrant 250mg IM (28 days + 3 days) or oral administration of anastrozole 1mg once a day. After a minimum follow-up duration of 14.6 months, the results of the trial ruled out the inferiority of Fulvestrant to anastrozole. After a follow-up duration of 2 years or more, there was no statistically significant difference in overall survival (OS) between the 2 treatment groups. The third study compared the Fulvestrant 500mg dose with the Fulvestrant 250mg dose. After a minimum follow-up duration of 18 months, the results of this study showed that the progression-free survival (PFS) of Fulvestrant 500mg was statistically significantly better than that of Fulvestrant 250mg (6.5 months versus 5.4 months, respectively). There was no statistically significant difference in OS between the 2 treatment groups (25.1 months for Fulvestrant 500mg and 22.8 months for Fulvestrant 250mg). Overall response rates were similar; 13.8% (95% confidence interval [CI] 9.7-18.8%) for the 500 mg dose and 14.6% (CI 10.5-19.4%) for the 250 mg dose (Astra Zeneca Faslodex Full Prescribing Information, revised March 2019). Summary of the invention

[0010] In one aspect, the present application relates to a method of treating breast cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I),

[0011] or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative or prodrug thereof, wherein:

[0012] Each R 1 and each R 2Independently selected from the group consisting of halo, OR5, N(R5)(R6), NO2, CN, SO2(R5), C1-C6 alkyl and C3-C6 cycloalkyl;

[0013] R3 and R4 are both hydrogen or, together with the carbon to which they are attached, form a carbonyl group;

[0014] Each R5 and each R6 are independently selected from the group consisting of hydrogen, C1-C6 alkyl and C3-C6 cycloalkyl;

[0015] m is 0, 1, 2, 3, 4 or 5; and

[0016] n is 0, 1, 2, 3 or 4.

[0017] In one embodiment, the breast cancer is ER+, HER2-.

[0018] In one embodiment, the breast cancer is metastatic or locally advanced.

[0019] In one embodiment, each R 1 and each R 2 Independently selected from the group consisting of halo and OR5.

[0020] In one embodiment, R3 and R4 are both hydrogen.

[0021] In one embodiment, R3 and R4 together with the carbon to which they are attached form a carbonyl group.

[0022] In one embodiment, m and n are each 0. In one embodiment, m and n are each 1. In one embodiment, one of m and n is 0 and the other is 1. For example, in one embodiment, m is 0 and n is 1. In another embodiment, m is 0 and n is 1.

[0023] In one embodiment, the compound of formula (I) is:

[0024]

[0025]

[0026]

[0027] Or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative or prodrug of any of the foregoing.

[0028] In one embodiment, the method comprises administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph or isotopic derivative thereof.

[0029] In one embodiment, the compound of Formula (I) is administered orally to a subject.

[0030] In one embodiment, a therapeutically effective amount of a compound of formula (I) is administered to a subject once a day, twice a day, three times a day, or four times a day. In one embodiment, a therapeutically effective amount of a compound of formula (I) is administered to a subject once a day. In one embodiment, a therapeutically effective amount of a compound of formula (I) is administered to a subject all at once, or is administered in two, three, or four portions.

[0031] In one embodiment, the therapeutically effective amount of the compound of Formula (I) is about 3 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg or 30 mg.

[0032] In one embodiment, the therapeutically effective amount of the compound of Formula (I) is from about 10 mg to about 1000 mg.

[0033] In one embodiment, the therapeutically effective amount of the compound of Formula (I) is from about 20 mg to about 700 mg.

[0034] In one embodiment, the therapeutically effective amount of the compound of Formula (I) is from about 30 mg to about 500 mg.

[0035] In one embodiment, the therapeutically effective amount of the compound of Formula (I) is from about 30 mg to about 120 mg.

[0036] In one embodiment, the therapeutically effective amount of the compound of formula (I) is from about 10 to about 40 mg, from about 20 to about 50 mg, from about 30 to about 60 mg, from about 40 to about 70 mg, from about 50 to about 80 mg, from about 60 to about 90 mg, from about 70 to about 100 mg, from about 80 to about 110 mg, from about 90 to about 120 mg, from about 100 to about 130 mg, from about 110 to about 140 mg, from about 120 to about 150 mg, from about 130 to about 160 mg, from about 140 to about 170 mg, from about 150 to about 180 mg, from about 160 to about 190 mg, from about 170 to about 200 mg, from about 180 to about 210 mg, from about 1 about 310 to about 340 mg, about 320 to about 350 mg, about 330 to about 360 mg, about 340 to about 370 mg, about 350 to about 380 mg, about 360 to about 390 mg, or about 370 to about 400 mg.

[0037] In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in a mean day 15 AUC of greater than about 3,500 ng*hr / mL, about 3,600 ng*hr / mL, about 3,700 ng*hr / mL, about 3,800 ng*hr / mL, about 3,900 ng*hr / mL, about 4,000 ng*hr / mL, about 4,100 ng*hr / mL, about 4,200 ng*hr / mL, about 4,300 ng*hr / mL, 4,400 ng*hr / mL, about 4,500 ng*hr / mL, about 4,600 ng*hr / mL, about 4,700 ng*hr / mL, about 4,800 ng*hr / mL, about 4,900 ng*hr / mL, or about 5,000 ng*hr / mL TAU .

[0038] In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in a mean Day 15 AUC of greater than about 3,500 ng*hr / mL and less than about 4,000 ng*hr / mL. TAU In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in a mean Day 15 AUC of greater than about 3,600 ng*hr / mL and less than about 4,100 ng*hr / mL TAUIn one embodiment, the therapeutically effective amount of the compound of Formula (I) results in a mean Day 15 AUC of greater than about 3,700 ng*hr / mL and less than about 4,200 ng*hr / mL TAU In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in a mean Day 15 AUC of greater than about 3,800 ng*hr / mL and less than about 4,300 ng*hr / mL TAU In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in a mean Day 15 AUC of greater than about 3,900 ng*hr / mL and less than about 4,400 ng*hr / mL TAU In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in a mean Day 15 AUC of greater than about 4,000 ng*hr / mL and less than about 4,500 ng*hr / mL TAU In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in a mean Day 15 AUC of greater than about 4,100 ng*hr / mL and less than about 4,600 ng*hr / mL TAU In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in a mean Day 15 AUC of greater than about 4,200 ng*hr / mL and less than about 4,700 ng*hr / mL TAU In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in a mean Day 15 AUC of greater than about 4,300 ng*hr / mL and less than about 4,800 ng*hr / mL TAU In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in a mean Day 15 AUC of greater than about 4,400 ng*hr / mL and less than about 4,900 ng*hr / mL TAU In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in a mean Day 15 AUC of greater than about 4,500 ng*hr / mL and less than about 5,000 ng*hr / mL TAU In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in a mean Day 15 AUC of greater than about 4,600 ng*hr / mL and less than about 5,100 ng*hr / mL TAU In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in a mean Day 15 AUC of greater than about 4,700 ng*hr / mL and less than about 5,200 ng*hr / mL TAU In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in a mean Day 15 AUC of greater than about 4,800 ng*hr / mL and less than about 5,300 ng*hr / mL TAUIn one embodiment, the therapeutically effective amount of the compound of Formula (I) results in a mean Day 15 AUC of greater than about 4,900 ng*hr / mL and less than about 5,400 ng*hr / mL TAU In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in a mean Day 15 AUC of greater than about 5,000 ng*hr / mL and less than about 5,500 ng*hr / mL TAU .

[0039] In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in a mean Day 15 AUC of greater than about 4,000 ng*hr / mL and less than about 4,200 ng*hr / mL. TAU In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in a mean Day 15 AUC of greater than about 3,900 ng*hr / mL and less than about 4,300 ng*hr / mL TAU In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in a mean Day 15 AUC of greater than about 3,800 ng*hr / mL and less than about 4,400 ng*hr / mL TAU In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in a mean Day 15 AUC of greater than about 3,700 ng*hr / mL and less than about 4,500 ng*hr / mL TAU In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in a mean Day 15 AUC of greater than about 3,600 ng*hr / mL and less than about 4,600 ng*hr / mL TAU .

[0040] In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in a mean Day 15 C of greater than about 200 ng / mL, about 205 ng / mL, about 210 ng / mL, about 215 ng / mL, about 220 ng / mL, about 225 ng / mL, about 230 ng / mL, about 235 ng / mL, about 240 ng / mL, about 245 ng / mL, or about 250 ng / mL. max .

[0041] In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in a mean Day 15 C of greater than about 200 ng / mL and less than about 220 ng / mL. max In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in an average Day 15 C of greater than about 205 ng / mL and less than about 225 ng / mL. max In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in an average Day 15 C of greater than about 210 ng / mL and less than about 230 ng / mL.max In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in an average Day 15 C of greater than about 215 ng / mL and less than about 235 ng / mL. max In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in an average Day 15 C of greater than about 220 ng / mL and less than about 240 ng / mL. max In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in an average Day 15 C of greater than about 225 ng / mL and less than about 245 ng / mL. max In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in an average Day 15 C of greater than about 230 ng / mL and less than about 250 ng / mL. max In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in an average Day 15 C of greater than about 235 ng / mL and less than about 255 ng / mL. max In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in an average Day 15 C of greater than about 240 ng / mL and less than about 260 ng / mL. max In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in an average Day 15 C of greater than about 245 ng / mL and less than about 265 ng / mL. max In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in an average Day 15 C of greater than about 250 ng / mL and less than about 270 ng / mL. max .

[0042] In one embodiment, a therapeutically effective amount of a compound of Formula (I) results in a mean Day 15 C of greater than about 214 ng / mL and less than about 236 ng / mL. max In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in an average Day 15 C of greater than about 213 ng / mL and less than about 237 ng / mL. max In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in an average Day 15 C of greater than about 212 ng / mL and less than about 238 ng / mL. max In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in an average Day 15 C of greater than about 211 ng / mL and less than about 239 ng / mL. max In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in an average Day 15 C of greater than about 210 ng / mL and less than about 240 ng / mL. max In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in an average Day 15 C of greater than about 205 ng / mL and less than about 245 ng / mL. maxIn one embodiment, the therapeutically effective amount of the compound of Formula (I) results in a mean Day 15 C of greater than about 200 ng / mL and less than about 250 ng / mL. max .

[0043] In one embodiment, a therapeutically effective amount of a compound of Formula (I) results in a mean Day 15 C of greater than about 223 ng / mL and less than about 225 ng / mL. max In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in an average Day 15 C of greater than about 222 ng / mL and less than about 226 ng / mL. max In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in an average Day 15 C of greater than about 221 ng / mL and less than about 227 ng / mL. max In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in an average Day 15 C of greater than about 220 ng / mL and less than about 228 ng / mL. max In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in an average Day 15 C of greater than about 219 ng / mL and less than about 229 ng / mL. max In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in an average Day 15 C of greater than about 218 ng / mL and less than about 230 ng / mL. max In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in an average Day 15 C of greater than about 217 ng / mL and less than about 231 ng / mL. max In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in an average Day 15 C of greater than about 216 ng / mL and less than about 232 ng / mL. max In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in an average Day 15 C of greater than about 215 ng / mL and less than about 233 ng / mL. max In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in an average Day 15 C of greater than about 214 ng / mL and less than about 234 ng / mL. max .

[0044] In one embodiment, the compound of formula (I) is formulated into a tablet. In one embodiment, the tablet comprises a compound of formula (I) and optionally one or more of the following: an emulsifier; a surfactant; a binder; a disintegrant; a glidant; and a lubricant. In one embodiment, the emulsifier is hypromellose. In one embodiment, the surfactant is vitamin E polyethylene glycol succinate. In one embodiment, the binder is microcrystalline cellulose or lactose monohydrate. In one embodiment, the disintegrant is cross-linked sodium carboxymethyl cellulose. In one embodiment, the glidant is silicon dioxide. In one embodiment, the lubricant is sodium stearyl fumarate. In one embodiment, the subject in need of treatment is in a fed state. In one embodiment, the subject in need of treatment is in a fasted state.

[0045] In one aspect, the present application relates to a method for treating breast cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I) as defined herein, further comprising administering to the subject in need thereof a therapeutically effective amount of a CDK4 / 6 inhibitor. In one embodiment, the CDK4 / 6 inhibitor is SHR6390, trilaciclib, lerociclib, AT7519M, dinaciclib, riboclib, abemaciclib or palbociclib. In one embodiment, the CDK4 / 6 inhibitor is palbociclib.

[0046] In one embodiment, the method for treating breast cancer in a subject in need comprises administering a therapeutically effective amount of a compound of formula (I) to the subject, and further comprises administering a therapeutically effective amount of palbociclib, the therapeutically effective amount of palbociclib being administered to the subject once a day. In one embodiment, the therapeutically effective amount of palbociclib is 60mg, 75mg, 100mg or 125mg. In one embodiment, palbociclib is administered once a day for up to 21 consecutive days, followed by a maximum of 7 consecutive days of stopping treatment, wherein the cycle of treatment with palbociclib followed by stopping treatment is repeated once, twice, three times, four times, five times or more. In one embodiment, the compound of formula (I) is administered once a day for up to 21 consecutive days, followed by a maximum of 7 consecutive days of stopping treatment, wherein the cycle of treatment with the compound of formula (I) followed by stopping treatment is repeated once, twice, three times, four times, five times or more. In one embodiment, when the subject is in a fed state, a compound of formula (I) and palbociclib are administered to a subject in need. In one embodiment, a compound of Formula (I) and palbociclib are administered to a subject in need thereof while the subject is in a fasting state.

[0047] In one aspect, the present application relates to a method of treating metastatic breast cancer in a subject in need thereof, the method comprising orally administering once daily a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative or prodrug thereof, wherein the compound of formula (I) is selected from the group consisting of:

[0048]

[0049]

[0050]

[0051] In one embodiment, a therapeutically effective amount of a compound of Formula (I) is administered to a subject all at once, or in two, three, or four portions.

[0052] In one embodiment, the therapeutically effective amount of the compound of Formula (I) is from about 30 mg to about 1000 mg.

[0053] In one embodiment, the therapeutically effective amount of the compound of formula (I) is from about 10 to about 40 mg, from about 20 to about 50 mg, from about 30 to about 60 mg, from about 40 to about 70 mg, from about 50 to about 80 mg, from about 60 to about 90 mg, from about 70 to about 100 mg, from about 80 to about 110 mg, from about 90 to about 120 mg, from about 100 to about 130 mg, from about 110 to about 140 mg, from about 120 to about 150 mg, from about 130 to about 160 mg, from about 140 to about 170 mg, from about 150 to about 180 mg, from about 160 to about 190 mg, from about 170 to about 200 mg, from about 180 to about 210 mg, from about 1 about 310 to about 340 mg, about 320 to about 350 mg, about 330 to about 360 mg, about 340 to about 370 mg, about 350 to about 380 mg, about 360 to about 390 mg, or about 370 to about 400 mg.

[0054] In one embodiment, the compound of formula (I) is formulated as a tablet.

[0055] In one aspect, the present application relates to a method for treating breast cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I), wherein the compound of formula (I) is a compound of formula (Ia), formula (Ib), formula (Ic), formula (Id), formula (Ie), formula (If), formula (Ig), formula (Ih), formula (Ii), or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug thereof, further comprising administering to the subject in need thereof a therapeutically effective amount of a CDK4 / 6 inhibitor. In one embodiment, the CDK4 / 6 inhibitor is SHR6390, treraciclib, leloxilib, AT7519M, denacil, ribociclib, abemaciclib, or palbociclib. In one embodiment, the CDK4 / 6 inhibitor is palbociclib.

[0056] In one embodiment, a method for treating breast cancer in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound of Formula (la)-77, lb)-78, lc)-79, d)-1e, If)-77, lg)-79, lgh)-71, or (Ii)-71, and further comprises administering a therapeutically effective amount of palbociclib, wherein the therapeutically effective amount of palbociclib is administered concurrently with the administration of the compound of Formula (la)-77, lb)-78, lc)-79, d)-1e, If)-77, lg)-79, lgh)-71, or (Ii)-71. In one embodiment, a method for treating breast cancer in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound of Formula (Ia)-72, (Ib)-73, (Ic)-75, (Id)-75, (If)-77, (Ig)-75, (Ih)-75, or (Ii)-75, and further comprises administering a therapeutically effective amount of palbociclib, wherein the therapeutically effective amount of palbociclib is administered prior to administering the compound of Formula (Ia)-72, (Ib)-73, (Ic)-75, (Id)-75, (If)-77, (Ig)-75, (Ih)-75, or (Ii). In one embodiment, a method for treating breast cancer in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound of Formula (Ia)-77, (Ib)-77, (Ic)-7d, (Ie), (If), (Ig), (Ih)-71, or (Ii), and further comprises administering a therapeutically effective amount of palbociclib, wherein the therapeutically effective amount of palbociclib is administered after administering the compound of Formula (Ia)-77, (Ib)-77, (Ic)-7d, (Ie), (If), (Ig), (Ih)-71, or (Ii). In some embodiments, a method for treating breast cancer in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound of Formula (Ia)-72), (Ib)-73), (Ic)-7d), (Ie)-73), (If)-73), (Ig)-7h), or (Ii)-73, and further comprises administering a therapeutically effective amount of palbociclib, wherein the administration of the compound of Formula (Ia)-72), (Ib)-73), (Ic)-7d), (Ie)-73), (If)-73), (Ig)-7h), or (Ii)-73, and the administration of palbociclib are separated in time such that the two compounds and their respective excipients, if present, do not mix in the stomach of the subject.

[0057] In one embodiment, a method for treating breast cancer in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound of Formula (la)-(la), (lb)-(lb), (lc)-(ld), (le), (If), (Ig), (Ih)-(Ii), or (Ii-(Ii)), and further comprises administering a therapeutically effective amount of palbociclib, wherein the therapeutically effective amount of palbociclib is administered at least 5, at least 10, at least 15, at least 20, at least 25, or at least 30 minutes prior to administering the compound of Formula (la)-(la), (lb)-(lb), (lc)-(ld), In one embodiment, the method for treating breast cancer in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound of Formula (la)-(la), (lb)-(lb), (lc)-(ld), (le), (If), (Ig), (Ih)-(Ii), or (Ii-(Ii)), and further comprises administering a therapeutically effective amount of palbociclib, wherein the therapeutically effective amount of palbociclib is administered at least 30 minutes prior to administering the compound of Formula (la)-(la), (lb)-(lb), (lc)-(ld), (le), (If), (Ig), (Ih)-(Ii) In one embodiment, a method for treating breast cancer in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound of Formula (la)-(la), (lb)-(lb), (lc)-(ld), (le), (If), (Ig), (Ih)-(Ii), or (Ii-(Ii)), and further comprises administering a therapeutically effective amount of palbociclib, wherein the therapeutically effective amount of palbociclib is administered 30 to 60 minutes prior to administering the compound of Formula (la)-(la), (lb)-(lb), (lc)-(ld), (le), (If), (Ig), (Ih)-(Ii)

[0058] In one embodiment, a method for treating breast cancer in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound of Formula (la)-(la), (lb)-(lb), (lc)-(ld), (le), (If), (Ig), (Ih)-(Ii), or (Ii-(Ii)), and further comprises administering a therapeutically effective amount of palbociclib, wherein the therapeutically effective amount of palbociclib is administered at least 5, at least 10, at least 15, at least 20, at least 25, or at least 30 minutes after administration of the compound of Formula (la)-(la), (lb)-(lb), (lc)-(ld), In one embodiment, a method for treating breast cancer in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound of Formula (Ia)-72, (Ib)-73, (Ic)-75, (Id)-80, (If)-90, (Ig)-100, (Ih)-101, or (Ii)-102, and further comprises administering a therapeutically effective amount of palbociclib, wherein the therapeutically effective amount of palbociclib is administered at least 30 minutes after administration of a compound of Formula (Ia)-72, (Ib)-73, (Ic)-75, (Id)-80, (If)-90, (Ig)-100, (Ih)-101, or (Ii)-102. In one embodiment, a method for treating breast cancer in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound of Formula (la)-(la), (lb)-(lb), (lc)-(ld), (le), (If), (Ig), (Ih)-(Ii), or (Ii-(Ii)), and further comprises administering a therapeutically effective amount of palbociclib, wherein the therapeutically effective amount of palbociclib is administered 30 to 60 minutes after administration of the compound of Formula (la)-(la), (lb)-(lb), (lc)-(ld), (le), (If), (Ig), (Ih)-(Ii) or (Ii)

[0059] In one embodiment, a method for treating breast cancer in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound of Formula (Ia)-75, (Ib)-75, (Ic)-75, (Id)-75, (Ie)-75, (If)-75, (Ig)-75, (Ih)-75, or (Ii)-75, and further comprises administering a therapeutically effective amount of palbociclib, wherein the therapeutically effective amount of palbociclib is administered to the subject once daily. In one embodiment, the therapeutically effective amount of palbociclib is 60 mg, 75 mg, 100 mg, or 125 mg. In one embodiment, palbociclib is administered once daily for up to 21 consecutive days, followed by up to 7 consecutive days of cessation of treatment, wherein the cycle of treatment with palbociclib followed by cessation of treatment is repeated once, twice, three times, four times, five times, or more. In one embodiment, a compound of Formula (Ia)-(Ib)-(Ic)-(Id)-(Ie)-(If)-(Ig)-(Ih) or (Ii)-(Ii) is administered once daily for up to 21 consecutive days, followed by up to 7 consecutive days of treatment cessation, wherein the cycle of treatment with a compound of Formula (Ia)-(Ib)-(Ic)-(Id)-(Ie)-(If)-(Ig)-(Ih) or (Ii) followed by treatment cessation is repeated once, twice, three times, four times, five times or more. In one embodiment, a compound of Formula (Ia)-(Ib)-(Ic)-(Id)-(Ie)-(If)-(Ig)-(Ih) or (Ii) and palbociclib are administered to a subject in need thereof while the subject is in a fed state. In one embodiment, a compound of Formula (la)-(la), (lb)-(lb), (lc)-(ld), (Id)-(le), (If), (Ig), (Ih) or (Ii) and palbociclib are administered to a subject in need thereof while the subject is in a fasting state.

[0060] In one aspect, the present application relates to a method of treating breast cancer in a subject in need thereof, the method comprising: (i) orally administering a therapeutically effective amount of a compound of formula (Ic) once daily,

[0061] Or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative or prodrug thereof, and (ii) oral administration of palbociclib once a day. In one aspect, the present application relates to a method for treating breast cancer in a subject in need thereof, the method comprising: (i) oral administration of a therapeutically effective amount of a compound of formula (Ic) once a day, and (ii) oral administration of palbociclib once a day. In one embodiment, the therapeutically effective amount of the compound of formula (Ic) is from about 30 mg to about 1000 mg. In one embodiment, the therapeutically effective amount of palbociclib is 60 mg, 75 mg, 100 mg or 125 mg. In one embodiment, palbociclib is administered once a day for up to 21 consecutive days, followed by cessation of treatment for up to 7 consecutive days, wherein the cycle of treatment with palbociclib followed by cessation of treatment is repeated once, twice, three times, four times, five times or more. In one embodiment, the compound of formula (Ic) is administered once daily for up to 21 consecutive days, followed by up to 7 consecutive days off treatment, wherein the cycle of treatment with the compound of formula (Ic) followed by off treatment is repeated once, twice, three times, four times, five times or more. In one embodiment, the compound of formula (Ic) and palbociclib are administered to a subject in need thereof while the subject is in a fed state. In one embodiment, the compound of formula (Ic) and palbociclib are administered to a subject in need thereof while the subject is in a fasting state.

[0062] In one embodiment, the method for treating breast cancer in a subject in need comprises orally administering a therapeutically effective amount of a compound of formula (Ic) once daily, and further orally administering palbociclib once daily, the administration of the compound of formula (Ic) and the administration of palbociclib being separated in time so that the two compounds and their respective excipients (if present) do not mix in the stomach of the subject. In one embodiment, the method for treating breast cancer in a subject in need comprises orally administering a therapeutically effective amount of a compound of formula (Ic) once daily, and further orally administering palbociclib once daily, palbociclib being administered prior to the administration of the compound of formula (Ic). In one embodiment, the method for treating breast cancer in a subject in need comprises orally administering a therapeutically effective amount of a compound of formula (Ic) once daily, and further orally administering palbociclib once daily, palbociclib being administered at least 5, at least 10, at least 15, at least 20, at least 25, or at least 30 minutes prior to the administration of the compound of formula (Ic). In one embodiment, a method for treating breast cancer in a subject in need thereof comprises orally administering a therapeutically effective amount of a compound of Formula (Ic) once daily, and further orally administering palbociclib once daily, palbociclib administered at least 30 minutes prior to the administration of the compound of Formula (Ic). In one embodiment, a method for treating breast cancer in a subject in need thereof comprises orally administering a therapeutically effective amount of a compound of Formula (Ic) once daily, and further orally administering palbociclib once daily, palbociclib administered 30 to 60 minutes prior to the administration of the compound of Formula (Ic).

[0063] In one embodiment, the method for treating breast cancer in a subject in need comprises orally administering a therapeutically effective amount of a compound of Formula (Ic) once daily, and further orally administering palbociclib once daily, administering palbociclib after administering the compound of Formula (Ic). In one embodiment, the method for treating breast cancer in a subject in need comprises orally administering a therapeutically effective amount of a compound of Formula (Ic) once daily, and further orally administering palbociclib once daily, administering palbociclib at least 5, at least 10, at least 15, at least 20, at least 25, or at least 30 minutes after administering the compound of Formula (Ic). In one embodiment, the method for treating breast cancer in a subject in need comprises orally administering a therapeutically effective amount of a compound of Formula (Ic) once daily, and further orally administering palbociclib once daily, administering palbociclib at least 30 minutes after administering the compound of Formula (Ic). In one embodiment, the method for treating breast cancer in a subject in need thereof comprises orally administering a therapeutically effective amount of a compound of Formula (Ic) once daily, and further orally administering palbociclib once daily, administering palbociclib 30 to 60 minutes after the administration of the compound of Formula (Ic).

[0064] In one aspect, the present application relates to a method for selective estrogen receptor degradation in a patient, the method comprising: (i) orally administering a therapeutically effective amount of a compound of formula (Ic) once daily, or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative or prodrug thereof, and (ii) orally administering palbociclib once daily.

[0065] In one aspect, the present application relates to a method for inhibiting cyclin-dependent kinases in a subject in need thereof, the method comprising: (i) orally administering a therapeutically effective amount of a compound of formula (Ic) once daily, or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative or prodrug thereof, and (ii) orally administering palbociclib once daily.

[0066] In one aspect, the present application relates to a kit comprising: a compound of formula (Ic),

[0067] Palbociclib and instructions for use.

[0068] In one aspect, the present application relates to a liquid composition comprising a surfactant, a solvent and a compound of formula (Ic),

[0069] In some embodiments, the surfactant is a sorbitan derivative. In some embodiments, the surfactant is Tween 80. In some embodiments, the solvent is a low molecular weight polyethylene glycol (PEG). In some embodiments, the solvent is polyethylene glycol (PEG)-400.

[0070] In one aspect, the present application relates to a method for preparing a liquid composition comprising a surfactant, a solvent and a compound of formula (Ic):

[0071]

[0072] The method further comprises the step of adding the solvent to the pre-aliquoted volume of the surfactant. In some embodiments, the method further comprises the step of adding the compound of formula (Ic) to the mixture of the solvent and the surfactant. In some embodiments, the surfactant is a sorbitan derivative. In some embodiments, the surfactant is Tween 80. In some embodiments, the solvent is a low molecular weight polyethylene glycol (PEG). In some embodiments, the solvent is polyethylene glycol (PEG)-400. BRIEF DESCRIPTION OF THE DRAWINGS

[0073] Figure 1 Results of tumor growth inhibition experiments associated with oral administration of compound (Ic) once daily at doses of 3 mg / kg, 10 mg / kg and 30 mg / kg compared to vehicle are shown (mean tumor volume (mm 3 ) versus time). In the MCF7 xenograft model, at doses of 3 mg / kg, 10 mg / kg and 30 mg / kg of compound (Ic), 85%, 98% and 124% tumor growth inhibition (TGI) were observed, respectively, compared to the control group.

[0074] Figure 2 is a Western blot experiment showing the reduction of ER in MCF7 xenograft tumors in response to administration of compound (Ic) at 3 mg / kg, 10 mg / kg and 30 mg / kg (oral, once a day).

[0075] Figure 3 is a pair of line graphs showing the mean concentration (ng / mL) of the compound of Formula (Ic) over a 24 hour period following dosing on Days 1 and 15 in a Phase I clinical trial.

[0076] Figure 4 is a line graph providing a representation of the mean trough concentrations (ng / mL) of compound (Ic) throughout the Phase I clinical trial.

[0077] Figure 5 are graphs and Western blot experiments showing the Erα-degrading activity of compound (Ic) after oral administration at 10 mg / kg 3 times daily.

[0078] Figure 6 Results of tumor growth inhibition experiments associated with oral once-daily administration of compound (Ic) at doses of 3 mg / kg, 10 mg / kg and 30 mg / kg for 28 days compared to vehicle are shown (mean tumor volume (mm 3 ) versus time). In the MCF7 xenograft model, at doses of 3 mg / kg, 10 mg / kg and 30 mg / kg of compound (Ic), 85%, 98% and 124% tumor growth inhibition (TGI) were observed, respectively, compared to the control group.

[0079] Figure 7 is a graph showing that daily oral dosing of compound (Ic) at 3 mg / kg, 10 mg / kg and 30 mg / kg for 28 days reduced ERa levels by >94% compared to mice administered vehicle alone.

[0080] Figure 8Shown are the results of tumor growth inhibition experiments associated with Compound (Ic) administered orally once daily at a dose of 30 mg / kg for 28 days, Compound (Ic) (30 mg / kg, orally, once daily for 28 days) plus palbociclib (administered orally once daily at 60 mg / kg for 28 days), fulvestrant (200 mg / kg, subcutaneously twice / week for 2 weeks), and fulvestrant (200 mg / kg, subcutaneously twice / week for 2 weeks) plus palbociclib (administered orally once daily at 60 mg / kg for 28 days) compared to vehicle (mean tumor volume (mm 3 ) versus time). The combination of Compound (Ic) and palbociclib provided significant tumor regression (131% TGI) when compared to the activity of single agent Compound (Ic) in this model (105% TGI). In contrast, subcutaneously administered single agent fulvestrant resulted in only modest tumor growth inhibition (46% TGI), while the combination of fulvestrant and palbociclib resulted in improved tumor growth inhibition (108% TGI), but not to the level achieved by Compound (Ic) and palbociclib.

[0081] Fig. 9 Results of experiments on tamoxifen-resistant MCF7 xenograft growth inhibition associated with Compound (Ic) administered orally once daily for 28 days at a dose of 30 mg / kg compared to Palbociclib (60 mg / kg, orally once daily for 28 days), Compound (Ic) (30 mg / kg, orally, once daily for 28 days) plus Palbociclib (60 mg / kg, orally once daily for 28 days) and vehicle are shown (mean tumor volume (mm 3 ) versus time). When compound (Ic) was combined with 60 mg / kg / day palbociclib, the combination regimen resulted in greater tumor growth inhibition (113% TGI) when compared to the palbociclib single agent group (91% TGI).

[0082] Fig.10 , Fig.11 and Fig.12 Compound (Ic) (30 mg / kg, oral, once daily, for 28 days) was shown to inhibit the growth of tamoxifen-resistant MCF7 xenografts. Fig.10 ), Palbociclib (60 mg / kg, oral, once a day, for 28 days, Fig.12 ) and compound (Ic) (30 mg / kg, orally, once daily for 28 days) plus palbociclib (60 mg / kg, orally, once daily for 28 days) ( Fig.11 ) doses on the level of ERα in vivo.

[0083] Fig.13 The results of several Western blot experiments comparing the in vitro ERa degradation activity of fulvestrant and compound (Ic) at various concentrations in several ER-positive breast cancer cell lines are presented.

[0084] Fig.14 The half-maximal degradation concentration (DC) of compound (Ic) in MCF7 cells is shown. 50 ) is a graph of 0.9 nM.

[0085] Fig.15 Results of several Western blot experiments comparing the in vitro ERα degradation activity of fulvestrant and compound (Ic) at various concentrations in the clinically relevant ESR1 cell line variants Y537S and D538G are presented.

[0086] Fig.16 is a graph showing the relative expression of GREB1 and PR in experiments performed with fulvestrant and compound (Ic) compared to vehicle (DMSO).

[0087] Fig.17 is a graph showing the effect of fulvestrant (100 mg / kg subcutaneously once daily) and Compound (Ic) (30 mg / kg orally once daily) on uterine weight compared to vehicle.

[0088] Fig.18 is a Western blot comparing the in vivo ERα degradation activity of compound (Ic) (administered orally at 10 mg / kg for 3 days) and vehicle in the MCF7 / E2 xenograft model.

[0089] Fig.19 Results of tumor growth inhibition experiments associated with oral administration of compound (Ic) once daily for 28 days at doses of 3 mg / kg, 10 mg / kg and 30 mg / kg compared to vehicle are shown (mean tumor volume (mm 3 ) versus time). In the MCF7 / estradiol xenograft model, at doses of 3 mg / kg, 10 mg / kg and 30 mg / kg of compound (Ic), 85%, 98% and 124% tumor growth inhibition (TGI) were observed, respectively, compared to the control group.

[0090] Fig. 20Shown is tumor growth inhibition (mean tumor volume (mm) in the MCF7 / estradiol model associated with administration of compound (Ic) at a once daily oral dose of 30 mg / kg for 28 days, fulvestrant (200 mg / kg, subcutaneously, twice / week for 2 weeks), compound (Ic) (oral, once daily, at a dose of 30 mg / kg for 28 days) plus palbociclib (oral, once daily, at a dose of 60 mg / kg for 28 days), and fulvestrant (200 mg / kg, subcutaneously, twice / week for 2 weeks) plus palbociclib (oral, once daily, at a dose of 60 mg / kg for 28 days) compared to vehicle. 3 ) versus time) experiment. When compared to the single agent compound (Ic) activity in this model (105% TGI), the combination of compound (Ic) and palbociclib provided significant tumor regression (131% TGI). In contrast, subcutaneously administered single agent fulvestrant resulted in only modest tumor growth inhibition (46% TGI), while the combination of fulvestrant and palbociclib resulted in improved inhibition of tumor growth (108% TGI), but not to the level achieved by compound (Ic) and palbociclib (131%).

[0091] Fig.21 Shown is tumor growth inhibition (mean tumor volume (mm) in the tamoxifen-resistant MCF7 model associated with administration of compound (Ic) at a once daily oral dose of 30 mg / kg for 28 days, palbociclib (oral, once daily, at a dose of 60 mg / kg for 28 days), and compound (Ic) (oral, once daily, at a dose of 30 mg / kg for 28 days) plus palbociclib (oral, once daily, at a dose of 60 mg / kg for 28 days) compared to vehicle. 3 ) vs. time) experiment. While compound (Ic) alone reduced tumor growth, the combination of compound (Ic) and palbociclib resulted in improved inhibition of tumor growth compared to compound (Ic) alone (113% vs. 65%).

[0092] Fig. 22 Tumor growth inhibition (mean tumor volume (mm)) in the ESR1 (Y537S) PDX model associated with once-daily oral administration of compound (Ic) for 28 days or fulvestrant (200 mg / kg, subcutaneously, twice / week for 2 weeks) at 10 mg / kg or 30 mg / kg was shown. 3) versus time) experiments. At 10 mg / kg or 30 mg / kg doses, compound (Ic) reduced tumor ERα levels by a greater amount than fulvestrant (79 / 88% versus 63%) and resulted in improved inhibition of tumor growth compared to fulvestrant (99 / 106% versus 62%). DETAILED DESCRIPTION

[0093] definition

[0094] "H" means hydrogen.

[0095] Halogen or "halo" refers to fluorine (F), chlorine (Cl), bromine (Br) or iodine (I).

[0096] "C1-C6 alkyl" refers to a straight or branched chain saturated hydrocarbon containing 1 to 6 carbon atoms. Examples of (C1-C6) alkyl groups include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, neopentyl, and isohexyl.

[0097] "C3-C6 cycloalkyl" means a monocyclic saturated carbocyclic ring containing 3 to 6 carbon atoms, ie, a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl moiety.

[0098] As used herein, "pharmaceutically acceptable salts" with respect to compounds of formula (I) means salt forms of compounds of formula (I) and hydrates of salt forms present together with one or more water molecules. Such salts and hydrated forms retain the biological activity of the compounds of formula (I) and are not biologically or otherwise undesirable, i.e., exhibit minimal toxicological effects, if any. Representative "pharmaceutically acceptable salts" include, for example, water-soluble and water-insoluble salts such as acetate, amsonate (4,4-diaminostilbene-2,2-disulfonate), benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium, calcium edetate, camphorsulfonate, carbonate, chloride, citrate, clavulariate, dihydrochloride, edetate, edisylate, propionate dodecyl sulfate, ethanesulfonate, fumarate, glucoheptonate, gluconate, glutamate, glycolyl p-aminophenylarsonic acid salt, hexafluorophosphate, hexylresorcinol salt, hydrabamine, hydrobromide, hydrochloride, hydroxy Naphthoate, iodide, isothionate, lactate, lactobionate, laurate, magnesium, malate, maleate, mandelate, methanesulfonate, methyl bromide, methyl nitrate, methyl sulfate, mucate, naphthenate, nitrate, N-methylglucamine ammonium salt, 3-hydroxy-2-naphthoate, oleate, oxalate, palmitate, pamoate (1,1-methylene-bis-2-hydroxy-3-naphthoate, einbonate), pantothenate, phosphate / diphosphate, picrate, polygalacturonate, propionate, p-toluenesulfonate, salicylate, stearate, subacetate, succinate, sulfate, sulfosalicylate, suramate, tannate, tartrate, theoclate, toluenesulfonate, triethyl iodide, and valerate.

[0099] The term "isomer" refers to salts and / or compounds having the same composition and molecular weight but differing in physical and / or chemical properties. The structural differences may be in the composition (geometric isomers) or the ability to rotate the plane of polarized light (stereoisomers). With respect to stereoisomers, salts of compounds of formula (I) may have one or more asymmetric carbon atoms and may occur as racemates, racemic mixtures and as individual enantiomers or diastereomers.

[0100] The compounds of formula (I) can exist in unsolvated forms as well as solvated forms, such as, for example, hydrates.

[0101] "Solvate" means a solvent-added form containing a stoichiometric or non-stoichiometric amount of solvent. Some compounds have a tendency to capture a fixed molar ratio of solvent molecules in the crystalline solid state, thereby forming a solvate. If the solvent is water, the solvate formed is a hydrate, and when the solvent is an alcohol, the solvate formed is an alcoholate. Hydrates are formed by a combination of one or more water molecules with one of the substances in which water retains its molecular state as H2O, and such combinations can form one or more hydrates. In hydrates, water molecules are connected by intermolecular forces, particularly hydrogen bridges, through secondary valence. Solid hydrates contain water as so-called crystal water in a stoichiometric ratio, wherein the water molecules do not have to be equivalent to their binding state. Examples of hydrates are sesquihydrates, monohydrates, dihydrates or trihydrates. Equally suitable are hydrates of salts of the compounds of the present invention.

[0102] When a compound is crystallized from a solution or slurry, it can crystallize in different arrangements of lattices in space (this property is called "polymorphism") to form crystals with different crystalline forms, each of which is called a "polymorph". As used herein, "polymorph" refers to a crystalline form of a compound of formula (I) in which the molecules are located at three-dimensional lattice sites. Different polymorphs of a compound of formula (I) may differ from one another in one or more physical properties, such as solubility and dissolution rate, true specific gravity, crystal form, accumulation pattern, flowability and / or solid state stability, etc.

[0103] As referred to herein, "isotopic derivatives" refer to compounds of formula (I) that are isotopically enriched or labeled (with respect to one or more atoms of the compound) with one or more stable isotopes. Thus, in the present application, compounds of formula (I) include, for example, compounds enriched or labeled (with respect to one or more atoms of the compound) with one or more stable isotopes. 2 H or D) or carbon-13 ( 13 C)) Isotopically enriched or labeled compounds.

[0104] As used herein, the term "pharmaceutically acceptable prodrugs" refers to those prodrugs of the compounds of formula (I) which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals, without excessive toxicity, irritation, allergic response, etc., commensurate with a reasonable benefit / risk ratio, and effective for their intended use, as well as zwitterionic forms of the compounds of the invention, if possible.

[0105] As used herein, "prodrug" refers to a compound that can be transformed in vivo by metabolic means (eg, by hydrolysis) to provide any of the compounds described by the formulae of the invention. Various forms of prodrugs are known in the art, for example, as described in Bundgaard, (ed.), Design of Prodrugs, Elsevier (1985); Widder et al., (eds.), Methods in Enzymology, Vol. 4, Academic Press (1985); Krogsgaard-Larsen et al., (eds.), Design and Application of Prodrugs, A Textbook of Drug Design and Development, Chapter 5, 1 13-191 (1991); Bundgaard et al., Journal of Drug Delivery Reviews, 8: 1 -38 (1992); Bundgaard, J. of Pharmaceutical Sciences, 77: 285 et seq. (1988); Higuchi and Stella (eds.), Prodrugs as Novel Drug Delivery Systems, 1993; Systems," American Chemical Society (1975); and Bernard Testa & Joachim Mayer, Hydrolysis In Drug And Prodrug Metabolism: Chemistry, Biochemistry And Enzymology, John Wiley and Sons, Ltd. (2002).

[0106] The present invention also encompasses pharmaceutical compositions comprising pharmaceutically acceptable prodrugs of compounds of the present invention, and methods for treating disorders by administering pharmaceutically acceptable prodrugs of compounds of the present invention. For example, compounds of the present invention having free amino groups, amide groups, hydroxyl groups, or carboxyl groups can be converted into prodrugs. Prodrugs include compounds wherein an amino acid residue or a polypeptide chain of two or more (e.g., two, three, or four) amino acid residues is covalently linked to a free amino group, hydroxyl group, or carboxyl group of a compound of the present invention via an amide or ester bond. Amino acid residues include, but are not limited to, 20 naturally occurring amino acids generally represented by three letter symbols, and also include 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvaline, β-alanine, γ-aminobutyric acid, citrulline, homocysteine, homoserine, ornithine, and methionine sulfone. Additional types of prodrugs are also included. For example, a free carboxyl group can be derived as an amide or an alkyl ester. As outlined in Advanced Drug Delivery Reviews, 1996, 19, 1 15, free hydroxyl groups can be derived using groups including but not limited to succinic acid half esters, phosphates, dimethylaminoacetates and phosphoryloxymethyloxycarbonyl groups. Also included are carbamate prodrugs of hydroxyl and amino groups, and carbonate prodrugs, sulfonates and sulfates of hydroxyl groups. Also included are hydroxyl groups derived as (acyloxy) methyl ethers and (acyloxy) ethyl ethers, wherein the acyl groups can be alkyl esters optionally substituted by groups including but not limited to ethers, amines and carboxylic acid functional groups, or wherein the acyl groups are amino acid esters as described above. This type of prodrug is described in J. Med. Chem. 1996, 39, 10. Free amines can also be derived as amides, sulfonamides or phosphoramides. All of these prodrug moieties can be incorporated with groups including but not limited to ethers, amines and carboxylic acid functional groups. The combinations of substituents and variables contemplated by the present invention are only those that result in the formation of stable compounds.

[0107] Metastatic breast cancer, or metastases, is breast cancer that has spread from the breast and nearby lymph nodes to other parts of the body, such as the bones, liver, lungs, or brain. (https: / / www.cancer.org / cancer / breast-cancer.)

[0108] Locally advanced breast cancer (LABC) is defined by the National Comprehensive Cancer Network as a subset of breast cancer characterized by the most advanced stage of breast cancer in the absence of distant metastases, with tumors greater than 5 cm in size and associated with regional lymphadenopathy; tumors of any size with direct extension to the chest wall or skin, or both (including ulcers or satellite nodules) not associated with regional lymphadenopathy; and the presence of regional lymphadenopathy (clinically fixed or tangled axillary nodes, or any infraclavicular, supraclavicular, or internal mammary lymphadenopathy) regardless of tumor stage. (Garg et al. Curr Oncol. 2015 Oct;22(5):e409–e410; National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Fort Washington, PA: NCCN; 2015. Ver. 2.2015.)

[0109] As used herein, ER+ estrogen receptor positive refers to breast cancer cells that have a receptor protein that binds the hormone estrogen. Cancer cells that are ER+ may require estrogen to grow and may stop growing or die when treated with substances that block the binding and action of estrogen. (https: / / www.cancer.gov / publications / dictionaries / cancer-terms / def / 44404.)

[0110] As used herein, HER2- human epidermal growth factor receptor 2 refers to breast cancer cells that do not have large amounts of a protein called HER2 on their surface. In normal cells, HER2 helps control cell growth. Cancer cells that are HER2- may grow more slowly and are less likely to come back or spread to other parts of the body than cancer cells that have large amounts of HER2 on their surface. (https: / / www.cancer.gov / publications / dictionaries / cancer-terms / def / her2-negative.)

[0111] As used herein, "treatment" describes the management and care of a subject for the purpose of combating a disease, condition, or disorder, and includes reducing or alleviating symptoms or complications, or eliminating the disease, condition, or disorder.

[0112] As used herein, "preventing" or "preventing" describes stopping the onset of symptoms or complications of a disease, condition or disorder.

[0113] "Administering" refers to the introduction of a medicament, such as a compound of Formula (I), into a subject. The related terms "administering" and "administration" (and grammatical equivalents) both refer to direct administration, which may be administered to a subject by a medical professional or self-administered by a subject, and / or indirect administration, which may be the act of prescribing a drug. For example, a doctor who instructs a patient to self-administer a drug and / or provides a patient with a prescription for a drug administers the drug to the patient.

[0114] As used herein, "therapeutically effective amount" means the amount of the free base of a compound of formula (I) sufficient to treat, improve or prevent a specified disease (e.g., breast cancer), disease symptoms, disorders or conditions, or to exhibit a detectable therapeutic or inhibitory effect. The effect can be detected by any assay method known in the art. The effective amount for a particular subject can depend on the subject's weight, size, and health; the nature and extent of the condition; and whether additional therapeutic agents are administered to the subject. The therapeutically effective amount for a given situation can be determined by routine experimentation within the skill and judgment of the clinician.

[0115] As used herein, “C max ” refers to the maximum (peak) plasma concentration of a specified compound observed in a subject following administration of a dose of that compound to the subject.

[0116] As used herein, "AUC" refers to the total area under the plasma concentration-time curve, which is a measure of exposure to the target compound and is the integral of the concentration-time curve after a single dose or steady state. AUC is expressed in ng*hr / mL (ng×hr / mL).

[0117] As used herein, “AUC tau ” refers to the AUC from 0 hours to the end of the dosing interval.

[0118] As used herein, "controlled release" or "CR" with respect to the oral dosage forms of the present disclosure means that the compound of Formula (I) is released from the dosage form according to a predetermined profile, which may include when and where the release occurs after oral administration and / or a specific release rate over a specific period of time. Controlled release can be contrasted with uncontrolled or immediate release.

[0119] As used herein, "controlled release agent" with respect to the oral dosage form of the present disclosure refers to one or more substances or materials that regulate the release of the compound of formula (I) from the dosage form. The controlled release agent can be an organic or inorganic, naturally occurring or synthetic material, such as a polymeric material, a triglyceride, a derivative of a triglyceride, a fatty acid and a salt of a fatty acid, talc, boric acid, and colloidal silicon dioxide.

[0120] As used herein, "oral dosage form" refers to a pharmaceutical product comprising a specified amount (dose) of a compound of formula (I) as an active ingredient, or a pharmaceutically acceptable salt and / or solvate thereof, and inactive components (excipients), formulated into a specific configuration suitable for oral administration and drug delivery, such as a tablet, capsule, or liquid oral formulation. In one embodiment, the composition is in the form of a tablet that can be scored.

[0121] As used in this disclosure, the term "carrier" encompasses carriers, excipients, and diluents and refers to a material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material, which is involved in carrying or transporting an agent from one organ or part of the body to another organ or part of the body of a subject.

[0122] The term "about" as part of a quantitative expression such as "about X" includes any value above or below 10% of X, and also includes any value between X-10% and X+10%. Thus, for example, a weight of about 40 g includes a weight of 36 to 44 g.

[0123] "Comprising" or "comprises" as applied to a particular dosage form, composition, use, method, or process described or claimed herein means that the dosage form, composition, use, method, or process includes all of the elements described in the specific description or claims, but does not exclude other elements. "Consists essentially of" and "consisting essentially of" mean that the described or claimed composition, dosage form, method, use, or process does not exclude other materials or steps that do not substantially affect the described physical, pharmacological, pharmacokinetic properties or therapeutic effects of the composition, dosage form, method, use, or process. "Consists of" and "consisting of" mean excluding other ingredients and substantial method or process steps beyond trace elements.

[0124] As used to describe a subject's "fasted condition" or "fasted state" means that the subject has not eaten for at least 4 hours before the target time point (e.g., the time of administration of the compound of Formula (I)). In one embodiment, the subject in the fasted state has not eaten for at least 6, 8, 10 or 12 hours before administration of the compound of Formula (I).

[0125] As used herein to describe a subject's "fed condition" or "fed state" means that the subject has eaten less than 4 hours prior to a target time point (e.g., the time of administration of a compound of Formula (I)). In one embodiment, a subject in a fed state has not eaten for any period of up to 4, 3, 2, 1, or 0.5 hours prior to administration of a compound of Formula (I).

[0126] As used herein, "Tween 80" refers to polysorbate 80, also known as polyoxyethylene (20) sorbitan monooleate, and (Z)-sorbitan mono-9-octadecanoate poly(oxy-1,2-ethanediyl) derivative.

[0127] As used herein, "low molecular weight polyethylene glycol" or "low molecular weight PEG" generally refers to a polyethylene glycol (PEG) polymer having a molecular weight of less than 1500, 1400, 1300, 1200, 1100, 1000, 900, 800, 700, 600, 500, 400 or 300 Daltons. Examples of low molecular weight PEGs include PEG-200, PEG-400 and PEG-600.

[0128] As used herein, the term "CDK4 / 6 inhibitor" refers to a compound that inhibits the enzymes in humans known as cyclin-dependent kinases (CDK) 4 and 6. Examples of CDK4 / 6 inhibitors include, but are not limited to, SHR6390, treraciclib, lelociclib, AT7519M, denacil, ribociclib, abemaciclib, palbociclib, or any pharmaceutically acceptable salt thereof. In one embodiment, the CDK4 / 6 inhibitor is palbociclib or a pharmaceutically acceptable salt thereof.

[0129] In this disclosure, the articles "a" and "an" are used to refer to one or more than one (ie, at least one) of the grammatical object of the article. For example, "an element" means one element or more than one element.

[0130] In this disclosure, the term "and / or" is used to mean "and" or "or" unless stated otherwise.

[0131] The terms "patient" and "subject" are used interchangeably herein and refer to a mammal, such as a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or a non-human primate, such as a monkey, chimpanzee, baboon, or rhesus monkey.

[0132] In one embodiment, the subject is a human.

[0133] In one embodiment, the subject is a human who has been diagnosed with breast cancer.

[0134] In one embodiment, the subject is a human who has been diagnosed with metastatic breast cancer.

[0135] In one embodiment, the subject is a human who has been diagnosed with ER+, HER2- breast cancer.

[0136] In one embodiment, the subject is a human who has been diagnosed with metastatic ER+, HER2- breast cancer.

[0137] Compounds of formula (I)

[0138] In one aspect, the present application relates to a method for treating and / or preventing cancer, comprising administering a compound of formula (I) to a subject in need thereof.

[0139] In one aspect, the present application relates to the use of a compound of formula (I) in the treatment and / or prevention of breast cancer.

[0140] In one aspect, the present application relates to the use of a compound of formula (I) in the manufacture of a medicament for treating and / or preventing breast cancer.

[0141] As mentioned herein, the compound of formula (I) refers to a compound having the following structure:

[0142] or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative or prodrug thereof, wherein:

[0143] Each R 1 and each R 2 Independently selected from the group consisting of halo, OR5, N(R5)(R6), NO2, CN, SO2(R5), C1-C6 alkyl and C3-C6 cycloalkyl;

[0144] R3 and R4 are both hydrogen or, together with the carbon to which they are attached, form a carbonyl group;

[0145] Each R5 and each R6 are independently selected from the group consisting of hydrogen, C1-C6 alkyl and C3-C6 cycloalkyl;

[0146] m is 0, 1, 2, 3, 4 or 5; and

[0147] n is 0, 1, 2, 3 or 4.

[0148] In one embodiment, each R 1 and each R 2 Independently selected from the group consisting of halo, OR5 and C1-C6 alkyl.

[0149] In one embodiment, R 1 is hydrogen, halo, OR5, N(R5)(R6) or C1-C6 alkyl. 1 In one embodiment, R 1 In one embodiment, R 1 is OR5. In one embodiment, R 1 is N(R5)(R6). In one embodiment, R 1 It is a C1-C6 alkyl group.

[0150] In one embodiment, R 2 is hydrogen, halo, OR5, N(R5)(R6) or C1-C6 alkyl. 2 In one embodiment, R 2 In one embodiment, R 2 is OR5. In one embodiment, R 2 is N(R5)(R6). In one embodiment, R 2 It is a C1-C6 alkyl group.

[0151] In one embodiment, R3 and R4 are both hydrogen.

[0152] In one embodiment, R3 and R4 together with the carbon to which they are attached form a carbonyl group.

[0153] In one embodiment, each R5 and each R6 are independently selected from the group consisting of hydrogen and C1-C6 alkyl. In one embodiment, R5 and R6 are each hydrogen.

[0154] In one embodiment, m is zero.

[0155] In one embodiment, m is 1.

[0156] In one embodiment, m is 2.

[0157] In one embodiment, m is 3.

[0158] In one embodiment, m is 4.

[0159] In one embodiment, m is 5.

[0160] In one embodiment, n is zero.

[0161] In one embodiment, n is 1.

[0162] In one embodiment, n is 2.

[0163] In one embodiment, n is 3.

[0164] In one embodiment, n is 4.

[0165] In one embodiment, m and n are each zero.

[0166] In one embodiment, m is 0 and n is 1.

[0167] In one embodiment, m is 1 and n is 0.

[0168] In one embodiment, m is 1 and n is 1.

[0169] In one embodiment, the compound of formula (I) is selected from the group consisting of:

[0170]

[0171]

[0172] as well as

[0173]

[0174] or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative or prodrug thereof.

[0175] In one embodiment, the compound of formula (I) is a compound of formula (Ia):

[0176] or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative or prodrug thereof.

[0177] In one embodiment, the compound of formula (I) is a compound of formula (Ib):

[0178] or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative or prodrug thereof.

[0179] In one embodiment, the compound of formula (I) is a compound of formula (Ic), ie, compound (Ic) or Cmp(Ic):

[0180] or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative or prodrug thereof.

[0181] In one embodiment, the compound of formula (I) is a compound of formula (Ic), ie, compound (Ic) or Cmp(Ic):

[0182]

[0183] In one embodiment, the compound of formula (I) is a compound of formula (Id):

[0184] or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative or prodrug thereof.

[0185] In one embodiment, the compound of formula (I) is a compound of formula (Ie):

[0186] or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative or prodrug thereof.

[0187] In one embodiment, the compound of formula (I) is a compound of formula (If):

[0188] or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative or prodrug thereof.

[0189] In one embodiment, the compound of formula (I) is a compound of formula (Ig):

[0190] or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative or prodrug thereof.

[0191] In one embodiment, the compound of formula (I) is a compound of formula (Ih):

[0192] or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative or prodrug thereof.

[0193] In one embodiment, the compound of formula (I) is a compound of formula (Ii):

[0194] or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative or prodrug thereof.

[0195] Compounds of formula (I) can be synthesized using standard synthetic methods and procedures for the preparation of organic molecules and functional group transformations and manipulations, including the use of protecting groups, such as can be obtained from the relevant scientific literature or from standard reference textbooks in the field according to the present disclosure. Although not limited to any one or more sources, recognized reference textbooks for organic synthesis include: Smith, MB; March, J., March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5th edition, ed.; John Wiley & Sons: New York, 2001; and Greene, TW; Wuts, PGM Protective Groups in Organic Synthesis, 3rd edition. 版 ; John Wiley & Sons: New York, 1999. Methods for preparing compounds of formula (I) are described in U.S. Patent Application Publication No. 2018 / 0155322 (which issued as U.S. Patent No. 10,647,698), the contents of which are incorporated herein in their entirety.

[0196] For example, compounds (Ib) and (Ic) can be prepared according to the following procedure:

[0197] Synthesis of 3-[5-[4-[[1-[4-[(1R,2S)-6-hydroxy-2-phenyl-tetrahydronaphthalen-1-yl]phenyl]-4-piperidinyl]methyl]piperazin-1-yl]-1-oxo-isoindolin-2-yl]piperidine-2,6-dione (Compound (Ib)):

[0198] Step 1: Preparation of 6-tert-butoxytetralin-1-one

[0199]

[0200] At 0°C, tert-butyl 2,2,2-trichloroacetimidate (67.36 g, 308.29 mmol, 55 mL, 1 eq) and pyridinium p-toluenesulfonate (7.75 g, 30.83 mmol, 0.1 eq) were added to a stirred solution of 6-hydroxytetrahydronaphthalene-1-one (50 g, 308.29 mmol, 1 eq) in anhydrous dichloromethane (2000 mL). The reaction mixture was stirred at 10°C for 3 hours. Another portion of tert-butyl 2,2,2-trichloroacetimidate (67.36 g, 308.29 mmol, 55 mL, 1 eq) and pyridinium p-toluenesulfonate (7.75 g, 30.83 mmol, 0.1 eq) were added, and the reaction mixture was stirred at 10°C for 15 hours. This process was repeated three times. Thin layer chromatography (petroleum ether: ethyl acetate = 3:1, R f =0.8) showed that most of the reactants were still retained, and the reaction mixture was stirred at 10 ° C for 72 hours. The reaction mixture was quenched by adding sodium bicarbonate solution (1500mL) at 15 ° C, and then extracted with dichloromethane (300mL×3). The combined organic layer was washed with brine (300mL×2), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (petroleum ether: ethyl acetate=100:1 to 50:1) to obtain 6-tert-butoxytetrahydronaphthalene-1-one (21g, 96.20mmol, 31% yield) as a yellow oil. 1 HNMR(400MHz, CDCl3) δ7.97(d,J=8.8Hz,1H),6.91(dd,J=2.4,8.8Hz,1H),6.82(d,J=2.0Hz ,1H),2.93-3.90(t,J=6.0Hz,2H),2.63-2.60(m,t,J=6.0Hz,2H),2.13(m,2H),1.43(s,9H).

[0201] Step 2: Preparation of (6-tert-butoxy-3,4-dihydronaphthalen-1-yl) trifluoromethanesulfonate

[0202]

[0203] At -70 ° C, to a solution of 6-tert-butoxytetrahydronaphthalene-1-one (40 g, 183.24 mmol, 1 equivalent) in tetrahydrofuran (500 mL) was added diisopropylamide lithium (2M, 137 mL, 1.5 equivalents). The mixture was stirred at -70 ° C for 1 hour, and then 1,1,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl)methanesulfonamide (72.01 g, 201.56 mmol, 1.1 equivalents) in tetrahydrofuran (200 mL) was added dropwise to the mixture. The reaction mixture was stirred at 20 ° C for 2 hours. Thin layer chromatography (petroleum ether: ethyl acetate = 5: 1) showed that the reaction was complete. Saturated ammonium chloride (300 mL) was added to the mixture and the organic phase was separated. Ethyl acetate (500 mL × 3) was added to the mixture and the resulting mixture was washed with brine (1000 mL × 2). The combined organic phases were dried over sodium sulfate, filtered and concentrated in vacuo. The residue was purified by silica gel chromatography (petroleum ether:ethyl acetate=1:0 to 50:1) to give trifluoromethanesulfonic acid (6-tert-butoxy-3,4-dihydronaphthalen-1-yl) ester (52 g, 144.64 mmol, 78% yield, 97% purity) as a yellow oil. LC-MS (ESI) m / z: 294.9 [M+1-56] + . 1 H-NMR (400MHz, CDCl3) δ: 7.30 (d, J = 6.4Hz, 1H), 6.91 (d, J = 8.4Hz, 1H), 6.84 (s, 1H), 5.95 (s, 1H), 2.93-2.78 (m, 2H), 2.59-2.46 (m, 2H), 1.42 (s, 9H).

[0204] Step 3: Preparation of 4-(6-tert-butoxy-3,4-dihydronaphthalen-1-yl)phenol

[0205]

[0206] To a solution of (6-tert-butoxy-3,4-dihydronaphthalen-1-yl) trifluoromethanesulfonate (52 g, 148.42 mmol, 1 eq.), (4-hydroxyphenyl)boronic acid (24.57 g, 178.11 mmol, 1.2 eq.) in dioxane (800 mL) and water (150 mL) under nitrogen was added potassium carbonate ((41.03 g, 296.84 mmol, 2 eq.) and (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride (10.86 g, 14.84 mmol, 0.1 eq.). The reaction mixture was stirred at 100°C for 10 hours. Thin layer chromatography (Petroleum ether: ethyl acetate = 5: 1) shows that the reaction is complete. The residue is diluted with water (500mL) and extracted with ethyl acetate (500mL×2). The combined organic layer is washed with brine (1000mL×2), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue is purified by silica gel chromatography (petroleum ether: tetrahydrofuran = 50: 1 to 20: 1) to obtain 4- (6-tert-butoxy-3,4-dihydronaphthalen-1-yl) phenol (43g, 131.46mmol, 88% yield, 90% purity) as a yellow oil. LCMS (ESI) m / z: 239.1 [M+1-56] + ; 1 H-NMR (400MHz, CDCl3) δ7.23(d,J=7.6Hz,2H),6.91(d,J=8.0Hz,1H),6.87-6.79(m,3H),6.73(d, J=8.4Hz,1H),5.95(s,1H),4.83-4.75(m,1H),2.87-2.73(m,2H),2.44-2.31(m,2H),1.37(s,9H).

[0207] Step 4: Preparation of 4-(2-bromo-6-tert-butoxy-3,4-dihydronaphthalen-1-yl)phenol

[0208]

[0209] N-bromosuccinimide (489 mg, 2.75 mmol, 0.9 equiv) was added to a solution of 4-(6-tert-butoxy-3,4-dihydronaphthalen-1-yl)phenol (1 g, 3.06 mmol, 1 equiv) in acetonitrile (20 mL) in three portions. The reaction mixture was stirred at 20 ° C for 1.5 hours. LC-MS showed that the reaction was complete. The residue was diluted with water (20 mL) and extracted with ethyl acetate (20 mL×2). The combined organic layers were washed with brine (20 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (petroleum ether: ethyl acetate = 1:0 to 20:1) to obtain 4-(2-bromo-6-tert-butoxy-3,4-dihydronaphthalen-1-yl)phenol (1 g, 2.46 mmol, 80% yield, 91% purity) as a yellow oil. LC-MS (ESI) m / z: 316.9 [M+1-56] + ; 1 H-NMR (400MHz, CDCl3) δ7.12(d,J=8.4Hz,2H),6.90(d,J=8.0Hz,2H),6.77(s,1H ),6.69-6.62(m,1H),6.60-6.53(m,1H),4.86(s,1H),2.96(s,4H),1.35(s,9H).

[0210] Step 5: Preparation of 4-(6-tert-butoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenol

[0211]

[0212] To a solution of 4-(2-bromo-6-tert-butoxy-3,4-dihydronaphthalen-1-yl)phenol (1 g, 2.46 mmol, 1 eq.), phenylboronic acid (314 mg, 2.58 mmol, 1.05 eq.) in dioxane (10 mL) and water (2 mL) was added potassium carbonate (678 mg, 4.91 mmol, 2 eq.) and (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride (179 mg, 0.24 mmol, 0.1 eq.) under nitrogen. The reaction mixture was stirred at 100 °C for 12 hours. LC-MS showed that the reaction was complete. The residue was diluted with water (20 mL) and extracted with ethyl acetate (20 mL x 2). The combined organic layers were washed with brine (20 mL x 3), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified by silica gel chromatography (petroleum ether:ethyl acetate=1:0 to 10:1) to give 4-(6-tert-butoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenol (930 mg, 2.35 mmol, 95% yield, 93% purity) as an orange oil. LCMS (ESI) m / z: 314.1 [M+1-56] + ; 1 H-NMR (400MHz, CDCl3) δ7.16-7.09(m,2H),7.08-6.99(m,3H),6.97-6.89(m,2H),6.86-6.82 (m,1H),6.74-6.66(m,4H),4.70(s,1H),2.99-2.89(m,2H),2.84-2.75(m,2H),1.37(s,9H).

[0213] Step 6: Preparation of 4-(6-tert-butoxy-2-phenyl-tetrahydronaphthalen-1-yl)phenol

[0214]

[0215] Under nitrogen, activated carbon-supported palladium catalyst (100 mg, 10% purity) was added to a solution of 4-(6-tert-butoxy-2-phenyl-3,4-dihydronaphthalene-1-yl)phenol (930 mg, 2.35 mmol, 1 equivalent) in tetrahydrofuran (20 mL) and methanol (4 mL). The suspension was degassed under vacuum and purged with hydrogen three times. The mixture was stirred at 30 ° C for 36 hours under hydrogen (50 psi). LC-MS showed that the reaction was complete. The reaction mixture was filtered and the solution was concentrated. The resulting material was used directly in the next step without further purification to obtain cis-4-(6-tert-butoxy-2-phenyl-tetrahydronaphthalene-1-yl)phenol (870 mg, 2.14 mmol, 91% yield, 91% purity) as a white solid. LC-MS (ESI) m / z: 317.0 [M+1-56] + ; 1 H-NMR (400MHz, CDCl3) δ7.22-7.12(m,3H),6.89-6.78(m,4H),6.74(dd,J=2.0,8.4Hz,1H),6.45(d,J=8.4Hz,2H),6.27(d,J=8.4Hz,2H), 4.51(s,1H),4.25(d,J=4.8Hz,1H),3.38(dd,J=3.2,12.8Hz,1H),3.08-2.99(m,2H),2.27-2.08(m,1H),1.87-1.76(m,1H),1.37(s,9H).

[0216] Step 7: Preparation of 4-[(1S,2R)-6-tert-butoxy-2-phenyl-tetrahydronaphthalen-1-yl]phenol

[0217]

[0218] 4-(6-tert-Butoxy-2-phenyl-tetrahydronaphthalen-1-yl)phenol (870 mg, 2.13 mmol, 1 eq) was subjected to supercritical fluid chromatography for chiral separation (column: AD, 250 mm×30 mm, 5 um; mobile phase: 0.1% ammonium hydroxide in methanol, 20%-20%, 4.2 min per run) to give 4-[(1S,2R)-6-tert-butoxy-2-phenyl-tetrahydronaphthalen-1-yl]phenol (420 mg, 1.04 mmol, 97% yield, 92% purity) as the first fraction and 4-[(1R,2S)-6-tert-butoxy-2-phenyl-tetrahydronaphthalen-1-yl]phenol (420 mg, 1.04 mmol, 97% yield, 92% purity) as the second fraction. Fraction 1: [α] D=+336.9 (C=0.50 g / 100 mL in ethyl acetate, 25°C), LC-MS (ESI) m / z: 395.1 [M+23] + ; 1 H NMR (400 MHz, DMSO-d6) δ 9.02 (s, 1H), 7.20-7.07 (m, 3H), 6.87-6.79 (m, 3H), 6.79-6.72 (m, 1H), 6.71-6.64 (m, 1H), 6.36 (d, J = 8.4 Hz, 2H), 6.15 (d, J = 8.4 Hz, 2H), 4.19 (d, J = 4.8 Hz, 1H), 3.31-3.26 (m, 1H), 3.09-2.89 (m, 2H), 2.17-2.04 (m, 1H), 1.79-1.65 (m, 1H), 1.29 (s, 9H). Fraction 2: [α] D =-334.1 (C = 0.50 g / 100 mL in ethyl acetate, 25 ° C), LC-MS (ESI) m / z: 395.2 [M+23] + ; 1 H-NMR (400MHz, DMSO-d6)δ:9.02(s,1H),7.21-7.06(m,3H),6.88-6.78(m,3H),6.78-6.72(m,1H),6.71-6.64(m,1H),6.36(d,J=8.4Hz,2H ), 6.15 (d, J = 8.4Hz, 2H), 4.19 (d, J = 4.8Hz, 1H), 3.30-3.27 (m, 1H), 3.08-2.90 (m, 2H), 2.16-2.04 (m, 1H), 1.79-1.65 (m, 1H), 1.29 (s, 9H).

[0219] Step 8: Preparation of 1,1,2,2,3,3,4,4,4-nonafluorobutane-1-sulfonic acid 4-(6-benzyloxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenyl]ester

[0220]

[0221] To a solution of 4-[(1R, 2S)-6-tert-butoxy-2-phenyl-tetrahydronaphthalene-1-yl]phenol (1 g, 2.68 mmol, 1 eq) and 1,1,2,2,3,3,4,4,4-nonafluorobutane-1-sulfonyl fluoride (811 mg, 2.68 mmol, 1 eq) in tetrahydrofuran (5 mL) and acetonitrile (5 mL), potassium carbonate (557 mg, 4.03 mmol, 1.5 eq) was added. The reaction mixture was stirred at 25 ° C for 16 hours. TLC (petroleum ether: ethyl acetate = 10: 1) showed that the starting material was completely consumed and a new spot was formed. The reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel chromatography (petroleum ether: ethyl acetate = 1: 0 to 50: 1). The desired compound 1,1,2,2,3,3,4,4,4-nonafluorobutane-1-sulfonic acid [4-[(1R,2S)-6-tert-butoxy-2-phenyl-tetrahydronaphthalen-1-yl]phenyl] ester (1.6 g, 2.44 mmol, 91% yield) was obtained as a colorless oil. 1 H NMR (400MHz, CDCl3) δ7.21-7.11(m,3H),6.94-6.86(m,3H),6.84-6.73(m,4H),6.46(d,J=8.8Hz,2H),4.33 (d,J=5.2Hz,1H),3.50-3.40(m,1H),3.16-2.95(m,2H),2.20-2.02(m,1H),1.91-1.79(m,1H),1.38(s,9H).

[0222] Step 9: Preparation of 1-[4-(6-benzyloxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenyl]-4-(dimethoxymethyl)piperidine

[0223]

[0224] A mixture of 1,1,2,2,3,3,4,4,4-nonafluorobutane-1-sulfonic acid [4-[(1R,2S)-6-tert-butoxy-2-phenyl-tetrahydronaphthalen-1-yl]phenyl]ester (1.6 g, 2.44 mmol, 1 eq), 4-(dimethoxymethyl)piperidine (584 mg, 3.67 mmol, 1.5 eq), sodium tert-butoxide (705 mg, 7.33 mmol, 3 eq), palladium acetate (82 mg, 0.37 mmol, 0.15 eq), and dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (233 mg, 0.49 mmol, 0.2 eq) in toluene (30 mL) was degassed and purged with nitrogen three times, and then the mixture was stirred at 90° C. under nitrogen atmosphere for 16 hours. LC-MS showed one major peak with the desired MS was detected. TLC (petroleum ether: ethyl acetate = 10: 1) shows that the starting material is completely consumed and a new spot is formed. The mixture is cooled, diluted with ethyl acetate (50 mL), filtered on a plug of diatomaceous earth, and the filter cake is washed with ethyl acetate (30 mL). The filtrate is concentrated. The residue is purified by silica gel chromatography (petroleum ether: ethyl acetate = 100: 1 to 10: 1). The desired compound 1- [4- [(1R, 2S) -6- tert-butoxy -2- phenyl - tetrahydronaphthalene -1- base] phenyl] -4- (dimethoxymethyl) piperidine (1.1 g, 2.14 mmol, 87% yield) is obtained as a white solid. LC-MS (ESI) m / z: 514.3 [M + 1] + ; 1 H NMR (400MHz, CDCl3) δ7.21-7.11(m,3H),6.88-6.78(m,4H),6.73(dd,J=2.4,8.0 Hz,1H),6.57(d,J=8.4Hz,2H),6.27(d,J=8.8Hz,2H),4.23(d,J=4.8Hz,1H),4.06 (d,J=7.2Hz,1H),3.63-3.52(m,2H),3.41-3.30(m,7H),3.13-2.96(m,2H),2.54( d,J=2.0,12.0Hz,2H),2.28-2.10(m,1H),1.85-1.63(m,4H),1.49-1.31(m,11H).

[0225] Step 10: Preparation of 1-[4-[(1R,2S)-6-hydroxy-2-phenyl-tetrahydronaphthalen-1-yl]phenyl]piperidine-4-carboxaldehyde

[0226]

[0227] To a solution of 1-[4-[(1R,2S)-6-tert-butoxy-2-phenyl-tetrahydronaphthalen-1-yl]phenyl]-4-(dimethoxymethyl)piperidine (1.1 g, 2.14 mmol, 1 equiv) in tetrahydrofuran (45 mL) was added sulfuric acid (2M, 43 mL, 40 equiv). The reaction mixture was stirred at 70 ° C for 1 hour. LC (petroleum ether: ethyl acetate = 3: 1) indicated that the starting material was completely consumed and a new spot was formed. The reaction mixture was quenched by adding saturated sodium bicarbonate solution to pH = 7-8 and extracted with ethyl acetate (20 mL×2). The combined organic layers were washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was used in the next step without further purification. The desired compound 1-[4-[(1R,2S)-6-hydroxy-2-phenyl-tetrahydronaphthalen-1-yl]phenyl]piperidine-4-carbaldehyde (900 mg, 2.14 mmol, 99% yield, 97% purity) was obtained as a light yellow solid. LCMS MS (ESI) m / z: 412.1 [M+1] +

[0228] Step 11: Preparation of 3-[5-[4-[[1-[4-[(1R,2S)-6-hydroxy-2-phenyl-tetrahydronaphthalen-1-yl]phenyl]-4-piperidinyl]methyl]piperazin-1-yl]-1-oxo-isoindolin-2-yl]piperidine-2,6-dione (Compound (Ib))

[0229]

[0230] To a solution of 3-(1-oxo-5-piperazin-1-yl-isoindolin-2-yl)piperidine-2,6-dione hydrochloride (319 mg, 0.87 mmol, prepared in step 17 described for exemplary compound 62) in methanol (4 mL) and dichloromethane (4 mL) was added sodium acetate (120 mg, 1.46 mmol, 2 eq). The mixture was stirred at 20° C. for 0.5 h, and then 1-[4-[(1R,2S)-6-hydroxy-2-phenyl-tetrahydronaphthalen-1-yl]phenyl]piperidine-4-carbaldehyde (300 mg, 0.73 mmol, 1 eq) and sodium cyanoborohydride (137 mg, 2.19 mmol, 3 eq) were added to the mixture. The mixture was stirred at 20° C. for 12 h. LC-MS showed that the starting material was completely consumed, and one major peak with the desired MW was detected. The reaction mixture was concentrated under reduced pressure. The residue was purified by preparative HPLC (Phenomenex luna C18 column, 250×50 mm, 10 um; mobile phase: [water (0.05% HCl)-acetonitrile]; B%: acetonitrile 10%-40% in 30 minutes). The desired compound 3-[5-[4-[[1-[4-[(1R,2S)-6-hydroxy-2-phenyl-tetrahydronaphthalen-1-yl]phenyl]-4-piperidin]methyl]piperazin-1-yl]-1-oxo-isoindolin-2-yl]piperidine-2,6-dione (288.4 mg, 0.37 mmol, 51% yield) was obtained as a white solid of hydrochloride. LC-MS (ESI) m / z: 724.4 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ10.97 (s, 1H), 10.83 (s, 0.9H, HCl), 7.60 (d, J = 8.5Hz, 1H), 7.40 (br s,2H),7.22-7.11(m,5H),6.83(d,J=6.0Hz,2H),6.69-6.63(m,2H),6.58-6.47(m,3H),5.07(dd,J=5.2,13.2Hz,1H ),4.41-4.30(m,2H),4.28-4.21(m,1H),4.00(d,J=12.7Hz,2H),3.61(d,J=11.0Hz,2H),3.54-3.36(m,6H),3.16(br s,4H),3.06-2.84(m,3H),2.76-2.53(m,1H),2.43-2.33(m,1H),2.27(br s,1H),2.16-2.04(m,3H),2.02-1.69(m,5H).

[0231] Synthesis of (3S)-3-[5-[4-[[1-[4-[(1R,2S)-6-hydroxy-2-phenyl-tetrahydronaphthalen-1-yl]phenyl]-4-piperidinyl]methyl]piperazin-1-yl]-1-oxo-isoindolin-2-yl]piperidine-2,6-dione (Compound (Ic))

[0232] Step 1: Preparation of (4S)-5-amino-4-(benzyloxycarbonylamino)-5-oxo-pentanoic acid tert-butyl ester

[0233]

[0234] A mixture of (2S)-2-(benzyloxycarbonylamino)-5-tert-butoxy-5-oxo-pentanoic acid (20 g, 59.28 mmol, 1.00 equiv), di-tert-butyl dicarbonate (94.85 mmol, 21.79 mL, 1.60 equiv) and pyridine (9.38 g, 118.57 mmol, 9.57 mL, 2.00 equiv) in 1,4-dioxane (200 mL) was degassed at 0°C and purged with nitrogen 3 times, then the mixture was stirred at 0°C under a nitrogen atmosphere for 0.5 hours. Ammonium bicarbonate (14.06 g, 177.85 mmol, 14.65 mL, 3.00 equiv) was added at 0°C. The mixture was stirred at 25°C for 16 hours. LC-MS showed the desired mass. Volatiles were removed under reduced pressure. The residue is diluted with water (300mL), and extracted with ethyl acetate (300mL×1). The combined organic phase is washed with aqueous hydrochloric acid (0.5M, 200mL×2), saturated sodium bicarbonate (300mL×3) and brine (500mL×3), dried over anhydrous sodium sulfate, filtered and concentrated in a vacuum to obtain a crude product. The crude product is ground (petroleum ether: ethyl acetate=10:1, 300mL) to provide tert-butyl (4S) -5- amino -4- (benzyloxycarbonylamino) -5- oxo - valeric acid (19g, 56.08mmol, 94% yield, 99% purity) as a white solid. LC-MS (ESI) m / z:359.0 [M+23] + . 1 H-NMR (400MHz, CDCl3) δ7.39-7.29(m,5H),6.38(s,1H),5.74(d,J=7.2Hz,1H),5.58(s,1H),5.11(s,2H),4.2 5(d,J=5.6Hz,1H),2.55-2.41(m,1H),2.39-2.27(m,1H),2.18-2.04(m,1H),2.02-1.85(m,1H),1.45(s,9H).

[0235] Step 2: Preparation of (4S)-4,5-diamino-5-oxo-pentanoic acid tert-butyl ester

[0236]

[0237] Under nitrogen atmosphere, to a solution of (4S)-5-amino-4-(benzyloxycarbonylamino)-5-oxo-pentanoic acid tert-butyl ester (19g, 56.48mmol, 1.00 equivalent) in methanol (200mL) was added palladium on carbon (2g, 10%). The suspension was degassed and purged with hydrogen 3 times. The mixture was stirred at 25 ° C for 16 hours under H2 (50psi). Thin layer chromatography (petroleum ether: ethyl acetate = 1: 2) showed that the reaction was complete. The reaction mixture was filtered and the filtrate was concentrated. Compound (4S)-4,5-diamino-5-oxo-pentanoic acid tert-butyl ester (11g, 54.39mmol, 96% yield) was obtained as a light green oil. 1 H NMR(400MHz, CDCl3)δ7.03(br s,1H),5.55(br s,1H),3.44(br s,1H),2.49-2.31(m,2H),2.11(dd,J=6.0,12.8Hz,1H),1.92-1.76(m,1H),1.66(s,2H),1.45(s,9H).

[0238] Step 3: Preparation of 4-[2-[(1S)-4-tert-butoxy-1-carbamoyl-4-oxo-butyl]-1-oxo-isoindolin-5-yl]piperazine-1-carboxylic acid tert-butyl ester

[0239]

[0240] To a solution of tert-butyl 4-[3-(bromomethyl)-4-methoxycarbonyl-phenyl]piperazine-1-carboxylate (1.5 g, 3.63 mmol, 1 equivalent, prepared in step 15, exemplary compound 62 in U.S. Patent Application Publication No. 2018 / 0155322) in acetonitrile (30 mL), (4S)-tert-butyl 4,5-diamino-5-oxo-pentanoate (1.10 g, 5.44 mmol, 1.5 equivalents) and diisopropylethylamine (1.41 g, 10.89 mmol, 1.90 mL, 3 equivalents) were added. The mixture was stirred at 80 ° C for 12 hours. LC-MS showed that the reaction was complete. The mixture was diluted with water (30 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (30 mL × 2), dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated in vacuo. The residue was purified by preparative reverse phase HPLC (column: Phenomenex Synergi Max-RP 250×50 mm, 10 microns; mobile phase: [water (0.225% formic acid)-acetonitrile]; B%: 40 acetonitrile%-70 acetonitrile% in 30 minutes) to provide 4-[2-[(1S)-4-tert-butoxy-1-carbamoyl-4-oxo-butyl]-1-oxo-isoindolin-5-yl]piperazine-1-carboxylic acid tert-butyl ester (1.6 g, 2.94 mmol, 81.05% yield, 92% purity) as an off-white solid. LC-MS (ESI) m / z: 503.2 [M+1] + .

[0241] Step 4: Preparation of (3S)-3-(1-oxo-5-(piperazin-1-yl-isoindolin-2-yl)piperidine-2,6-dione

[0242]

[0243] To a solution of tert-butyl 4-[2-[(1S)-4-tert-butoxy-1-carbamoyl-4-oxo-butyl]-1-oxo-isoindolin-5-yl]piperazine-1-carboxylate (700 mg, 1.39 mmol, 1 eq) in acetonitrile (15 mL) was added benzenesulfonic acid (440 mg, 2.79 mmol, 2 eq). The mixture was stirred at 85 ° C for 12 hours. LC-MS showed that the reaction was complete. The mixture was concentrated in vacuo. The residue was triturated with ethyl acetate (30 mL×3) to give (3S)-3-(1-oxo-5-piperazine-1-yl-isoindolin-2-yl)piperidine-2,6-dione (630 mg, crude) as a gray solid. LC-MS (ESI) m / z: 329.1[M+1] + ; 100% ee from chiral SFC analysis.

[0244] Step 5: Preparation of (3S)-3-[5-[4-[[1-[4-[(1R,2S)-6-hydroxy-2-phenyl-tetrahydronaphthalen-1-yl]phenyl]-4-piperidinyl]methyl]piperazin-1-yl]-1-oxo-isoindolin-2-yl]piperidine-2,6-dione (Compound (Ic))

[0245]

[0246] To a mixture of (3S)-3-(1-oxo-5-piperazin-1-yl-isoindolin-2-yl)piperidine-2,6-dione (1.30 g, 3.47 mmol, 1 eq., benzenesulfonate) in dichloromethane (8 mL) and methanol (32 mL) at 20°C was added a portion of sodium acetate (854 mg, 10.41 mmol, 3 eq.). The mixture was stirred at 20°C for 10 minutes. Then 1-[4-[(1R,2S)-6-hydroxy-2-phenyl-tetrahydronaphthalen-1-yl]phenyl]piperidine-4-carbaldehyde (1 g, 2.43 mmol, 0.7 eq., which was prepared as described above in the synthesis of compound (Ib)) was added. The mixture was stirred at 20°C for 10 minutes. After this, a portion of acetic acid (0.2 mL) and sodium cyanoborohydride (436 mg, 6.94 mmol, 2 eq.) were added. The mixture was stirred at 20 ° C for 40 minutes. The mixture was concentrated in vacuo, and 50 mL of tetrahydrofuran and 20 mL of water were added. The mixture was stirred for 20 minutes. Saturated aqueous sodium bicarbonate solution was added to adjust the pH to 8-9. The aqueous phase was extracted with ethyl acetate and tetrahydrofuran (v:v=2:1, 60 mL×3). The combined organic phase was washed with brine (60 mL×1), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified by preparative reverse phase HPLC (column: Phenomenex luna C18 250×50 mm, 10 microns; mobile phase: [water (0.225% formic acid)-acetonitrile]; B%: 20%-50%, within 30 minutes). The product (3S)-3-[5-[4-[[1-[4-[(1R,2S)-6-hydroxy-2-phenyl-tetrahydronaphthalen-1-yl]phenyl]-4-piperidinyl]methyl]piperazin-1-yl]-1-oxo-isoindolin-2-yl]piperidine-2,6-dione (964 mg, 1.23 mmol, 35% yield, 98% purity, formate salt) was obtained as a white solid as formate salt after lyophilization. The chiral purity was analyzed by chiral SFC (Chiralcel OJ-3 50×4.6 mm, 3 microns; mobile phase: 50% ethanol (0.05% DEA) in CO2; flow rate: 3 mL / min, wavelength: 220 nm) and t p = 2.89 minutes, where de exceeds 95%. D=-267.5 (c = 0.2 in DMF, 25°C). LC-MS (ESI) m / z: 724.2 [M+1] + . 1 HNMR (400MHz, DMSO-d6) δ10.94(s,1H),8.16(s,1H,formate),7.51(d,J=8.8Hz,1H),7.21-6.98(m,5H),6.83(d,J=6.4Hz,2H),6.68-6.57(m,2H),6.56 -6.44(m,3H),6.20(d,J=8.8Hz,2H),5.04(dd,J=5.2,13.2Hz,1H),4.32(d,J=16.8Hz,1H),4.19(d,J=17.2Hz,1H),4.12(d,J=4.8Hz,1H),3.51(br d,J=10.0Hz,4H),3.27(br s,8H),3.03-2.82(m,3H),2.63-2.54(m,1H),2.43-2.28(m,2H),2.19(d,J=6.8Hz ,2H),2.15-2.02(m,1H),2.01-1.89(m,1H),1.83-1.51(m,4H),1.28-1.04(m,2H).

[0247] Free non-salt form 1 H-NMR: (400MHz, DMSO-d6) δ10.93(s,1H),9.09(s,1H),7.51(d,J=8.8Hz,1H),7.18-7.09(m,3H),7.08-7.02(m,2H),6.83(d,J=6.4Hz,2H),6 .64(d,J=8.4Hz,1H),6.60(d,J=2.0Hz,1H),6.53(d,J=8.8Hz,2H),6.48(dd,J=2.4,8.4Hz,1H),6.20(d,J=8.8Hz,2H),5.04(dd,J=5.2,13.2 Hz,1H),4.39-4.27(m,1H),4.24-4.15(m,1H),4.12(d,J=4.8Hz,1H),3.51(d,J=9.6Hz,2H),3.29-3.24(m,5H),3.03-2.83(m,3H),2.62-2.5 4(m,4H),2.52(s,3H),2.41-2.36(m,1H),2.19(d,J=7.2Hz,2H),2.15- 2.08(m,1H),2.00-1.89(m,1H),1.81-1.58(m,4H),1.22-1.06(m,2H).

[0248] Pabocini

[0249] Palbociclib, also known as 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one, has the following structural formula:

[0250]

[0251] Palbociclib is an inhibitor of cyclin-dependent kinases (CDKs) 4 and 6. Cyclin D1 and CDK4 / 6 are downstream of signaling pathways that lead to cell proliferation. In vitro, palbociclib reduced cell proliferation of estrogen receptor (ER)-positive breast cancer cell lines by blocking cells from entering the S phase of the cell cycle from G1. Treatment of breast cancer cell lines with a combination of palbociclib and antiestrogen resulted in reduced retinoblastoma (Rb) protein phosphorylation, resulting in reduced E2F expression and signaling, and increased growth arrest compared to treatment with each drug alone. In vitro treatment of ER-positive breast cancer cell lines with a combination of palbociclib and antiestrogen resulted in increased cellular senescence compared to each drug alone, which lasted up to 6 days after palbociclib removal, and longer if anti-estrogen treatment was continued. In vivo studies using patient-derived ER-positive breast cancer xenograft models confirmed that the combination of palbociclib with letrozole increased inhibition of Rb phosphorylation, downstream signaling, and tumor growth compared to each drug alone.

[0252] Human bone marrow mononuclear cells treated with palbociclib in the presence or absence of antiestrogens in vitro did not undergo senescence and resumed proliferation after cessation of palbociclib.

[0253] In one embodiment, the present application relates to any method for treating and / or preventing breast cancer disclosed herein, wherein the method comprises co-administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of a CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof to a subject in need thereof, or co-administering a therapeutically effective amount of a compound of formula (Ic) or a pharmaceutically acceptable salt thereof and a CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof to a subject in need thereof. In one embodiment, the compound of formula (Ic) is a free base or a pharmaceutically acceptable salt thereof. In one embodiment, the CDK4 / 6 inhibitor is a free base or a pharmaceutically acceptable salt thereof. In one embodiment, the CDK4 / 6 inhibitor is palbociclib or a pharmaceutically acceptable salt thereof. In one embodiment, the CDK4 / 6 inhibitor is palbociclib dihydrochloride. The dihydrochloride salt of palbociclib can be prepared, for example, by reacting palbociclib free base in an ether solution of hydrogen chloride. Palbociclib was developed by Pfizer and marketed under the trade name A commercially available drug marketed for the treatment of breast cancer.

[0254] Methods for ubiquitination / degradation of target proteins in cells

[0255] The present invention provides a method for ubiquitinating / degrading a target protein (e.g., an intracellular target protein) in a cell. The method comprises applying a bifunctional compound, the bifunctional compound comprising an E3 ubiquitin ligase binding portion and a protein targeting portion preferably connected by a linker portion, wherein the E3 ubiquitin ligase binding portion recognizes ubiquitin pathway proteins (e.g., ubiquitin ligase, preferably E3 ubiquitin ligase), and the protein targeting portion recognizes the target protein (e.g., an intracellular target protein) so that when the target protein is placed near the E3 ubiquitin ligase, ubiquitination of the target protein occurs, causing the target protein to be degraded by the proteasome pathway and affecting the control (e.g., reduction) of the target protein level. In one embodiment, the protein targeting portion is bound to a nuclear hormone receptor. In certain embodiments, the protein targeting portion is bound to an estrogen receptor or an estrogen-related receptor. In one embodiment, the intracellular target protein is an estrogen receptor or an estrogen-related receptor. In one embodiment, the linker portion is a bond or chemical group that covalently couples the protein targeting portion to the E3 ubiquitin ligase binding portion. In certain embodiments, the linker may comprise one or more alkanes and one or more heterocyclic moieties. In certain embodiments, the alkane is a C1-C6 alkyl group and the heterocyclic moiety is pyrrolidine, imidazolidine, piperidine or piperazine. In one embodiment, the E3 ubiquitin ligase is cereblon. In certain embodiments, the cereblon binding moiety is thalidomide, lenalidomide, pomalidomide, an analog thereof, an isostere thereof or a derivative thereof. The control (e.g., reduction) of protein levels provided by the present invention provides treatment of a disease state or condition that is regulated by a target protein by reducing the level of the protein in the patient's cells.

[0256] In one embodiment, the present invention relates to a method of treating a disease state or condition causally related to a protein in a patient in need thereof, wherein degradation of the protein will produce a therapeutic effect in the patient, the method comprising administering to the patient in need thereof an effective amount of a compound according to the present invention, optionally in combination with another biologically active agent. The disease state or condition may be a disease state or condition causally related to the expression or overexpression of the protein.

[0257] Treatment

[0258] In one aspect, the present application relates to a method for treating and / or preventing cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative or prodrug thereof.

[0259] The methods of treating cancer described herein include a reduction in tumor size.Alternatively or additionally, the cancer is a metastatic cancer, and the method of treating includes inhibiting invasion of metastatic cancer cells.

[0260] In one embodiment, the cancer is breast cancer.

[0261] In one embodiment, the breast cancer is metastatic breast cancer.

[0262] In one embodiment, the breast cancer is locally advanced breast cancer.

[0263] In one embodiment, the breast cancer is ER+, HER2- breast cancer.

[0264] In one embodiment, the breast cancer is metastatic ER+, HER2- breast cancer.

[0265] In one embodiment, the breast cancer is metastatic ER+, HER2- breast cancer that is also locally advanced.

[0266] In one aspect, the present application relates to treating breast cancer with a compound of formula (I), wherein the compound of formula (I) refers to a compound having the following structure:

[0267] or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative or prodrug thereof, wherein R 1 , R 2 , R3, R4, m and n are defined herein. In one embodiment, the breast cancer is metastatic breast cancer. In one embodiment, the breast cancer is locally advanced breast cancer. In one embodiment, the breast cancer is ER+, HER2-. In one embodiment, the breast cancer is metastatic ER+, HER2- breast cancer. In one embodiment, the breast cancer is locally advanced metastatic ER+, HER2- breast cancer.

[0268] In one aspect, the present application relates to treating breast cancer with a compound of formula (I), wherein the compound of formula (I) is selected from the group consisting of:

[0269]

[0270]

[0271]

[0272] or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative or prodrug thereof. In one embodiment, the compound of formula (I) is a compound of formula (Ic). In one embodiment, the breast cancer is metastatic breast cancer. In one embodiment, the breast cancer is locally advanced breast cancer. In one embodiment, the breast cancer is ER+, HER2-. In one embodiment, the breast cancer is metastatic ER+, HER2- breast cancer. In one embodiment, the breast cancer is locally advanced metastatic ER+, HER2- breast cancer.

[0273] In one aspect, treating cancer results in a decrease in tumor size. A decrease in tumor size may also be referred to as "tumor regression." Preferably, after treatment, the tumor size decreases by 5% or more relative to its size before treatment; more preferably, the tumor size decreases by 10% or more; more preferably, by 20% or more; more preferably, by 30% or more; more preferably, by 40% or more; even more preferably, by 50% or more; and most preferably, by greater than 75% or more. Tumor size can be measured by any reproducible means of measurement. In a preferred aspect, tumor size can be measured as the diameter of the tumor.

[0274] In another aspect, treating cancer results in a decrease in tumor volume. Preferably, after treatment, the tumor volume is reduced by 5% or more relative to its size before treatment; more preferably, the tumor volume is reduced by 10% or more; more preferably, by 20% or more; more preferably, by 30% or more; more preferably, by 40% or more; even more preferably, by 50% or more; and most preferably, by greater than 75% or more. Tumor volume can be measured by any reproducible means of measurement.

[0275] In another aspect, treating cancer results in a reduction in the number of tumors. Preferably, after treatment, the number of tumors is reduced by 5% or more relative to the number before treatment; more preferably, the number of tumors is reduced by 10% or more; more preferably, by 20% or more; more preferably, by 30% or more; more preferably, by 40% or more; even more preferably, by 50% or more; and most preferably, by greater than 75%. The number of tumors can be measured by any reproducible measurement means. In a preferred aspect, the number of tumors can be measured by counting tumors visible to the naked eye or visible at a specified magnification. In a preferred aspect, the specified magnification is 2x, 3x, 4x, 5x, 10x or 50x.

[0276] In another aspect, treating cancer results in a reduction in the number of metastatic lesions in other tissues or organs away from the primary tumor site. Preferably, after treatment, the number of metastatic lesions is reduced by 5% or more relative to the number before treatment; more preferably, the number of metastatic lesions is reduced by 10% or more; more preferably, by 20% or more; more preferably, by 30% or more; more preferably, by 40% or more; even more preferably, by 50% or more; and most preferably, by greater than 75%. The number of metastatic lesions can be measured by any reproducible measurement means. In a preferred aspect, the number of metastatic lesions can be measured by counting metastatic lesions visible to the naked eye or visible at a specified magnification. In a preferred aspect, the specified magnification is 2x, 3x, 4x, 5x, 10x or 50x.

[0277] In another aspect, treating cancer results in an increase in the average survival time of a population of treated subjects compared to a population receiving only the vehicle. Preferably, the average survival time is increased by more than 30 days; more preferably, more than 60 days; more preferably, more than 90 days; and most preferably, more than 120 days. The increase in the average survival time of a population can be measured by any reproducible means. In a preferred aspect, the increase in the average survival time of a population can be measured, for example, by calculating the average survival length of a population after starting treatment with an active agent or compound. In another preferred aspect, the increase in the average survival time of a population can also be measured, for example, by calculating the average survival length of a population after completing a first round of treatment with an active agent or compound.

[0278] In another aspect, treating cancer results in an increase in the average survival time of a population of treated subjects compared to a population of untreated subjects. Preferably, the average survival time increases by more than 30 days; more preferably, more than 60 days; more preferably, more than 90 days; and most preferably, more than 120 days. The increase in the average survival time of a population can be measured by any reproducible means. In a preferred aspect, the increase in the average survival time of a population can be measured, for example, by calculating the average survival length of a population after starting treatment with an active agent or compound. In another preferred aspect, the increase in the average survival time of a population can also be measured, for example, by calculating the average survival length of a population after completing the first round of treatment with a compound of formula (I).

[0279] In another aspect, treating cancer results in a reduction in tumor growth rate. Preferably, after treatment, the tumor growth rate is reduced by at least 5% relative to the number before treatment; more preferably, the tumor growth rate is reduced by at least 10%; more preferably, by at least 20%; more preferably, by at least 30%; more preferably, by at least 40%; more preferably, by at least 50%; even more preferably, by at least 50%; and most preferably, by at least 75%. Tumor growth rate can be measured by any reproducible means of measurement. In a preferred aspect, tumor growth rate is measured based on the change in tumor diameter per unit time.

[0280] In another aspect, treating cancer results in a reduction in tumor regrowth. Preferably, after treatment, tumor regrowth is less than 5%; more preferably, tumor regrowth is less than 10%; more preferably, less than 20%; more preferably, less than 30%; more preferably, less than 40%; more preferably, less than 50%; even more preferably, less than 50%; and most preferably, less than 75%. Tumor regrowth can be measured by any reproducible means of measurement. In a preferred aspect, tumor regrowth is measured, for example, by measuring an increase in the diameter of a tumor following a previous tumor reduction following treatment. In another preferred aspect, a reduction in tumor regrowth is indicated by a failure of tumor recurrence following cessation of treatment.

[0281] The dosage of the compound of formula (I) for any of the methods and uses described herein varies according to the agent, the age, weight and clinical condition of the recipient subject, and the experience and judgment of the clinician or practitioner administering the therapy, as well as other factors that influence the selected dosage.

[0282] A therapeutically effective amount of a compound of formula (I) may be administered once, twice, three times, four times, five times or more in a day for 5, 10, 15, 30, 60, 90, 120, 150, 180 or more days, followed by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or more days of discontinuation of the compound of formula (I). This type of treatment schedule, i.e., administration of a compound of formula (I) on consecutive days followed by discontinuation of the compound of formula (I) on consecutive days, may be referred to as a treatment cycle.

[0283] In one embodiment, a therapeutically effective amount of a compound of Formula (I) may be administered once or twice a day for up to 5, 10, 15, 20, 25, or 30 days, followed by 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days off of the compound of Formula (I).

[0284] In one embodiment, a therapeutically effective amount of a compound of Formula (I) may be administered once daily for up to 5, 10, 15, 20, 25, or 30 days, followed by 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days off of the compound of Formula (I).

[0285] In one embodiment, a treatment cycle involving a compound of formula (I) may be repeated as many times as necessary to achieve the desired effect.

[0286] In one embodiment, the therapeutically effective amount of the compound of formula (I) is 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55 2,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93, 94,95,96,97,98,99,100,105,110,115,120,125,130,135,140,145,150,155,160,165,170,175,180,185,190,195,200,205,210,215,220,225,230 ,235,240,245,250,255,260,265,270,275,280,285,290,295,300,305,310,315,320,325,330,335,340,345,350,355,360,365,370,375,380,385, 390,395,400,405,410,415,420,425,430,435,440,445,450,455,460,465,470,475,480,485,490,495,500,505,510,515,520,525,530,535,540,5 45,550,555,560,565,570,575,580,585,590,595,600,605,610,615,620,625,630,635,640,645,650,655,660,665,670,675,680,685,690,695,70 0,705,710,715,720,725,730,735,740,745,750,755,760,765,770,775,780,785,790,795,800,805,810,815,820,825,830,835,840,845,850,855,860,865,870,875,880,885,890,895,900,905,910,915,920,925,930,935,940,945,950,955,960,965,970,975,980,985,990,995 or 1,000 mg, administered once, twice, three times, four times or more daily in a single dose or divided doses for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 30 consecutive days, or for 2, 3, 4, 5, 6 months or longer. ,

[0287] In one embodiment, the therapeutically effective amount of the compound of formula (I) is about 30 mg, about 60 mg, about 90 mg, about 120 mg, about 150 mg, about 180 mg, about 210 mg, about 240 mg, about 270 mg, about 300 mg, about 330 mg, about 360 mg, about 390 mg, about 420 mg, about 450 mg, about 480 mg, about 510 mg, about 540 mg, about 570 mg, about 600 mg, about 630 mg, about 660 mg, about 690 mg, about 720 mg, about 750 mg, about 780 mg, about 810 mg, about 840 mg, about 870 mg, about 900 mg, about 930 mg, about 960 mg or about 990 mg, which can be administered in a single dose or divided doses (the dose can be based on the patient's weight (kg), body surface area (m 2 ) and age (years)) once, twice, three times, four times or more per day.

[0288] In one embodiment, the therapeutically effective amount of the compound of formula (I) is about 30 mg to about 1000 mg, which is administered in a single dose or divided doses (the dose can be based on the patient's body weight (kg), body surface area (m 2 ) and age (years)) once, twice, three times, four times or more per day.

[0289] In one embodiment, the therapeutically effective amount of the compound of formula (I) is about 10 to about 40 mg, about 20 to about 50 mg, about 30 to about 60 mg, about 40 to about 70 mg, about 50 to about 80 mg, about 60 to about 90 mg, about 70 to about 100 mg, about 80 to about 110 mg, about 90 to about 120 mg, about 100 to about 130 mg, about 110 to about 140 mg, about 120 to about 150 mg, about 130 to about 160 mg, about 140 to about 170 mg, about 150 to about 180 mg, about 160 to about 190 mg, about 170 to about 200 mg, about 180 to about 210 mg, about 190 to about 220 mg, about 200 to about 230 mg, about 210 to about 240 mg, about 220 to about 250 mg, about 230 to about 260 mg, about 240 to about 270 mg, about 250 to about 280 mg, about 260 to about 290 mg, about 270 to about 300 mg, about 280 to about 310 mg, about 290 to about 320 mg, about 300 to about 330 mg, about 310 to about 340 mg, about 320 to about 350 mg, about 330 to about 360 mg, about 340 to about 370 mg, about 350 to about 380 mg, about 360 to about 390 mg, about 370 to about 400 mg, about 380 to about 410 mg, about 390 to about 420 mg, about 400 to about 430 mg, about 410 to about 440 mg 0 mg, about 420 to about 450 mg, about 430 to about 460 mg, about 440 to about 470 mg, about 450 to about 480 mg, about 460 to about 490 mg, about 470 to about 500 mg, about 480 to about 510 mg, about 490 to about 520 mg, about 500 to about 530 mg, about 510 to about 540 mg, about 520 to about 550 mg, about 530 to about 560 mg, about 540 to about 570 mg, about 550 to about 580 mg, about 560 to about 590 mg, about 570 to about 600 mg, about 580 to about 610 mg, about 590 to about 620 mg, about 600 to about 630 mg, about 610 to about 640 mg, about 620 about 750 to about 780 mg, about 760 to about 790 mg, about 770 to about 800 mg, about 780 to about 810 mg, about 790 to about 820 mg, about 800 to about 830 mg, about 810 to about 840 mg, about 820 to about 850 mg,about 830 to about 860 mg, about 840 to about 870 mg, about 850 to about 880 mg, about 860 to about 890 mg, about 870 to about 900 mg, about 880 to about 910 mg, about 890 to about 920 mg, about 900 to about 930 mg, about 910 to about 940 mg, about 920 to about 950 mg, about 930 to about 960 mg, about 940 to about 970 mg, about 950 to about 980 mg, about 960 to about 990 mg, or about 970 to about 1,000 mg, in a single dose or divided doses (the dose can be based on the patient's weight (kg), body surface area (m2), 2 ) and age (years)) once, twice, three times, four times or more per day.

[0290] The therapeutically effective amount of the compound of formula (I) can also be in the range of about 0.01mg / kg / day to about 100mg / kg / day. In one aspect, the therapeutically effective amount of the compound of formula (I) can be in the range of about 0.05mg / kg / day to about 10mg / kg / day. In one aspect, the therapeutically effective amount of the compound of formula (I) can be in the range of about 0.075mg / kg / day to about 5mg / kg / day. In one aspect, the therapeutically effective amount of the compound of formula (I) can be in the range of about 0.10mg / kg / day to about 1mg / kg / day. In one aspect, the therapeutically effective amount of the compound of formula (I) can be in the range of about 0.20mg / kg / day to about 0.70mg / kg / day.

[0291] In one embodiment, the therapeutically effective amount of the compound of Formula (I) is about 0.10 mg / kg / day, about 0.15 mg / kg / day, about 0.20 mg / kg / day, about 0.25 mg / kg / day, about 0.30 mg / kg / day, about 0.35 mg / kg / day, about 0.40 mg / kg / day, about 0.45 mg / kg / day, about 0.50 mg / kg / day, about 0.55 mg / kg / day, about 0.60 mg / kg / day, about 0.65 mg / kg / day, about 0.70 mg / kg / day, about 0.75 mg / kg / day, about 0.80 mg / kg / day, about 0.85 mg / kg / day, about 0.90 mg / kg / day, about 0.95 mg / kg / day, or about 1.00 mg / kg / day.

[0292] In one embodiment, the therapeutically effective amount of the compound of Formula (I) is about 1.05 mg / kg / day, about 1.10 mg / kg / day, about 1.15 mg / kg / day, about 1.20 mg / kg / day, about 1.25 mg / kg / day, about 1.30 mg / kg / day, about 1.35 mg / kg / day, about 1.40 mg / kg / day, about 1.45 mg / kg / day, about 1.50 mg / kg / day, about 1.55 mg / kg / day, about 1.60 mg / kg / day, about 1.65 mg / kg / day, about 1.70 mg / kg / day, about 1.75 mg / kg / day, about 1.80 mg / kg / day, about 1.85 mg / kg / day, about 1.90 mg / kg / day, about 1.95 mg / kg / day, or about 2.00 mg / kg / day.

[0293] In one embodiment, the therapeutically effective amount of the compound of Formula (I) is about 2 mg / kg / day, about 2.5 mg / kg / day, about 3 mg / kg / day, about 3.5 mg / kg / day, about 4 mg / kg / day, about 4.5 mg / kg / day, about 5 mg / kg / day, about 5.5 mg / kg / day, about 6 mg / kg / day, about 6.5 mg / kg / day, about 7 mg / kg / day, about 7.5 mg / kg / day, about 8.0 mg / kg / day, about 8.5 mg / kg / day, about 9.0 mg / kg / day, about 9.5 mg / kg / day, or about 10 mg / kg / day.

[0294] In one embodiment, the compound of formula (I) of a therapeutically effective amount is applied to the subject once a day. In one embodiment, the daily dose of the compound of formula (I) is applied to the subject in one go. In one embodiment, the daily dose of the compound of formula (I) is applied to the subject in two parts (divided doses). In one embodiment, the daily dose of the compound of formula (I) is applied to the subject in three parts. In one embodiment, the daily dose of the compound of formula (I) is applied to the subject in four parts. In one embodiment, the daily dose of the compound of formula (I) is applied to the subject in five or more parts. In one embodiment, these parts are applied to the subject at regular intervals throughout the day, for example, every 12 hours, every 8 hours, every 6 hours, every 5 hours, every 4 hours, etc.

[0295] In one embodiment, the therapeutically effective amount of the compound of Formula (I) results in greater than about 3,500 ng*hr / mL, about 3,550 ng*hr / mL, about 3,600 ng*hr / mL, about 3,650 ng*hr / mL, about 3,700 ng*hr / mL, about 3,750 ng*hr / mL, about 3,800 ng*hr / mL, about 3,850 ng*hr / mL, about 3,900 ng*hr / mL, about 3,950 ng*hr / mL, about 4,000 ng*hr / mL, about 4,050 ng*hr / mL, about 4,100 ng*hr / mL, about 4,150 ng*hr / mL, about 4,200 ng*hr / mL The mean day 15 AUC of about 4,250 ng*hr / mL, about 4,300 ng*hr / mL, about 4,350 ng*hr / mL, 4,400 ng*hr / mL, about 4,450 ng*hr / mL, about 4,500 ng*hr / mL, about 4,550 ng*hr / mL, about 4,600 ng*hr / mL, about 4,650 ng*hr / mL, about 4,700 ng*hr / mL, about 4,750 ng*hr / mL, about 4,800 ng*hr / mL, about 4,850 ng*hr / mL, about 4,900 ng*hr / mL, about 4,950 ng*hr / mL, or about 5,000 ng*hr / mL. TAU .

[0296] In one embodiment, a therapeutically effective amount of a compound of Formula (I) results in a mean C max greater than about 150 ng / mL, about 155 ng / mL, about 160 ng / mL, about 165 ng / mL, about 170 ng / mL, about 175 ng / mL, about 180 ng / mL, about 185 ng / mL, about 190 ng / mL, about 195 ng / mL, about 200 ng / mL, about 205 ng / mL, about 210 ng / mL, about 215 ng / mL, about 220 ng / mL, about 225 ng / mL, about 230 ng / mL, about 235 ng / mL, about 240 ng / mL, about 245 ng / mL, about 250 ng / mL, about 255 ng / mL, about 260 ng / mL, about 265 ng / mL, about 270 ng / mL, about 275 ng / mL, about 280 ng / mL, about 285 ng / mL, about 290 ng / mL, about 295 ng / mL, about 300 ng / mL, about 305 ng / mL, about 310 ng / mL, about 315 ng / mL, about 320 ng / mL, about 325 ng / mL, about 330 ng / mL, about 335 ng / mL, about 340 ng / mL, about 345 ng / mL or about 350 ng / mL.

[0297] The therapeutically effective amount of a compound of formula (I) can be initially estimated in cell culture assays or in animal models (usually rats, mice, rabbits, dogs or pigs). Animal models can also be used to determine appropriate concentration ranges and routes of administration. Such information can then be used to determine useful doses and routes for administration in humans. Therapeutic / prophylactic efficacy and toxicity can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, such as ED 50 (the dose that is therapeutically effective in 50% of the population) and LD 50 (the dose lethal to 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, and it can be expressed as LD 50 / ED 50 Ratio. Pharmaceutical compositions that exhibit large therapeutic indices are preferred. The dosage may vary within this range depending on the dosage form employed, sensitivity of the patient, and route of administration.

[0298] Dosage and administration are adjusted to provide sufficient levels of the compound of formula (I) or to maintain the desired effect. Factors that may be considered include the severity of the disease state, the general health of the subject, the age, weight and sex of the subject, diet, the time and frequency of administration, drug combination, reaction sensitivity and tolerance / response to therapy. Long-acting pharmaceutical compositions may be administered once every 3 to 4 days, weekly or biweekly, depending on the half-life and clearance rate of the particular formulation.

[0299] A method of treating comprising administering a compound of formula (I) and a CDK4 / 6 inhibitor

[0300] In one aspect, the present application relates to a method for treating and / or preventing breast cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I) and a therapeutically effective amount of a CDK4 / 6 inhibitor. These methods include a reduction in tumor size. Alternatively or in addition, breast cancer is metastatic breast cancer, and the method of treatment includes inhibiting invasion of metastatic cancer cells. In one embodiment, breast cancer is metastatic breast cancer. In one embodiment, breast cancer is locally advanced breast cancer. In one embodiment, breast cancer is ER+, HER2-. In one embodiment, breast cancer is metastatic ER+, HER2- breast cancer. In one embodiment, breast cancer is locally advanced metastatic ER+, HER2- breast cancer. In one embodiment, breast cancer is locally advanced metastatic ER+, HER2- breast cancer.

[0301] In one embodiment, a therapeutically effective amount of a compound of Formula (I) and a therapeutically effective amount of a CDK4 / 6 inhibitor are administered simultaneously (in the same formulation or in separate formulations).

[0302] In one embodiment, a therapeutically effective amount of a compound of formula (I) and a therapeutically effective amount of a CDK4 / 6 inhibitor are administered sequentially, i.e., the compound of formula (I) is administered first, followed by the CDK4 / 6 inhibitor; or the CDK4 / 6 inhibitor is administered first, followed by the compound of formula (I). In one embodiment, the CDK4 / 6 inhibitor is administered first, followed by the compound of formula (I) one hour later.

[0303] In one embodiment, a therapeutically effective amount of a compound of Formula (I) and a therapeutically effective amount of a CDK4 / 6 inhibitor are administered close in time.

[0304] In some embodiments, "time proximity" means that the administration of the compound of formula (I) occurs within a certain period of time before or after the administration of the CDK inhibitor (e.g., Palbociclib), so that the therapeutic effect of the compound of formula (I) overlaps with the therapeutic effect of the CDK inhibitor (e.g., Palbociclib). In some embodiments, the therapeutic effect of the compound of formula (I) completely overlaps with the therapeutic effect of the CDK inhibitor (e.g., Palbociclib). In some embodiments, "time proximity" means that the administration of the compound of formula (I) occurs within a certain period of time before or after the administration of the CDK inhibitor (e.g., Palbociclib), so that there is a synergistic effect between the compound of formula (I) and the CDK inhibitor.

[0305] "Time proximity" can vary according to a variety of factors, including but not limited to the age, sex, weight, genetic background, medical condition, disease history and treatment history of the subject to whom the therapeutic agent is to be administered; the disease or condition to be treated or improved; the therapeutic outcome to be achieved; the dosage, frequency of administration and duration of administration of the therapeutic agent; the pharmacokinetics and pharmacodynamics of the therapeutic agent; and the route of administering the therapeutic agent. In some embodiments, "time proximity" means within 15 minutes, within 30 minutes, within 1 hour, within 2 hours, within 4 hours, within 6 hours, within 8 hours, within 12 hours, within 18 hours, within 24 hours, within 36 hours, within 2 days, within 3 days, within 4 days, within 5 days, within 6 days, within 1 week, within 2 weeks, within 3 weeks, within 4 weeks, within 6 weeks or within 8 weeks. In some embodiments, multiple administrations of a therapeutic agent can occur with a single administration of another therapeutic agent in a time-closed situation. In some embodiments, time proximity can be changed during a treatment cycle or within a dosing regimen.

[0306] In one aspect, the present application relates to a method for treating and / or preventing breast cancer in a subject in need thereof, the method comprising administering to the subject a compound of formula (I) and a CDK4 / 6 inhibitor, wherein the compound of formula (I) refers to a compound having the following structure:

[0307] or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative or prodrug thereof, wherein R 1 , R 2 , R3, R4, m and n are defined herein, and a CDK4 / 6 inhibitor or a pharmaceutically acceptable salt thereof is a compound that inhibits enzymes known as cyclin-dependent kinases (CDKs) 4 and 6 in humans. In one embodiment, the CDK4 / 6 inhibitor is palbociclib, palbociclib dihydrochloride or any other pharmaceutically acceptable salt thereof. In one embodiment, the breast cancer is metastatic breast cancer. In one embodiment, the breast cancer is locally advanced breast cancer. In one embodiment, the breast cancer is ER+, HER2-. In one embodiment, the breast cancer is metastatic ER+, HER2- breast cancer. In one embodiment, the breast cancer is locally advanced metastatic ER+, HER2- breast cancer. In one embodiment, the breast cancer is locally advanced metastatic ER+, HER2- breast cancer.

[0308] In one aspect, the present application relates to a method for treating and / or preventing breast cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I) and a CDK4 / 6 inhibitor, wherein the compound of formula (I) is selected from the group consisting of:

[0309]

[0310]

[0311] as well as

[0312]

[0313] Or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative or prodrug thereof, and the CDK4 / 6 inhibitor is SHR6390, treracili, leroxilim, AT7519M, denacil, ribociclib, abemaciclib or palbociclib or any pharmaceutically acceptable salt thereof. In one embodiment, the compound of formula (I) is a compound of formula (Ic). In one embodiment, breast cancer is metastatic breast cancer. In one embodiment, breast cancer is locally advanced breast cancer. In one embodiment, breast cancer is ER+, HER2-. In one embodiment, breast cancer is metastatic ER+, HER2- breast cancer. In one embodiment, breast cancer is locally advanced metastatic ER+, HER2- breast cancer. In one embodiment, breast cancer is locally advanced metastatic ER+, HER2- breast cancer.

[0314] In one aspect, the present application relates to a combination preparation of a compound of formula (I) as defined herein and a CDK4 / 6 inhibitor as defined herein, for simultaneous, separate or sequential use in the treatment and / or prevention of breast cancer. In one embodiment, the breast cancer is metastatic breast cancer. In one embodiment, the breast cancer is locally advanced breast cancer. In one embodiment, the breast cancer is ER+, HER2-. In one embodiment, the breast cancer is metastatic ER+, HER2- breast cancer. In one embodiment, the breast cancer is locally advanced metastatic ER+, HER2- breast cancer.

[0315] In one aspect, the present application relates to a combination preparation of a compound of formula (Ic) as defined herein and a CDK4 / 6 inhibitor as defined herein, for simultaneous, separate or sequential use in the treatment and / or prevention of breast cancer. In one embodiment, the breast cancer is metastatic breast cancer. In one embodiment, the breast cancer is locally advanced breast cancer. In one embodiment, the breast cancer is ER+, HER2-. In one embodiment, the breast cancer is metastatic ER+, HER2- breast cancer. In one embodiment, the breast cancer is locally advanced metastatic ER+, HER2- breast cancer.

[0316] In one aspect, the present application relates to a combination preparation of a compound of formula (I) as defined herein and a palbociclib inhibitor as defined herein, for simultaneous, separate or sequential use in the treatment and / or prevention of breast cancer. In one embodiment, the breast cancer is metastatic breast cancer. In one embodiment, the breast cancer is locally advanced breast cancer. In one embodiment, the breast cancer is ER+, HER2-. In one embodiment, the breast cancer is metastatic ER+, HER2- breast cancer. In one embodiment, the breast cancer is locally advanced metastatic ER+, HER2- breast cancer.

[0317] In one aspect, the present application relates to a combination preparation of a compound of formula (Ic) as defined herein and a palbociclib inhibitor as defined herein, for simultaneous, separate or sequential use in the treatment and / or prevention of breast cancer. In one embodiment, the breast cancer is metastatic breast cancer. In one embodiment, the breast cancer is locally advanced breast cancer. In one embodiment, the breast cancer is ER+, HER2-. In one embodiment, the breast cancer is metastatic ER+, HER2- breast cancer. In one embodiment, the breast cancer is locally advanced metastatic ER+, HER2- breast cancer.

[0318] In one aspect, treatment of cancer with a compound of formula (I) and a CDK4 / 6 inhibitor results in a reduction in tumor size. A reduction in tumor size may also be referred to as "tumor regression". Preferably, after treatment, the tumor size is reduced by 5% or more relative to its size before treatment; more preferably, the tumor size is reduced by 10% or more; more preferably, by 20% or more; more preferably, by 30% or more; more preferably, by 40% or more; even more preferably, by 50% or more; and most preferably, by more than 75% or more. Tumor size can be measured by any reproducible means of measurement. In a preferred aspect, tumor size can be measured as the diameter of the tumor.

[0319] In another aspect, treatment of cancer with a compound of formula (I) and a CDK4 / 6 inhibitor results in a reduction in tumor volume. Preferably, after treatment, the tumor volume is reduced by 5% or more relative to its size before treatment; more preferably, the tumor volume is reduced by 10% or more; more preferably, by 20% or more; more preferably, by 30% or more; more preferably, by 40% or more; even more preferably, by 50% or more; and most preferably, by greater than 75% or more. Tumor volume can be measured by any reproducible means of measurement.

[0320] In another aspect, treatment of cancer with a compound of formula (I) and a CDK4 / 6 inhibitor results in a reduction in the number of tumors. Preferably, after treatment, the number of tumors is reduced by 5% or more relative to the number before treatment; more preferably, the number of tumors is reduced by 10% or more; more preferably, by 20% or more; more preferably, by 30% or more; more preferably, by 40% or more; even more preferably, by 50% or more; and most preferably, by more than 75%. The number of tumors can be measured by any reproducible measurement means. In a preferred aspect, the number of tumors can be measured by counting tumors visible to the naked eye or visible at a specified magnification. In a preferred aspect, the specified magnification is 2x, 3x, 4x, 5x, 10x or 50x.

[0321] In another aspect, treatment of cancer with a compound of formula (I) and a CDK4 / 6 inhibitor results in a reduction in the number of metastatic lesions in other tissues or organs away from the primary tumor site. Preferably, after treatment, the number of metastatic lesions is reduced by 5% or more relative to the number before treatment; more preferably, the number of metastatic lesions is reduced by 10% or more; more preferably, by 20% or more; more preferably, by 30% or more; more preferably, by 40% or more; even more preferably, by 50% or more; and most preferably, by more than 75%. The number of metastatic lesions can be measured by any reproducible measurement means. In a preferred aspect, the number of metastatic lesions can be measured by counting metastatic lesions visible to the naked eye or visible at a specified magnification. In a preferred aspect, the specified magnification is 2x, 3x, 4x, 5x, 10x or 50x.

[0322] In another aspect, the treatment of cancer with a compound of formula (I) and a CDK4 / 6 inhibitor results in an increase in the average survival time of a population of treated subjects compared to a population receiving a single carrier. Preferably, the average survival time increases by more than 30 days; more preferably, more than 60 days; more preferably, more than 90 days; and most preferably, more than 120 days. The increase in the average survival time of a population can be measured by any reproducible means. In a preferred aspect, the increase in the average survival time of a population can be measured, for example, by calculating the average survival length of a population after starting treatment with an active agent or compound. In another preferred aspect, the increase in the average survival time of a population can also be measured, for example, by calculating the average survival length of a population after completing the first round of treatment with an active agent or compound.

[0323] In another aspect, treatment of cancer with a compound of formula (I) and a CDK4 / 6 inhibitor results in an increase in the average survival time of a population of treated subjects compared to a population of untreated subjects. Preferably, the average survival time increases by more than 30 days; more preferably, more than 60 days; more preferably, more than 90 days; and most preferably, more than 120 days. The increase in the average survival time of a population can be measured by any reproducible means. In a preferred aspect, the increase in the average survival time of a population can be measured, for example, by calculating the average survival length of a population after starting treatment with an active agent or compound. In another preferred aspect, the increase in the average survival time of a population can also be measured, for example, by calculating the average survival length of a population after completing the first round of treatment with a compound of formula (I) and a CDK4 / 6 inhibitor.

[0324] In another aspect, treatment of cancer with a compound of formula (I) and a CDK4 / 6 inhibitor results in a reduction in tumor growth rate. Preferably, after treatment, the tumor growth rate is reduced by at least 5% relative to the number before treatment; more preferably, the tumor growth rate is reduced by at least 10%; more preferably, by at least 20%; more preferably, by at least 30%; more preferably, by at least 40%; more preferably, by at least 50%; even more preferably, by at least 50%; and most preferably, by at least 75%. Tumor growth rate can be measured by any reproducible means of measurement. In a preferred aspect, the tumor growth rate is measured based on the change in tumor diameter per unit time.

[0325] In another aspect, treatment of cancer with a compound of formula (I) and a CDK4 / 6 inhibitor results in reduced tumor regrowth. Preferably, after treatment, tumor regrowth is less than 5%; more preferably, tumor regrowth is less than 10%; more preferably, less than 20%; more preferably, less than 30%; more preferably, less than 40%; more preferably, less than 50%; even more preferably, less than 50%; and most preferably, less than 75%. Tumor regrowth can be measured by any reproducible measurement means. In a preferred aspect, tumor regrowth is measured, for example, by measuring an increase in the diameter or volume of a tumor after a previous tumor shrinkage after treatment. In another preferred aspect, a reduction in tumor regrowth is indicated by the failure of tumor recurrence after cessation of treatment.

[0326] The dosage of the compounds of Formula (I) and CDK4 / 6 inhibitors used in any of the methods and uses described herein varies according to the agent, the age, weight and clinical condition of the recipient subject, and the experience and judgment of the clinician or practitioner administering the therapy, as well as other factors that influence the selected dosage.

[0327] A therapeutically effective amount of a CDK4 / 6 inhibitor can be administered once, twice, three times, four times, five times or more in a day for 5, 10, 15, 30, 60, 90, 120, 150, 180 or more days, followed by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or more days of discontinuation of the CDK4 / 6 inhibitor. This type of treatment schedule, i.e., administration of a CDK4 / 6 inhibitor on consecutive days followed by discontinuation of the CDK4 / 6 inhibitor on consecutive days, can be referred to as a treatment cycle.

[0328] In one embodiment, a therapeutically effective amount of a CDK4 / 6 inhibitor can be administered once or twice a day for up to 5, 10, 15, 20, 25, or 30 days, followed by 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days off of the CDK4 / 6 inhibitor.

[0329] In one embodiment, a therapeutically effective amount of a CDK4 / 6 inhibitor can be administered once daily for up to 5, 10, 15, 20, 25, or 30 days, followed by 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days off of the CDK4 / 6 inhibitor.

[0330] In one embodiment, a treatment cycle involving a CDK4 / 6 inhibitor can be repeated as many times as necessary to achieve the desired effect.

[0331] In one embodiment, the treatment period with the CDK4 / 6 inhibitor is the same as the treatment period with the compound of Formula (I).

[0332] In one embodiment, the treatment period with the CDK4 / 6 inhibitor is different from the treatment period with the compound of Formula (I).

[0333] The therapeutically effective amount of the compound of formula (I) and the CDK4 / 6 inhibitor can be administered once or multiple times in a day for up to 30 days or more, followed by 1 day or more of discontinuation of the compound of formula (I) and / or the CDK4 / 6 inhibitor. This type of treatment schedule, i.e., administering the compound of formula (I) and / or the CDK4 / 6 inhibitor for several consecutive days, followed by discontinuation of the compound of formula (I) and / or the CDK4 / 6 inhibitor for several consecutive days, can be referred to as a treatment cycle or cycle. In one embodiment, the treatment cycle can be repeated once, twice, three times, four times, five times, six times, seven times, eight times, nine times, ten times or more. In one embodiment, the treatment cycle of the CDK4 / 6 inhibitor can be repeated multiple times as needed to achieve the desired effect.

[0334] In one embodiment, for the methods disclosed herein comprising administering a compound of formula (I) and a CDK4 / 6 inhibitor, the therapeutically effective amount of the compound of formula (I) is 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82 ,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,105,110,115,120,125,130,135,140,145,150,155,160,165,170,175,180,185,1 90,195,200,205,210,215,220,225,230,235,240,245,250,255,260,265,270,275,280,285,290,295,300,305,310,315,320,325,330,335,340,3 45,350,355,360,365,370,375,380,385,390,395,400,405,410,415,420,425,430,435,440,445,450,455,460,465,470,475,480,485,490,495,50 0,505,510,515,520,525,530,535,540,545,550,555,560,565,570,575,580,585,590,595,600,605,610,615,620,625,630,635,640,645,650,655 ,660,665,670,675,680,685,690,695,700,705,710,715,720,725,730,735,740,745,750,755,760,765,770,775,780,785,790,795,800,805,810,815,820,825,830,835,840,845,850,855,860,865,870,875,880,885,890,895,900,905,910,915,920,925,930,935,940,945,950,955,960,965,970,975,980,985,990,995 or 1,000 mg, administered once, twice, three times, four times or more daily in a single dose or in divided doses for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 30 consecutive days, or for 2, 3, 4, 5, 6 months or longer. ,

[0335] In one embodiment, for the methods disclosed herein comprising administering a compound of formula (I) and a CDK4 / 6 inhibitor, the therapeutically effective amount of the compound of formula (I) is about 30 mg, about 60 mg, about 90 mg, about 120 mg, about 150 mg, about 180 mg, about 210 mg, about 240 mg, about 270 mg, about 300 mg, about 330 mg, about 360 mg, about 390 mg, about 420 mg, about 450 mg, about about 480 mg, about 510 mg, about 540 mg, about 570 mg, about 600 mg, about 630 mg, about 660 mg, about 690 mg, about 720 mg, about 750 mg, about 780 mg, about 810 mg, about 840 mg, about 870 mg, about 900 mg, about 930 mg, about 960 mg or about 990 mg, in a single dose or divided doses (the dose can be based on the patient's weight (kg), body surface area (m 2 ) and age (years)) once, twice, three times, four times or more per day.

[0336] In one embodiment, for the methods disclosed herein comprising administering a compound of formula (I) and a CDK4 / 6 inhibitor, the therapeutically effective amount of the compound of formula (I) is from about 30 mg to about 1000 mg, which is administered in a single dose or divided doses (the dose can be based on the patient's weight (kg), body surface area (m 2 ) and age (years)) once, twice, three times, four times or more per day.

[0337] In one embodiment, for the methods disclosed herein comprising administering a compound of formula (I) and a CDK4 / 6 inhibitor, a therapeutically effective amount of the compound of formula (I) is about 10 to about 40 mg, about 20 to about 50 mg, about 30 to about 60 mg, about 40 to about 70 mg, about 50 to about 80 mg, about 60 to about 90 mg, about 70 to about 100 mg, about 80 to about 110 mg, about 90 to about 120 mg, about 100 to about 130 mg, about 110 to about 140 mg, about 120 to about 150 mg, about 130 to about 160 mg, about 140 to about 170 mg, about 150 to about 180 mg, about 160 to about 190 mg, about 170 to about 200 mg, about 180 to about about 210 mg, about 190 to about 220 mg, about 200 to about 230 mg, about 210 to about 240 mg, about 220 to about 250 mg, about 230 to about 260 mg, about 240 to about 270 mg, about 250 to about 280 mg, about 260 to about 290 mg, about 270 to about 300 mg, about 280 to about 310 mg, about 290 to about 320 mg, about 300 to about 330 mg, about 310 to about 340 mg, about 320 to about 350 mg, about 330 to about 360 mg, about 340 to about 370 mg, about 350 to about 380 mg, about 360 to about 390 mg, about 370 to about 400 mg, about 380 to about 410 mg, about 420 to about 430 mg about 420 mg, about 400 to about 430 mg, about 410 to about 440 mg, about 420 to about 450 mg, about 430 to about 460 mg, about 440 to about 470 mg, about 450 to about 480 mg, about 460 to about 490 mg, about 470 to about 500 mg, about 480 to about 510 mg, about 490 to about 520 mg, about 500 to about 530 mg, about 510 to about 540 mg, about 520 to about 550 mg, about 530 to about 560 mg, about 540 to about 570 mg, about 550 to about 580 mg, about 560 to about 590 mg, about 570 to about 600 mg, about 580 to about 610 mg, about 590 to about 620 mg, about 6 700 to about 730 mg, about 710 to about 740 mg, about 720 to about 750 mg, about 730 to about 760 mg, about 740 to about 770 mg, about 750 to about 780 mg, about 760 to about 790 mg, about 770 to about 800 mg, about 780 to about 810 mg, about 790 to about 820 mg, about 800 to about 830 mg,about 810 to about 840 mg, about 820 to about 850 mg, about 830 to about 860 mg, about 840 to about 870 mg, about 850 to about 880 mg, about 860 to about 890 mg, about 870 to about 900 mg, about 880 to about 910 mg, about 890 to about 920 mg, about 900 to about 930 mg, about 910 to about 940 mg, about 920 to about 950 mg, about 930 to about 960 mg, about 940 to about 970 mg, about 950 to about 980 mg, about 960 to about 990 mg, or about 970 to about 1,000 mg, in a single dose or in divided doses (the dose can be based on the patient's weight (kg), body surface area (m2), 2 ) and age (years)) once, twice, three times, four times or more per day.

[0338] In one embodiment, for the methods disclosed herein comprising administering a compound of Formula (I) and a CDK4 / 6 inhibitor, a therapeutically effective amount of a compound of Formula (I) may also be in the range of about 0.01 mg / kg / day to about 100 mg / kg / day, about 0.05 mg / kg / day to about 10 mg / kg / day, about 0.075 mg / kg / day to about 5 mg / kg / day, about 0.10 mg / kg / day to about 1 mg / kg / day, or about 0.20 mg / kg / day to about 0.70 mg / kg / day.

[0339] In one embodiment, for the methods disclosed herein comprising administering a compound of Formula (I) and a CDK4 / 6 inhibitor, the therapeutically effective amount of the compound of Formula (I) is about 0.10 mg / kg / day, about 0.15 mg / kg / day, about 0.20 mg / kg / day, about 0.25 mg / kg / day, about 0.30 mg / kg / day, about 0.35 mg / kg / day, about 0.40 mg / kg / day, about 0.45 mg / kg / day, about 0.50 mg / kg / day, about 0.55 mg / kg / day, about 0.60 mg / kg / day, about 0.65 mg / kg / day, about 0.70 mg / kg / day, about 0.75 mg / kg / day, about 0.80 mg / kg / day, about 0.85 mg / kg / day, about 0.90 mg / kg / day, about 0.95 mg / kg / day, or about 1.00 mg / kg / day.

[0340] In one embodiment, for the methods disclosed herein comprising administering a compound of formula (I) and a CDK4 / 6 inhibitor, the therapeutically effective amount of the compound of formula (I) is about 1.05 mg / kg / day, about 1.10 mg / kg / day, about 1.15 mg / kg / day, about 1.20 mg / kg / day, about 1.25 mg / kg / day, about 1.30 mg / kg / day, about 1.35 mg / kg / day, about 1.40 mg / kg / day In some embodiments, the present invention may be used in an amount of at least about 1.5 mg / kg / day, about 1.45 mg / kg / day, about 1.50 mg / kg / day, about 1.55 mg / kg / day, about 1.60 mg / kg / day, about 1.65 mg / kg / day, about 1.70 mg / kg / day, about 1.75 mg / kg / day, about 1.80 mg / kg / day, about 1.85 mg / kg / day, about 1.90 mg / kg / day, about 1.95 mg / kg / day, or about 2.00 mg / kg / day.

[0341] In one embodiment, for the methods disclosed herein comprising administering a compound of Formula (I) and a CDK4 / 6 inhibitor, the therapeutically effective amount of the compound of Formula (I) is about 2 mg / kg / day, about 2.5 mg / kg / day, about 3 mg / kg / day, about 3.5 mg / kg / day, about 4 mg / kg / day, about 4.5 mg / kg / day, about 5 mg / kg / day, about 5.5 mg / kg / day, about 6 mg / kg / day, about 6.5 mg / kg / day, about 7 mg / kg / day, about 7.5 mg / kg / day, about 8.0 mg / kg / day, about 8.5 mg / kg / day, about 9.0 mg / kg / day, about 9.5 mg / kg / day, or about 10 mg / kg / day.

[0342] In one embodiment, for the methods disclosed herein comprising administering a compound of formula (I) and a CDK4 / 6 inhibitor, the therapeutically effective amount of the CDK4 / 6 inhibitor is 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 ,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,8 2,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,105,110,115,120,125,130,135,140,145,150,155,160,165,170,175,180,185, 190,195,200,205,210,215,220,225,230,235,240,245,250,255,260,265,270,275,280,285,290,295,300,305,310,315,320,325,330,335,340,3 45,350,355,360,365,370,375,380,385,390,395,400,405,410,415,420,425,430,435,440,445,450,455,460,465,470,475,480,485,490,495,50 0,505,510,515,520,525,530,535,540,545,550,555,560,565,570,575,580,585,590,595,600,605,610,615,620,625,630,635,640,645,650,655 ,660,665,670,675,680,685,690,695,700,705,710,715,720,725,730,735,740,745,750,755,760,765,770,775,780,785,790,795,800,805,810,815,820,825,830,835,840,845,850,855,860,865,870,875,880,885,890,895,900,905,910,915,920,925,930,935,940,945,950,955,960,965,970,975,980,985,990,9 95 or 1,000 mg, administered once, twice, three times, four times or more per day in a single dose or divided doses for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 30 consecutive days, or once, twice, three times, four times or more per day in a single dose or divided doses for 2 months, 3 months, 4 months, 5 months, 6 months or longer. In one embodiment, the CDK4 / 6 inhibitor is palbociclib. ,

[0343] In one embodiment, the compound of formula (I) and palbociclib can be administered simultaneously. In one embodiment, the compound of formula (I) is administered first, and then palbociclib is administered. In one embodiment, palbociclib is administered first, and then the compound of formula (I) is administered. For example, in some embodiments, the administration of the compound of formula (I) and the administration of palbociclib are concomitant. In some embodiments, the administration of the compound of formula (I) and the administration of palbociclib are sequential.

[0344] In one embodiment, palbociclib is administered prior to administration of the compound of formula (I) so that the two compounds and their respective excipients do not mix in the subject's stomach. In one embodiment, the maximum time between administration of palbociclib and administration of the compound of formula (I) is such that the benefit of the combination is achieved. In one embodiment, palbociclib is administered at least 5, at least 10, at least 15, at least 20, at least 25, or at least 30 minutes prior to administration of the compound of formula (I). In one embodiment, palbociclib is administered 5 to 35, 10 to 40, 15 to 25, 20 to 50, 25 to 55, or 30 to 60 minutes prior to administration of the compound of formula (I). In one embodiment, palbociclib is administered 30 to 60, 30 to 70, 30 to 80, 30 to 90, 30 to 120, 30 to 180, 30 to 240, 30 to 300, 30 to 360, 30 to 480, 30 to 600, or 30 to 720 minutes prior to administration of the compound of Formula (I).

[0345] In one embodiment, palbociclib is administered after administration of the compound of formula (I) so that the two compounds and their respective excipients (if present) do not mix in the subject's stomach. In one embodiment, the maximum time between administration of palbociclib and administration of the compound of formula (I) is such that the benefit of the combination is achieved. In one embodiment, palbociclib is administered at least 5, at least 10, at least 15, at least 20, at least 25, or at least 30 minutes after administration of the compound of formula (I). In one embodiment, palbociclib is administered 5 to 35, 10 to 40, 15 to 25, 20 to 50, 25 to 55, or 30 to 60 minutes after administration of the compound of formula (I). In one embodiment, palbociclib is administered 30 to 60, 30 to 70, 30 to 80, 30 to 90, 30 to 120, 30 to 180, 30 to 240, 30 to 300, 30 to 360, 30 to 480, 30 to 600, or 30 to 720 minutes after administration of the compound of Formula (I).

[0346] In one embodiment, for the methods disclosed herein comprising administering a compound of formula (I) and a CDK4 / 6 inhibitor, the therapeutically effective amount of the CDK4 / 6 inhibitor is 60 mg, 75 mg, 100 mg or 125 mg, administered once a day in a single dose or divided doses. In one embodiment, a therapeutically effective amount of a CDK4 / 6 inhibitor is administered once a day for 21 consecutive days, followed by 7 days of cessation of treatment. In one embodiment, the CDK4 / 6 inhibitor is palbociclib.

[0347] Treatment with a CDK4 / 6 inhibitor for 21 consecutive days followed by 7 days of cessation of treatment is referred to herein as a treatment cycle or cycle. In one embodiment, a treatment cycle of a CDK4 / 6 inhibitor can be repeated once, twice, three times, four times, five times, six times, seven times, eight times, nine times, ten times or more. In one embodiment, a treatment cycle of a CDK4 / 6 inhibitor can be repeated multiple times as needed to achieve a desired effect. In one embodiment, the CDK4 / 6 inhibitor is palbociclib.

[0348] In one embodiment, for the methods disclosed herein comprising administering a compound of formula (I) and a CDK4 / 6 inhibitor, the therapeutically effective amount of the CDK4 / 6 inhibitor is about 0.1 mg / kg / day, about 0.2 mg / kg / day, about 0.3 mg / kg / day, about 0.4 mg / kg / day, about 0.5 mg / kg / day, 0.6 mg / kg / day, about 0.7 mg / kg / day, about 0.8 mg / kg / day, about 0.9 mg / kg / day, about 1 mg / kg / day, about 1.1 mg / kg / day, about 1.2 mg / kg / day, about 1.3 mg / kg / day, about 1.4 mg / kg / day, about 1.5 mg / kg / day, 1.6 mg / kg / day, about 1.7 mg / kg / day, about 1.8 mg / kg / day, about 1.9 mg / kg / day, about 2.1 mg / kg / day, about 2.2 mg / kg / day, about 2.3 mg / kg / day, about 2.4 mg / kg / day, about 2.5 mg / kg / day, about 2.6 mg / kg / day, about 2.7 mg / kg / day, about 2.8 mg / kg / day, about 2.9 mg / kg / day, about 3. In one embodiment, the CDK4 / 6 inhibitor is palbociclib.

[0349] In one embodiment, for the methods disclosed herein comprising administering a compound of Formula (I) and a CDK4 / 6 inhibitor, the therapeutically effective amount of the CDK4 / 6 inhibitor is from about 0.5 mg / kg / day to about 3.0 mg / kg / day.

[0350] In one embodiment, for the method disclosed herein comprising administering a compound of formula (I) and a CDK4 / 6 inhibitor, a therapeutically effective amount of a compound of formula (I) is administered to a subject once a day. In one embodiment, the daily dose of the compound of formula (I) is administered to the subject in one go. In one embodiment, the daily dose of the compound of formula (I) is administered to the subject in two parts (divided doses). In one embodiment, the daily dose of the compound of formula (I) is administered to the subject in three parts. In one embodiment, the daily dose of the compound of formula (I) is administered to the subject in four parts. In one embodiment, the daily dose of the compound of formula (I) is administered to the subject in five or more parts. In one embodiment, these parts are administered to the subject at regular intervals throughout the day, for example, every 12 hours, every 8 hours, every 6 hours, every 5 hours, every 4 hours, etc.

[0351] In one embodiment, for the methods disclosed herein comprising administering a compound of formula (I) and a CDK4 / 6 inhibitor, a therapeutically effective amount of a CDK4 / 6 inhibitor is administered to a subject once a day. In one embodiment, the daily dose of the CDK4 / 6 inhibitor is administered to the subject in one go. In one embodiment, the daily dose of the CDK4 / 6 inhibitor is administered to the subject in two parts (divided doses). In one embodiment, the daily dose of the CDK4 / 6 inhibitor is administered to the subject in three parts. In one embodiment, the daily dose of the CDK4 / 6 inhibitor is administered to the subject in four parts. In one embodiment, the daily dose of the CDK4 / 6 inhibitor is administered to the subject in five or more parts. In one embodiment, these parts are administered to the subject at regular intervals throughout the day, for example, every 12 hours, every 8 hours, every 6 hours, every 5 hours, every 4 hours, etc.

[0352] Therapeutically effective amounts of compounds of Formula (I) and CDK4 / 6 inhibitors can be initially estimated in cell culture assays or in animal models (usually rats, mice, rabbits, dogs or pigs). Animal models can also be used to determine appropriate concentration ranges and routes of administration. Such information can then be used to determine useful doses and routes for administration in humans. Therapeutic / preventive efficacy and toxicity can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, such as ED 50 (the dose that is therapeutically effective in 50% of the population) and LD 50 (the dose lethal to 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, and it can be expressed as LD 50 / ED 50 Ratio. Pharmaceutical compositions that exhibit large therapeutic indices are preferred. The dosage may vary within this range depending on the dosage form employed, sensitivity of the patient, and route of administration.

[0353] Adjust dosage and administration to provide sufficient levels of the compound of formula (I) and / or CDK4 / 6 inhibitor or maintain the desired effect. Factors that may be considered include the severity of the disease state, the general health of the subject, the age, weight and sex of the subject, diet, time and frequency of administration, drug combination, reaction sensitivity and tolerance / response to therapy. Long-acting pharmaceutical compositions may be administered once every 3 to 4 days, weekly or biweekly, depending on the half-life and clearance rate of the particular formulation.

[0354] Pharmaceutical composition

[0355] The compounds of formula (I) and CDK4 / 6 inhibitors may be administered according to the present invention by any suitable route, including oral, parenteral (subcutaneous, intramuscular, intravenous (supplement or infusion), depot, intraperitoneal), intrathecal, intranasal, intravaginal, sublingual, buccal, intraocular or rectal.

[0356] In one embodiment, the compound of formula (I) and the CDK4 / 6 inhibitor can be formulated into separate dosage forms. These separate dosage forms can be suitable for administration by any appropriate route, including, for example, oral, parenteral (subcutaneous, intramuscular, intravenous, reservoir), intrathecal, intranasal, intravaginal, sublingual, oral, intraocular or rectal.

[0357] In one embodiment, the compound of formula (I) and the CDK4 / 6 inhibitor can be combined and formulated into a single dosage form. The single dosage form can be suitable for administration by any appropriate route, including, for example, oral, parenteral (subcutaneous, intramuscular, intravenous, reservoir), intrathecal, intranasal, intravaginal, sublingual, buccal, intraocular or rectal.

[0358] In one embodiment, the compound of formula (I) and the CDK4 / 6 inhibitor can be formulated into separate dosage forms, each of which is suitable for oral administration. In one embodiment, the CDK4 / 6 inhibitor is SHR6390, treraciclib, lerosiclib, AT7519M, denacil, ribociclib, abemaciclib, palbociclib or any pharmaceutically acceptable salt thereof. In one embodiment, the CDK4 / 6 inhibitor is palbociclib, palbociclib dihydrochloride or any other pharmaceutically acceptable salt of palbociclib.

[0359] In one embodiment, the compound of formula (I) and the CDK4 / 6 inhibitor can be formulated into a single dosage form suitable for oral administration. In one embodiment, the CDK4 / 6 inhibitor is SHR6390, treraciclib, lerosiclib, AT7519M, denacil, ribociclib, abemaciclib, palbociclib or any pharmaceutically acceptable salt thereof. In one embodiment, the CDK4 / 6 inhibitor is palbociclib, palbociclib dihydrochloride or any other pharmaceutically acceptable salt of palbociclib.

[0360] In one embodiment, the compound of formula (I) and the CDK4 / 6 inhibitor are each formulated for oral administration, either alone or together. For example, in one embodiment, the compound of formula (I) and the CDK4 / 6 inhibitor are both formulated, either alone or together, as tablets, comprising zero, one, two or more of each of the following: an emulsifier, a surfactant, a binder, a disintegrant, a glidant, and a lubricant, or alternatively, the compound of formula (I) and the CDK4 / 6 inhibitor can be formulated, either alone or together, as an oral liquid in a capsule, or a combination thereof.

[0361] In one embodiment, the emulsifier is hypromellose.

[0362] In one embodiment, the surfactant is vitamin E polyethylene glycol succinate.

[0363] In one embodiment, the binder (also referred to herein as a filler) is selected from the group consisting of microcrystalline cellulose, lactose monohydrate, sucrose, glucose, and sorbitol.

[0364] In one embodiment, the disintegrant is croscarmellose sodium.

[0365] In one embodiment, the glidant refers to a substance used to promote powder flow by reducing inter-particle adhesion. In one embodiment, in the dosage form of the present disclosure, the glidant is selected from the group consisting of silicon dioxide, anhydrous colloidal silicon dioxide, starch and talc.

[0366] In one embodiment, a lubricant refers to a substance that prevents ingredients from sticking and / or clumping together in a machine used to prepare the dosage form of the present disclosure. In one embodiment, in the dosage form of the present disclosure, the lubricant is selected from the group consisting of magnesium stearate, sodium stearyl fumarate, stearic acid, and vegetable stearin.

[0367] In some embodiments, the present disclosure provides a liquid composition comprising a compound of formula (I). In some embodiments, the liquid composition comprises a compound of formula (I) and a surfactant. In some embodiments, the liquid composition comprises a compound of formula (I) and a solvent. In some embodiments, the composition comprises a therapeutically effective amount of a compound of formula (I), a surfactant, and a solvent.

[0368] In some embodiments, the present disclosure provides a liquid composition comprising a compound of formula (Ic). In some embodiments, the liquid composition comprises a compound of formula (Ic) and a surfactant. In some embodiments, the liquid composition comprises a compound of formula (Ic) and a solvent. In some embodiments, the composition comprises a therapeutically effective amount of a compound of formula (Ic), a surfactant and a solvent. In some embodiments, the ratio of surfactant to solvent in the composition is 0.001 to 0.035 g surfactant: 1 mL solvent. In some embodiments, the ratio of surfactant to solvent in the composition is 0.005 to 0.035 g surfactant: 1 mL solvent. In some embodiments, the ratio of surfactant to solvent in the composition is 0.01 to 0.03 g surfactant: 1 mL solvent. In some embodiments, the ratio of surfactant to solvent in the composition is 0.015 to 0.025 g surfactant: 1 mL solvent. In some embodiments, the ratio of surfactant to solvent in the composition is 0.016 to 0.024 g surfactant: 1 mL solvent. In some embodiments, the ratio of surfactant to solvent in the composition is 0.017 to 0.023 g surfactant: 1 mL solvent. In some embodiments, the ratio of surfactant to solvent in the composition is 0.018 to 0.022g surfactant: 1mL solvent. In some embodiments, the ratio of surfactant to solvent in the composition is 0.019 to 0.021g surfactant: 1mL solvent. In some embodiments, the ratio of surfactant to solvent in the composition is about 0.02g surfactant: about 1mL solvent. In some embodiments, the ratio of surfactant to solvent in the composition is 0.02g surfactant: 1mL solvent. In some embodiments, the surfactant is a sorbitan derivative. In some embodiments, the surfactant is Tween 80. In some embodiments, the solvent is a low molecular weight polyethylene glycol (PEG). In some embodiments, the solvent is polyethylene glycol (PEG)-400.

[0369] In some embodiments, the present disclosure provides a liquid composition comprising a compound of formula (Ic). In some embodiments, the liquid composition comprises a compound of formula (Ic) and Tween 80. In some embodiments, the liquid composition comprises a compound of formula (Ic) and polyethylene glycol (PEG)-400. In some embodiments, the composition comprises a therapeutically effective amount of a compound of formula (Ic), Tween 80 and PEG-400. In some embodiments, the ratio of Tween 80 to PEG-400 in the composition is 0.001 to 0.035 g Tween 80:1 mL PEG-400. In some embodiments, the ratio of Tween 80 to PEG-400 in the composition is 0.005 to 0.035 g Tween 80:1 mL PEG-400. In some embodiments, the ratio of Tween 80 to PEG-400 in the composition is 0.01 to 0.03 g Tween 80:1 mL PEG-400. In some embodiments, the ratio of Tween 80 to PEG-400 in the composition is 0.015 to 0.025 g Tween 80: 1 mL PEG-400. In some embodiments, the ratio of Tween 80 to PEG-400 in the composition is 0.016 to 0.024 g Tween 80: 1 mL PEG-400. In some embodiments, the ratio of Tween 80 to PEG-400 in the composition is 0.017 to 0.023 g Tween 80: 1 mL PEG-400. In some embodiments, the ratio of Tween 80 to PEG-400 in the composition is 0.018 to 0.022 g Tween 80: 1 mL PEG-400. In some embodiments, the ratio of Tween 80 to PEG-400 in the composition is 0.019 to 0.021 g Tween 80: 1 mL PEG-400. In some embodiments, the ratio of Tween 80 to PEG-400 in the composition is about 0.02 g Tween 80: about 1 mL PEG-400. In some embodiments, the ratio of Tween 80 to PEG-400 in the composition is 0.02 g Tween 80: 1 mL PEG-400.

[0370] In some embodiments, the present disclosure provides a method for preparing a liquid composition comprising a surfactant, a solvent and a compound of formula (Ic), the method comprising the step of adding a solvent to a pre-aliquoted volume of surfactant. In some embodiments, the method further comprises the step of adding a compound of formula (Ic) to a mixture of a solvent and a surfactant. In some embodiments, the present disclosure provides a method for preparing a liquid composition, the method comprising the following steps: (i) adding a solvent to a pre-aliquoted volume of surfactant, and (ii) adding a compound of formula (Ic) to a mixture of a solvent and a surfactant. In some embodiments, the surfactant is a sorbitan derivative. In some embodiments, the surfactant is Tween 80. In some embodiments, the solvent is a low molecular weight polyethylene glycol (PEG). In some embodiments, the solvent is polyethylene glycol (PEG)-400.

[0371] In some embodiments, the present disclosure provides a liquid composition comprising a surfactant, a solvent and a compound of formula (Ic), the liquid composition being prepared by a method comprising the step of adding a solvent to a pre-aliquoted volume of a surfactant. In some embodiments, the method further comprises the step of adding a compound of formula (Ic) to a mixture of a solvent and a surfactant. In some embodiments, the present disclosure provides a liquid composition comprising a surfactant, a solvent and a compound of formula (Ic), the liquid composition being prepared by a method comprising the following steps: (i) adding a solvent to a pre-aliquoted volume of a surfactant, and (ii) adding a compound of formula (Ic) to a mixture of a solvent and a surfactant. In some embodiments, the surfactant is a sorbitan derivative. In some embodiments, the surfactant is Tween 80. In some embodiments, the solvent is a low molecular weight polyethylene glycol (PEG). In some embodiments, the solvent is polyethylene glycol (PEG)-400.

[0372] Pharmaceutical compositions containing a compound of formula (I) and a CDK4 / 6 inhibitor (alone or together) can be manufactured in a generally known manner, for example, by conventional mixing, dissolving, granulating, sugar coating, grinding, emulsifying, encapsulating, embedding or lyophilizing processes. Pharmaceutical compositions can be formulated in a conventional manner using one or more pharmaceutically acceptable carriers, wherein the one or more pharmaceutically acceptable carriers contain excipients and / or adjuvants that facilitate the processing of the compound of formula (I) into a pharmaceutically usable preparation. Of course, the appropriate formulation depends on the selected route of administration.

[0373] Pharmaceutical compositions containing a compound of formula (I) and a CDK4 / 6 inhibitor (alone or together) suitable for injection include sterile aqueous solutions (where they are water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL TM (BASF, Parsippany, New Jersey) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that it is easy to inject. It must be stable under the conditions of manufacture and storage and must be preserved to resist the contaminating effects of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyols (such as glycerol, propylene glycol and liquid polyethylene glycol, etc.) and suitable mixtures thereof. Suitable fluidity can be maintained, for example, by using a coating such as lecithin, by maintaining the desired particle size in the case of dispersions, and by using a surfactant. Prevention of the effects of microorganisms can be achieved by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, ascorbic acid, sulfur isomers, etc. In many cases, it will be preferred to include isotonic agents in the composition, such as sugars, polyols such as mannitol, sorbitol, sodium chloride. Long-term absorption of injectable compositions can be achieved by including agents that delay absorption in the composition, such as aluminum monostearate and gelatin.

[0374] Sterile injectable solutions can be prepared by incorporating the desired amount of a compound of formula (I) and / or a CDK4 / 6 inhibitor with one or a combination of the ingredients listed above (as required) into an appropriate solvent, followed by filtration sterilization. Typically, dispersions are prepared by incorporating the active agent or compound into a sterile vehicle containing an alkaline dispersion medium and other required ingredients from those listed above. In the case of sterile powders for the preparation of sterile injectable solutions, the method of preparation is vacuum drying and freeze drying, which produces a powder of the active ingredient plus any other required ingredients from its previously sterile filtered solution.

[0375] Oral compositions typically include an inert diluent or an edible pharmaceutically acceptable carrier. They can be encapsulated in a gelatin capsule or compressed into tablets. For the purpose of oral therapeutic administration, the compound of formula (I) and / or the CDK4 / 6 inhibitor can be mixed with an excipient and used in the form of a tablet, lozenge or capsule. Oral compositions used as mouthwashes can also be prepared using a fluid carrier, wherein the agent or compound in the fluid carrier is orally administered and gargled and spit out or swallowed. Pharmaceutically compatible binders and / or adjuvant materials can be included as part of the composition. Tablets, pills, capsules, lozenges, etc. may contain any of the following ingredients or compounds of similar nature: binders such as microcrystalline cellulose, tragacanth or gelatin; excipients such as starch or lactose, dispersants such as alginic acid, Primogel or corn starch; lubricants such as magnesium stearate; glidants such as colloidal silicon dioxide; sweeteners such as sucrose or saccharin; or flavorings such as mint, methyl salicylate or orange flavoring.

[0376] For administration by inhalation, the compound of formula (I) and / or CDK4 / 6 inhibitor is delivered in the form of an aerosol spray from a pressurized container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

[0377] Systemic administration of the compound of formula (I) and / or CDK4 / 6 inhibitor can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, a penetrant suitable for the barrier to be penetrated is used in the formulation. Such penetrants are generally known in the art and include, for example, for transmucosal administration, detergents, bile salts and fusidic acid derivatives. Transmucosal administration can be achieved by using nasal sprays or suppositories. For transdermal administration, the active agent or compound is formulated into an ointment, paste, gel or cream as generally known in the art.

[0378] In one aspect, the compound of formula (I) and / or CDK4 / 6 inhibitor is prepared together with a pharmaceutically acceptable carrier, which protects the agent or compound from rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid can be used. Methods for preparing such preparations are obvious to those skilled in the art. Materials can also be obtained from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

[0379] For ease of administration and uniformity of dosage, it is particularly advantageous to formulate oral or parenteral compositions of compounds of formula (I) and / or CDK4 / 6 inhibitors in dosage unit form. As used herein, dosage unit form refers to physically discrete units suitable as unit doses for subjects to be treated; each unit contains a predetermined amount of active agent or compound, which is calculated to produce the desired therapeutic effect in combination with the desired pharmaceutical carrier. The specifications of the dosage unit form administered are indicated by and directly depend on the unique characteristics of the compound of formula (I) and the specific therapeutic effect to be achieved.

[0380] The pharmaceutical compositions of the compounds of formula (I) and / or CDK4 / 6 inhibitors may be included in a container, pack, or dispenser together with instructions for administration.

[0381] Illustrative modes of administration of compounds of formula (I) and / or CDK4 / 6 inhibitors include systemic or topical administration, such as oral, intranasal, parenteral, transdermal, subcutaneous, vaginal, oral, rectal or topical administration. In one embodiment, the compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof is administered orally. In one embodiment, the compound of formula (I) is administered as a tablet, capsule, capsule, solution, suspension, syrup, granule, bead, powder or pellet.

[0382] Exemplary pharmaceutical compositions are tablets and gelatin capsules comprising a salt of a compound of formula (I) and / or a CDK4 / 6 inhibitor and a pharmaceutically acceptable carrier, such as a) a diluent, such as purified water, a triglyceride oil, such as a hydrogenated or partially hydrogenated vegetable oil, or a mixture thereof, corn oil, olive oil, sunflower oil, cauliflower oil, fish oil, such as EPA or DHA, or an ester or triglyceride thereof or a mixture thereof, omega-3 fatty acids or derivatives thereof, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, sodium, saccharin, glucose and / or glycine; b) a lubricant, such as silicon dioxide, talc, stearic acid, its magnesium or calcium salt, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, for tablets; c) binders, for example, magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, magnesium carbonate, natural sugars such as glucose or β-lactose, corn sweeteners, natural and synthetic gums such as gum arabic, tragacanth or sodium alginate, waxes and / or polyvinylpyrrolidone, if desired; d) disintegrants, for example, starch, agar, methylcellulose, bentonite, xanthan gum, alginic acid or its sodium salt or an effervescent mixture; e) absorbents, colorants, flavorings and sweeteners; f) emulsifiers or dispersants, for example, Tween 80, caprylic / capric polyethylene glycol glycerol (Labrasol), HPMC, DOSS, caproyl 909, labrafac, labrafil, peceol, transcutol, capmul MCM, capmul PG-12, captex355, gelucire, vitamin E TGPS or other acceptable emulsifiers; and / or g) agents that enhance the absorption of salts, such as cyclodextrin, hydroxypropyl-cyclodextrin, PEG400 and / or PEG200.

[0383] For preparing pharmaceutical compositions from compounds of formula (I) and / or CDK4 / 6 inhibitors, or any salt or hydrate thereof, the inert pharmaceutically acceptable carrier may be a solid or a liquid. Solid form preparations include powders, pills, tablets, dispersible granules, capsules (including timed release capsules), cachets and suppositories. Powders and tablets may consist of about 5% to about 95% of the active ingredient. Suitable solid carriers are known in the art, such as magnesium carbonate, magnesium stearate, talc, sugar or lactose. Tablets, powders, cachets and capsules may be used as solid dosage forms suitable for oral administration. Examples of pharmaceutically acceptable carriers and methods of manufacture for various compositions may be found in A. Gennaro (ed.), Remington's Pharmaceutical Sciences, 18th ed., (1990), Mack Publishing Co., Easton, Pennsylvania.

[0384] Liquid form preparations of compounds of formula (I) and / or CDK4 / 6 inhibitors include solutions, suspensions, suppositories, tinctures, emulsions, syrups, suspensions and emulsions. For example, water or water-propylene glycol solutions for parenteral injection, or sweeteners and opacifiers are added to oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions for intranasal administration.

[0385] Liquid (particularly injectable) compositions, compounds of formula (I) and / or CDK4 / 6 inhibitors can be prepared, for example, by dissolution, dispersion, etc. For example, the disclosed salts are dissolved in a pharmaceutically acceptable solvent such as water, saline, aqueous dextrose, glycerol, ethanol, etc. or mixed with the pharmaceutically acceptable solvent to form an injectable isotonic solution or suspension. Proteins such as albumin, frozen microparticles or serum proteins can be used to dissolve the disclosed compounds.

[0386] Also included are solid form preparations of compounds of formula (I) and / or CDK4 / 6 inhibitors that are intended to be converted to liquid form preparations for oral or parenteral administration shortly before use. Such liquid forms include solutions, suspensions and emulsions.

[0387] The parenteral administration of the compound of formula (I) and / or CDK4 / 6 inhibitor is generally for subcutaneous, intramuscular or intravenous injection and infusion. Injectables can be prepared in conventional forms as liquid solutions or suspensions or solid forms suitable for dissolution in liquid prior to injection.

[0388] Aerosol formulations of compounds of formula (I) and / or CDK4 / 6 inhibitors suitable for inhalation may include solutions and solids in powder form, which may be combined with a pharmaceutically acceptable carrier such as an inert compressed gas, eg nitrogen.

[0389] Pharmaceutical compositions of compounds of formula (I) and / or CDK4 / 6 inhibitors can be prepared according to conventional mixing, granulation or coating methods, respectively, and the pharmaceutical compositions of the present invention may contain about 0.1% to about 99%, about 5% to about 90%, or about 1% to about 20% by weight of compounds of formula (I) and / or CDK4 / 6 inhibitors.

[0390] Unless otherwise indicated, all amounts of any component of an oral dosage form (eg, tablet) described herein indicated on a % w / w basis refer to the total weight of the oral dosage form.

[0391] Examples

[0392] The present disclosure is further illustrated by the following examples, which should not be construed as limiting the scope or spirit of the present disclosure to the specific procedures described herein. It should be understood that examples are provided to illustrate certain embodiments, and it is not intended to limit the scope of the present disclosure thereby. It should be further understood that, without departing from the spirit of the present disclosure and / or the scope of the appended claims, various other embodiments, modifications and their equivalents that can be thought of by those skilled in the art may be resorted to.

[0393] Example 1 - Compound (Ic) - ER degrader for subjects with locally advanced or metastatic breast cancer

[0394] Breast cancer is the second most common cancer in women. In 2019, an estimated 268,000 women in the United States will be diagnosed with invasive breast cancer. (American Cancer Society). Metastatic breast cancer accounts for approximately 6% of newly diagnosed cases. (Malmgren, JA, Breast Cancer Res Treat (2018) 167:579–590.). 80% of newly diagnosed breast cancers are estrogen receptor (ER) positive. (National Cancer Institute, Hormone Therapy for Breast Cancer).

[0395] Fulvestrant has validated the relevance of ER degradation in breast cancer.

[0396] After 6 months of fulvestrant treatment, up to 50% of baseline ER levels were maintained (Gutteridge et al., Breast Cancer Res Treat 2004;88 Suppl 1:S177).

[0397] Compound (Ic) is a potent degrader of estrogen receptors (DC 50 =1.8 nM), which is being developed for the treatment of patients with ER+ locally advanced or metastatic breast cancer.

[0398] Example 2 - Preclinical Effective Exposure Range of Compound (Ic)

[0399] In preclinical animal studies, compound (Ic) was administered at doses of 3 mg / kg, 10 mg / kg and 30 mg / kg (oral, once daily). The pharmacokinetic results are shown in Table 1 below. In the MCF7 xenograft model, 85%, 98% and 124% tumor growth inhibition (TGI) were observed at doses of 3 mg / kg, 10 mg / kg and 30 mg / kg of compound (Ic), respectively, compared to the control group.

[0400] Figure 1 Results of tumor growth inhibition experiments at the tested doses are shown (mean tumor volume (mm 3 ) relative to time).

[0401] Figure 2 It is shown that ER is reduced in MCF7 xenograft tumors in response to administration of compound (Ic) at 3 mg / kg, 10 mg / kg and 30 mg / kg (oral, once daily).

[0402] Table 1.

[0403] Dosage (oral, once daily) <![CDATA[Average AUC 0-24 (ng*hr / mL)]]> <![CDATA[Average C max (ng / mL)]]> 3mg / kg 658 84 10mg / kg 2538 312 <![CDATA[30mg / kg a ]]> 5717 962

[0404] a Single dose

[0405] Values ​​represent total drug concentration

[0406] Example 3 – Toxicology Study

[0407] Animals were orally administered compound (Ic) once daily for 28 days, followed by a 28-day recovery period for high-dose animals. In dogs, 15 mg / kg, 45 mg / kg or 90 mg / kg oral doses of compound (Ic) were administered once daily. In rats, 3 mg / kg, 10 mg / kg, 30 mg / kg or 100 mg / kg oral doses of compound (Ic) were administered once daily. These studies have shown that no clinical signs of toxicity occurred after oral administration of compound (Ic) once daily at doses up to 100 mg / kg / day in rats and up to 90 mg / kg / day in dogs. In addition, no effects on the overall animal health or well-being of the animals were observed.

[0408] Example 4 - Phase I clinical trial study design using compound (Ic)

[0409] A Phase I clinical trial using compound (Ic) was conducted. A traditional 3+3 dose escalation design was implemented. The starting dose of compound (Ic) was 30 mg, administered orally with food once a day. Dose increases depended on toxicity.

[0410] Key entry criteria for the trial were: ER+ / HER2- advanced breast cancer; at least two prior endocrine therapies and a CDK4 / 6 inhibitor in any setting; and up to three prior cytotoxic chemotherapy regimens.

[0411] The key objective of this trial is to obtain the maximum tolerated dose and recommended Phase II trial dose of compound (Ic). Additional objectives include evaluating the overall safety, pharmacokinetics, antitumor activity (e.g., RECIST, CBR) and biomarkers of compound (Ic), including, for example, ER gene (ESR1) mutation status in ctDNA and / or tumor tissue; and the levels of ER, progesterone receptor and Ki-67 in pre- and post-treatment tumor biopsies of patients with palpable tumor tissue.

[0412] Example 5 - Phase I Pharmacokinetic Data - Oral Administration of Compound (Ic)

[0413] In a Phase I clinical trial, Compound (Ic) was orally administered at a dose of 30 mg / day. Treatment with 30 mg / day of Compound (Ic) was observed to enter the preclinical effective range associated with tumor growth inhibition.

[0414] Initial pharmacokinetic results are shown in Table 2 below and Figure 3 and Figure 4 Shown in. Figure 3 A representation of the concentration of Compound (Ic) during the 24 hours following dosing on Days 1 and 15 is provided. Figure 4 A representation of the mean trough concentrations of Compound (Ic) throughout the clinical trial is provided.

[0415] Table 2.

[0416]

[0417] a AUC on day 15 calculated using estimated 24-hour values

[0418] Example 6 - Phase I dose escalation study using compound (Ic)

[0419] Compound (Ic) was orally administered to subjects at 30 mg / day or 60 mg / day. (n=3 for both dose groups). No dose-limiting toxicity was observed in the 30 mg / day cohort. In addition, no treatment-related adverse events were observed in the 30 mg / day cohort group.

[0420] Example 7 - Evaluation of the anti-tumor and estrogen receptor α degradation activities of compound (Ic) in the ER-positive orthotopic xenograft model MCF7

[0421] Part 1: ERα degradation in vivo

[0422] The acute estrogen receptor α (ERα) degradation activity of compound (Ic) was evaluated in the MCF7 orthotopic xenograft model after 3 daily oral administrations of compound (Ic). To evaluate the in vivo degradation of ERα induced by compound (Ic), compound (Ic) was administered at 10 mg / kg by oral gavage to NOD / SCID mice bearing MCF7 tumors, and the changes in ERα levels were evaluated after 3 daily oral doses. Figure 5 As shown, compound (Ic) reduced tumor ERa levels by up to 95% when compared to ERa levels in tumors in vehicle-treated mice.

[0423] NOD / SCID mice bearing MCF7 tumors were administered vehicle or compound (Ic) (10 mg / kg, oral) once daily for three consecutive days. Approximately 18 hours after the last administration, mice were sacrificed, and MCF7 xenografts were harvested and lysed to determine ER levels by immunoblotting. Compared to vehicle, compound (Ic) reduced ER levels by up to 95% (as determined by Figure 5 3 samples from each group are represented in Figure 3). β-actin was used as a loading control for immunoblots. The diet was supplemented with peanut butter to help maintain body weight.

[0424] Details of the Animal Studies:

[0425] Species: NOD / SCID female mice (Charles River, 6-7 weeks of age upon arrival).

[0426] Animal treatment: 5 × 10 per mouse 6 MCF7 cells / 200 μL of axial mammary fat pad implanted (17β-estradiol 0.36 mg 90 day pellet implanted the day before).

[0427] Dosing: Oral (gavage), once a day (QD), for 3 days (QDx3). Vehicle: 2% Tween 80 / PEG400 ("PEG / Tween").

[0428] Table 3. Study groups

[0429] Group Compound mg / kg Route of administration / days vehicle Dose volume Number of animals 1 vehicle 0 Oral / QDx3 PEG / Tween 5mL / kg 6 2 Compound (Ic) 10 Oral / QDx3 PEG / Tween 5mL / kg 6

[0430] Sampling: Terminal sacrifice was approximately 18 hours after the last dose; tumors were harvested, split and snap frozen. ERα levels were determined by immunoblotting.

[0431] Detailed procedure of ERα degradation assay:

[0432] Cell lysis: Remove snap-frozen tumors from storage at -80°C and place on dry ice. RIPA lysis buffer and Halt protease inhibitor were used at 400 μl / tumor sample. Steel balls (5 mm) were placed in each sample for tissue disruption. The samples were lysed using a TissueLyzer at 24 Hz for 4 minutes. Homogenization was stopped halfway through the process and the block was flipped for the duration of the process. The steel balls were pulled out of the tube and the lysates were spun at 21,000 x g for 15 minutes at 4°C. The total protein concentration of the lysates was then measured by BCA (according to the manufacturer's protocol).

[0433] Detection of proteins by immunoblotting: Lysates were mixed with sample buffer and reducing agent (according to the manufacturer's protocol). Samples were denatured at 95°C for 5 minutes in a thermocycler. Samples were cooled and spun (5000 x g; 1 minute) before loading onto the gel. The gel was loaded with 10 μg of total protein / lane. Samples were loaded onto a 4-15% standard Tris / glycine gel and run at 250 constant volts for 25 minutes in 1X Tris / glycine / SDS buffer. Proteins were transferred from the gel to nitrocellulose using a Bio-Rad Turbo at default settings. All blots were rinsed with distilled water on a rocker and blocked in 5% BSA in TBS-T (TBS with 0.1% Tween) for 1 hour at room temperature. Blots were cut so that β-actin and ERα could be detected from the same lane / sample.

[0434] The blots were incubated in 5% BSA in TBST (0.1%) overnight at 4°C on a rocker with primary antibodies:

[0435] ERα from Bethyl laboratory (1:2000);

[0436] β-Actin from CST (1:3000).

[0437] The blot was washed three times with TBST (0.1%) on a rocker at room temperature for 5 minutes. Secondary antibody was added and the blot was incubated on a rocker at room temperature for 1 hour (1:18,000 anti-rabbit HRP in TBS-T). The blot was washed 3 times with TBST (0.1%) on a rocker at room temperature for 5 minutes. The signal was developed for 5 minutes using Pierce West Femto maximum sensitivity substrate and the blot was imaged on a BioRad ChemiDoc.

[0438] Part 2: Antitumor effects in the MCF7 xenograft model.

[0439] The antitumor activity and prolonged ERα degradation activity of compound (Ic) were evaluated in the MCF7 orthotopic xenograft model.

[0440] In this MCF7 xenograft model, compound (Ic) showed dose-dependent efficacy ( Figure 6 ), with doses of 3 mg / kg / day and 10 mg / kg / day showing 85% and 98% tumor growth inhibition (TGI) relative to vehicle, respectively, and 30 mg / kg / day resulting in tumor shrinkage (124% TGI) (Table 4).

[0441] In the experiment, compound (Ic) inhibited tumor growth in a dose-dependent manner in an orthotopic MCF7 mouse xenograft model. Female NOD / SCID mice were implanted with MCF7 cells in the mammalian fat pad, and once tumors reached 200 mm 3 At 14:00, administration of compound (Ic) was started (QDx28; oral). Tumor volume was assessed twice a week for twenty-eight days. 3 mg / kg, 10 mg / kg or 30 mg / kg of compound (Ic) inhibited the growth of MCF7 xenografts stimulated by estradiol (85%, 98% and 124% TGI, respectively).

[0442] Table 4 Tumor Growth Inhibition (TGI)

[0443]

[0444] *Tumor volumes are mean ± SD.

[0445] Sampling: Tumors were measured twice a week. Terminal sacrifice was approximately 18 hours after the last dose; tumors were harvested, split and snap frozen. ERα levels were determined by immunoblotting.

[0446] Tumor volume calculation: Tumor volume = (width × width × length) / 2, where all measurements are in mm and tumor volume is in mm 3 As unit.

[0447] Tumor growth inhibition (TGI) calculation: TGI (%)

[0448]

[0449] The tumor volume is expressed in mm 3 As unit.

[0450] At study termination, tumors were removed from mice, and ERα levels were determined by immunoblotting of tumor homogenates. Figure 7As seen in Figure 2, all doses of compound (Ic) significantly reduced Erα levels (>94% reduction) compared to mice administered vehicle alone. Taken together, these data demonstrate that compound (Ic) exhibits potent antitumor activity against a well-established in vivo ER-positive breast cancer model, with robust degradation of ERα occurring in tumors.

[0451] Table 5. Study groups:

[0452] Group Compound mg / kg Route of administration / days vehicle Dose volume Number of animals 1 vehicle 0 Oral / QDx28 PEG / Tween 5mL / kg 10 2 Compound (Ic) 3 Oral / QDx28 PEG / Tween 5mL / kg 10 3 Compound (Ic) 10 Oral / QDx28 PEG / Tween 5mL / kg 10 4 Compound (Ic) 30 Oral / QDx28 PEG / Tween 5mL / kg 10

[0453] Part 2: Antitumor effects in combination with CDK4 / 6 inhibitors

[0454] To evaluate the anti-tumor activity of the combination of compound (Ic) and a CDK4 / 6 inhibitor in the MCF7 orthotopic xenograft model, the effect of the combination of compound (Ic) and a CDK4 / 6 inhibitor was evaluated in mice bearing MCF7 tumors.

[0455] NOD / SCID female mice (Charles River, 6-7 weeks old upon arrival) received 5x10 6 MCF7 cells / 200 μL of axial mammary fat pad implants (17β-estradiol 0.36 mg 90 day pellet implanted the day before). Once tumors reach 200 mm 3 Administration of the compound was initiated at 4 pm. The diet was supplemented with peanut butter to help maintain body weight.

[0456] Compound (Ic) (30 mg / kg / day) and the CDK4 / 6 inhibitor palbociclib (60 mg / kg / day) were administered for 28 days. When compared to the activity of single-agent compound (Ic) in this model (105% TGI), the combination of compound (Ic) and palbociclib provided significant tumor regression (131% TGI). In contrast, subcutaneously administered single-agent fulvestrant resulted in only modest tumor growth inhibition (46% TGI), while the combination of fulvestrant and palbociclib resulted in improved tumor growth inhibition (108% TGI), but not to the level achieved by compound (Ic) and palbociclib. ( Figure 8 and Table 6)

[0457] Table 6. Tumor growth inhibition (TGI) studies.

[0458]

[0459] *Tumor volumes are mean ± SD.

[0460] Dosage:

[0461] ●Compound (Ic) and palbociclib: Oral (gavage), once a day for 28 days (QDx28)

[0462] • Palbociclib was administered 30-60 minutes prior to administration of Compound (Ic). Without wishing to be bound by theory, this is to prevent mixing of Palbociclib and Compound (Ic) and their respective excipients in the acidic compartment of the stomach.

[0463] Fulvestrant: Subcutaneous (SC), twice weekly (BIW) for 2 weeks (BIWx2), then once weekly (QW) for 2 weeks (QWx2)

[0464] vehicle:

[0465] • For compound (Ic): 2% Tween 80 / PEG-400 ("PEG / Tween"). The ratio of Tween 80 to PEG-400 is 0.02 g Tween 80: 1 ml PEG-400. PEG-400 is added to a pre-aliquoted volume of Tween 80.

[0466] ● For fulvestrant: 10% w / v ethanol, 10% w / v benzyl alcohol, and 15% w / v benzyl benzoate as co-solvents, formulated up to 100% w / v with castor oil ("EBB / castor oil")

[0467] For palbociclib: 50 mM sodium lactate, pH 4.0 ("sodium lactate")

[0468] Table 7. Study groups

[0469]

[0470]

[0471] Sampling: Tumors were measured twice a week. Terminal sacrifice was approximately 18 hours after the last dose; tumors were harvested, split and snap frozen. ERα levels were determined by immunoblotting.

[0472] Example 8 - Evaluation of the Antitumor and Estrogen Receptor α Degrading Activities of Compound (Ic) in an ER-Positive Orthotopic Xenograft Model of Tamoxifen-Resistant MCF7 Cells

[0473] The antitumor activity of compound (Ic) as a single agent and in combination with a CDK4 / 6 inhibitor was evaluated in a tamoxifen-resistant estrogen receptor-positive (ER+) breast cancer orthotopic xenograft model. In addition, the ERα degradation activity of compound (Ic) was evaluated in a tamoxifen-resistant ER+ breast cancer orthotopic xenograft model.

[0474] Data Summary

[0475] exist Fig. 9 As shown in Table 8, the growth of tamoxifen-resistant MCF7 xenografts was inhibited by 65% ​​after once daily oral administration of 30 mg / kg / day of compound (Ic) for 28 days. When compound (Ic) was combined with 60 mg / kg / day of palbociclib, the combination regimen resulted in greater tumor growth inhibition (113% TGI) when compared to the single-agent group of palbociclib (91% TGI).

[0476] At study termination, tumors were removed from mice, and ERα levels were determined by immunoblotting of tumor homogenates. Fig.10 As shown, 30 mg / kg of compound (Ic) reduced ERα levels by 73% compared to vehicle, while the combination with 60 mg / kg of palbociclib also reduced ERα levels by 72% ( Fig.11 However, palbociclib alone (60 mg / kg) did not reduce ERα levels ( Fig.12 ). ERα levels from the different compound groups were compared to vehicle-treated animals by analyzing tumor lysates on separate immunoblots ( Fig.10 , Fig.11 and Fig.12 The graphs in depict data from separate immunoblots) and show mean ERa levels with standard deviation.

[0477] Table 8. Tumor Growth Inhibition (TGI)

[0478]

[0479] *Tumor volumes are mean ± SD.

[0480] Details of the Animal Studies:

[0481] Species: Ovariectomized Nu / Nu female mice. Animal treatment: Axial mammary fat pad implantation of tamoxifen-resistant tumor fragments (from passage E45). Each mouse was SC. Tamoxifen pellets (5 mg, 60-day release) were implanted under the same anesthesia as the tumor fragments (pellets - dorsal; tumors - ventral).

[0482] Dosage: Oral (gavage), once a day for 28 days (QDx28)

[0483] Vehicle: for compound (Ic): 2% Tween 80 / PEG400 ("PEG / Tween"); for palbociclib: 50 mM sodium lactate, pH 4 ("sodium lactate")

[0484] Table 9. Study groups

[0485]

[0486] Sampling: Tumors were measured twice a week. Terminal sacrifice was approximately 18 hours after the last dose; tumors were harvested, split and snap frozen. ERα levels were determined by immunoblotting (see Appendix 1 for details).

[0487] Detailed procedure of ERα degradation assay:

[0488] Cell lysis

[0489] Snap frozen tumors were removed from storage at -80°C and placed on dry ice. RIPA lysis buffer and Halt protease inhibitor were used at 400 μl / tumor sample. Steel balls (5 mm) were placed in each sample for tissue disruption. The samples were lysed at 24 Hz for 4 minutes using a TissueLyzer. Homogenization was stopped halfway through the process and the block was flipped for the duration of the process. The steel balls were pulled out of the tube and the lysates were spun at 21,000 x g for 15 minutes at 4°C. The total protein concentration of the lysates was then measured by BCA (according to the manufacturer's protocol).

[0490] Proteins were detected by immunoblotting.

[0491] The lysate was mixed with sample buffer and reducing agent (according to the manufacturer's protocol). The samples were denatured at 95°C for 5 minutes in a thermal cycler. The samples were cooled and spun (5000 x g; 1 minute) and then loaded onto the gel. The gel was loaded with 10 μg of total protein / lane. The samples were loaded onto a 4-15% standard Tris / glycine gel and run at 250 constant volts for 25 minutes in 1X Tris / glycine / SDS buffer.

[0492] Proteins were transferred from gels to nitrocellulose using a Bio-Rad Turbo at default settings. All blots were rinsed with distilled water and blocked in 5% BSA in TBS-T (TBS with 0.1% Tween) for 1 hour at room temperature on a rocker. Blots were cut so that β-actin and ERα could be detected from the same lane / sample. Blots were incubated with primary antibodies in 5% BSA in TBST (0.1%) at 4°C overnight on a rocker.

[0493] ERα from Bethyl Laboratory (1:2000)

[0494] β-Actin from CST (1:3000)

[0495] The blot was washed three times with TBST (0.1%) on a rocker at room temperature for 5 minutes. Secondary antibody was added and the blot was incubated on a rocker at room temperature for 1 hour (1:18,000 anti-rabbit HRP in TBS-T). The blot was washed 3 times with TBST (0.1%) on a rocker at room temperature for 5 minutes. The signal was developed for 5 minutes using Pierce West Femto maximum sensitivity substrate and the blot was imaged on a BioRad ChemiDoc.

[0496] Example 9 - Summary of in vivo data for Compound (Ic)

[0497] The compounds of formula (I) disclosed herein, including compound (Ic), are heterobifunctional molecules that promote the interaction between ERα and the intracellular E3 ligase complex, leading to ubiquitination and subsequent degradation of the estrogen receptor by the proteasome. Orally bioavailable compound (Ic) exhibits single-digit nanomolar ERα degradation potency in wild-type and variant ERα expressing cell lines.

[0498] Compound (Ic) was degraded at a half-maximal degradation concentration (DC) of about 1 nM. 50 ) strongly degrades ER in ER-positive breast cancer cell lines ( Fig.13 and Fig.14 ). ER degradation mediated by compound (Ic) decreased the classically regulated ER target genes MCF7 and T47D ( Figures 13 to 16 ) expression and inhibited cell proliferation of ER-dependent cell lines. In addition, compound (Ic) degraded the clinically relevant ESR1 variants Y537S and D538G ( Fig.15 ), and inhibited the growth of cell lines expressing those variants. In the immature rat uterine nutrition model, compound (Ic) degraded rat uterine ER and did not show agonist activity ( Fig.17 Daily oral administration of single-agent Compound (Ic) (3 mg / kg, 10 mg / kg, and 30 mg / kg) resulted in significant antitumor activity in estradiol-dependent MCF7 xenografts and concomitant reductions in tumor ER protein by >90% at study termination ( Figure 1 , Figure 5 and Figure 7 Furthermore, even more significant tumor growth inhibition (131% TGI) was observed when a CDK4 / 6 inhibitor was combined with compound (Ic) in the MCF7 model ( Figure 8Compound (Ic) inhibited growth by 65% ​​in tamoxifen-resistant MCF7 xenografts and resulted in even greater tumor growth inhibition (113% TGI) when combined with palbociclib compared to the palbociclib monotherapy group (91% TGI) (Tables 8 and Fig. 9 In the clinically relevant ESR1 Y537S mutation model, a hormone-independent patient-derived xenograft model, compound (Ic) at 10 mg / kg completely inhibited growth and also significantly reduced mutant ER protein levels ( Fig. 22 ). In summary, the preclinical data for compound (Ic) support its continued development as an orally bioavailable ER protein degrader.

[0499] Table 10. Summary of in vivo studies with compound (Ic).

[0500]

[0501]

[0502] nd = not determined

[0503] Oral administration of compound (Ic) provided more robust tumor growth inhibition and ERα degradation compared to fulvestrant in an orthotopic MCF7 / estradiol xenograft model ( Fig.19 and Fig. 20 , Table 10). The combination of compound (Ic) and palbociclib resulted in significant tumor regression and overall superior antitumor activity when compared to the combination of fulvestrant and palbociclib ( Figure 20 to Figure 22 and Table 10).

[0504] Compound (Ic) inhibited the growth of tamoxifen-resistant tumors and ESR1(Y537S) tumors, while also reducing tumor ERα levels ( Fig. 22 , Table 10).

[0505] Equivalent

[0506] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments described specifically herein. Such equivalents are intended to be encompassed by the scope of the appended claims.

[0507] The method of the present disclosure has been described herein by reference to certain preferred embodiments. However, since certain changes thereto will become apparent to those skilled in the art based on the disclosure described herein, the present disclosure should not be considered limited thereto.

[0508] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present disclosure belongs. In the specification and claims, the singular also includes the plural, unless the context clearly indicates otherwise.

[0509] It should be understood that at least some of the descriptions of the present disclosure have been simplified to focus on elements relevant to a clear understanding of the present disclosure, while for the sake of clarity, other elements that will be understood by those of ordinary skill in the art may also comprise a portion of the present disclosure. However, since such elements are well known in the art and because they do not necessarily promote a better understanding of the present disclosure, a description of such elements is not provided herein.

[0510] Additionally, the specific order of steps recited in a claim should not be construed as a limitation on that claim, to the extent that the method does not rely on the specific order of steps set forth herein.

[0511] All patents, patent applications, references, and publications cited herein are fully and completely incorporated by reference as if set forth in their entirety. No such documents are admitted to be prior art to the present disclosure.

[0512] Embodiments of the present invention also include:

[0513] Embodiment 1. A method of treating breast cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I),

[0514] or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative or prodrug thereof, wherein:

[0515] Each R 1 and each R 2 Independently selected from the group consisting of halo, OR5, N(R5)(R6), NO2, CN, SO2(R5), C1-C6 alkyl and C3-C6 cycloalkyl;

[0516] R3 and R4 are both hydrogen or, together with the carbon to which they are attached, form a carbonyl group;

[0517] Each R5 and each R6 are independently selected from the group consisting of hydrogen, C1-C6 alkyl and C3-C6 cycloalkyl;

[0518] m is 0, 1, 2, 3, 4 or 5; and

[0519] n is 0, 1, 2, 3, or 4,

[0520] The therapeutically effective amount of the compound of formula (I) is about 10 mg to about 1000 mg.

[0521] Embodiment 2. The method according to embodiment 1, wherein the breast cancer is ER+, HER2-.

[0522] Embodiment 3. The method of embodiment 1 or 2, wherein the breast cancer is metastatic or locally advanced.

[0523] Embodiment 4. The method according to any one of embodiments 1 to 3, wherein R 1 and R 2 are each independently selected from the group consisting of halo and OR5.

[0524] Embodiment 5. The method according to any one of Embodiments 1 to 4, wherein R3 and R4 are both hydrogen.

[0525] Embodiment 6. A method according to any one of Embodiments 1 to 4, wherein R3 and R4 together with the carbon to which they are attached form a carbonyl group.

[0526] Embodiment 7. The method according to any one of embodiments 1 to 3, 5 or 6, wherein m and n are each 0.

[0527] Embodiment 8. The method according to any one of Embodiments 1 to 6, wherein m and n are each 1.

[0528] Embodiment 9. The method according to any one of embodiments 1 to 3, 5 or 6, wherein one of m and n is 0 and the other is 1.

[0529] Embodiment 10. The method according to any one of embodiments 1 to 3, wherein the compound of formula (I) is:

[0530]

[0531]

[0532] Or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative or prodrug of any of the foregoing.

[0533] Embodiment 11. The method according to any one of Embodiments 1 to 3, wherein the compound of formula (I) is a compound of formula (Ic):

[0534]

[0535] Embodiment 12. The method according to any one of Embodiments 1 to 11, wherein the compound of formula (I) is administered orally to the subject.

[0536] Embodiment 13. The method according to any one of Embodiments 1 to 12, wherein the therapeutically effective amount of the compound of Formula (I) is administered to the subject once a day, twice a day, three times a day, or four times a day.

[0537] Embodiment 14. The method according to any one of Embodiments 1 to 13, wherein the therapeutically effective amount of the compound of Formula (I) is administered to the subject once a day.

[0538] Embodiment 15. The method according to embodiments 1 to 12, wherein the therapeutically effective amount of the compound of formula (I) is administered to the subject all at once, or in two, three or four portions.

[0539] Embodiment 16. The method according to any one of Embodiments 1 to 15, wherein the therapeutically effective amount of the compound of formula (I) is about 3 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg or 30 mg.

[0540] Embodiment 17. The method according to any one of Embodiments 1 to 15, wherein the therapeutically effective amount of the compound of formula (I) is from about 20 mg to about 750 mg.

[0541] Embodiment 18. The method according to any one of Embodiments 1 to 15, wherein the therapeutically effective amount of the compound of formula (I) is from about 30 mg to about 500 mg.

[0542] Embodiment 19. The method according to any one of Embodiments 1 to 15, wherein the therapeutically effective amount of the compound of formula (I) is from about 30 mg to about 120 mg.

[0543] Embodiment 20. The method of any one of Embodiments 1 to 19, wherein the therapeutically effective amount of the compound of Formula (I) results in a mean Day 15 AUC of greater than about 3,500 ng*hr / mL, greater than about 3,600 ng*hr / mL, greater than about 3,700 ng*hr / mL, greater than about 3,800 ng*hr / mL, greater than about 3,900 ng*hr / mL, greater than about 4,000 ng*hr / mL, greater than about 4,100 ng*hr / mL, greater than about 4,200 ng*hr / mL, greater than about 4,300 ng*hr / mL, greater than about 4,400 ng*hr / mL, greater than about 4,500 ng*hr / mL, greater than about 4,600 ng*hr / mL, greater than about 4,700 ng*hr / mL, greater than about 4,800 ng*hr / mL, greater than about 4,900 ng*hr / mL, or greater than about 5,000 ng*hr / mL TAU .

[0544] Embodiment 21. The method according to any one of Embodiments 1 to 19, wherein the therapeutically effective amount of the compound of Formula (I) results in a mean day 15 AUC of greater than about 4,000 ng*hr / mL and less than about 4,500 ng*hr / mL TAU .

[0545] Embodiment 22. The method of any one of Embodiments 1 to 21, wherein the therapeutically effective amount of the compound of Formula (I) results in a mean Day 15 C of greater than about 200 ng / mL, greater than about 205 ng / mL, greater than about 210 ng / mL, greater than about 215 ng / mL, greater than about 220 ng / mL, greater than about 225 ng / mL, greater than about 230 ng / mL, greater than about 235 ng / mL, greater than about 240 ng / mL, greater than about 245 ng / mL, or greater than about 250 ng / mL. max .

[0546] Embodiment 23. The method of any one of Embodiments 1 to 21, wherein the therapeutically effective amount of the compound of Formula (I) results in a mean Day 15 C of greater than about 215 ng / mL and less than about 235 ng / mL. max .

[0547] Embodiment 24. The method according to any one of embodiments 1 to 23, wherein the compound of formula (I) is formulated as a tablet.

[0548] Embodiment 25. The method of embodiment 24, wherein the tablet comprises a compound of formula (I), and optionally one or more of: an emulsifier; a surfactant; a binder; a disintegrant; a glidant; and a lubricant.

[0549] Embodiment 26. The method of embodiment 25, wherein the emulsifier is hypromellose.

[0550] Embodiment 27. The method of embodiment 25, wherein the surfactant is vitamin E polyethylene glycol succinate.

[0551] Embodiment 28. The method of embodiment 25, wherein the binder is microcrystalline cellulose or lactose monohydrate.

[0552] Embodiment 29. The method of embodiment 25, wherein the disintegrant is croscarmellose sodium.

[0553] Embodiment 30. The method of embodiment 25, wherein the glidant is silicon dioxide.

[0554] Embodiment 31. The method of embodiment 25, wherein the lubricant is sodium stearyl fumarate.

[0555] Embodiment 32. The method according to any one of Embodiments 1 to 31, further comprising administering a therapeutically effective amount of a CDK4 / 6 inhibitor to the subject in need thereof.

[0556] Embodiment 33. The method according to embodiment 32, wherein the CDK4 / 6 inhibitor is SHR6390, treraciclib, lelociclib, AT7519M, dinaciclib, ribociclib, abemaciclib or palbociclib.

[0557] Embodiment 34. The method of embodiment 32, wherein the CDK4 / 6 inhibitor is palbociclib.

[0558] Embodiment 35. The method of embodiment 34, wherein the therapeutically effective amount of palbociclib is administered to the subject once daily.

[0559] Embodiment 36. The method of embodiment 34 or 35, wherein the therapeutically effective amount of palbociclib is 60 mg, 75 mg, 100 mg or 125 mg.

[0560] Embodiment 37. The method of any one of Embodiments 33 to 36, wherein palbociclib is administered once daily for up to 21 consecutive days, followed by up to 7 consecutive days off treatment, wherein the cycle of treatment with palbociclib followed by off treatment is repeated one, two, three, four, five or more times.

[0561] Embodiment 38. The method according to any one of Embodiments 1 to 37, wherein the compound of formula (I) is administered once daily for up to 21 consecutive days, followed by up to 7 consecutive days off treatment, wherein the cycle of treatment with the compound of formula (I) followed by off treatment is repeated one, two, three, four, five or more times.

[0562] Embodiment 39. A method according to any one of embodiments 1 to 38, wherein the subject is in a fed state.

[0563] Embodiment 40. A method according to any one of embodiments 1 to 38, wherein the subject is in a fasting state.

[0564] Embodiment 41. A method of treating metastatic breast cancer in a subject in need thereof, the method comprising orally administering once daily a therapeutically effective amount of a compound of formula (I), wherein the compound of formula (I) is:

[0565]

[0566]

[0567]

[0568] Or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative or prodrug of any of the foregoing.

[0569] Embodiment 42. The method according to embodiment 41, wherein the compound of formula (I) is a compound of formula (Ic):

[0570]

[0571] Embodiment 43. The method according to embodiment 41 or 42, wherein the therapeutically effective amount of the compound of formula (I) is administered to the subject all at once, or in two, three or four portions.

[0572] Embodiment 44. The method according to any one of Embodiments 41 to 43, wherein the therapeutically effective amount of the compound of formula (I) is from about 30 mg to about 1000 mg.

[0573] Embodiment 45. The method according to any one of embodiments 41 to 44, wherein the compound of formula (I) is formulated as a tablet.

[0574] Embodiment 46. The method of any one of Embodiments 41 to 45, further comprising administering to said subject in need thereof a therapeutically effective amount of a CDK4 / 6 inhibitor.

[0575] Embodiment 47. The method according to Embodiment 46, wherein the CDK4 / 6 inhibitor is SHR6390, treraciclib, lelocil, AT7519M, dinaciclib, ribociclib, abemaciclib or palbociclib.

[0576] Embodiment 48. The method of Embodiment 46, wherein the CDK4 / 6 inhibitor is palbociclib.

[0577] Embodiment 49. The method of Embodiment 48, wherein the therapeutically effective amount of palbociclib is administered to the subject once daily.

[0578] Embodiment 50. The method of embodiment 48 or 49, wherein the therapeutically effective amount of palbociclib is 60 mg, 75 mg, 100 mg or 125 mg.

[0579] Embodiment 51. The method of any one of Embodiments 48 to 50, wherein palbociclib is administered once daily for up to 21 consecutive days, followed by up to 7 consecutive days off treatment, wherein the cycle of treatment with palbociclib followed by off treatment is repeated one, two, three, four, five or more times.

[0580] Embodiment 52. The method according to any one of Embodiments 41 to 51, wherein the compound of formula (I) is administered once daily for up to 21 consecutive days, followed by up to 7 consecutive days off treatment, wherein the cycle of treatment with the compound of formula (I) followed by off treatment is repeated one, two, three, four, five or more times.

[0581] Embodiment 53. A method according to any one of Embodiments 41 to 52, wherein the subject is in a fed state.

[0582] Embodiment 54. A method according to any one of Embodiments 41 to 52, wherein the subject is in a fasting state.

[0583] Embodiment 55. The method of any one of Embodiments 46 to 54, wherein administration of the CDK4 / 6 inhibitor occurs prior to administration of the compound of formula (I).

[0584] Embodiment 56. The method of Embodiment 55, wherein administration of the CDK4 / 6 inhibitor occurs at least 30 minutes prior to administration of the compound of Formula (I).

[0585] Embodiment 57. The method of any one of Embodiments 46 to 54, wherein administration of the CDK4 / 6 inhibitor occurs after administration of the compound of formula (I).

[0586] Embodiment 58. The method of Embodiment 57, wherein administration of the CDK4 / 6 inhibitor occurs at least 30 minutes after administration of the compound of Formula (I).

[0587] Embodiment 59. A method of treating metastatic breast cancer in a subject in need thereof, the method comprising:

[0588] (i) orally administering a therapeutically effective amount of a compound of formula (Ic) once a day, or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative or prodrug thereof, and

[0589] (ii) palbociclib is administered orally once daily.

[0590] Embodiment 60. A method of treating metastatic breast cancer in a subject in need thereof, the method comprising:

[0591] (i) orally administering a therapeutically effective amount of a compound of formula (Ic) once a day, as well as

[0592] (ii) palbociclib is administered orally once daily.

[0593] Embodiment 61. The method of Embodiment 59 or Embodiment 60, wherein the therapeutically effective amount of the compound of Formula (Ic) is from about 30 mg to about 1000 mg.

[0594] Embodiment 62. The method of any one of Embodiments 59 to 61, wherein the therapeutically effective amount of palbociclib is 60 mg, 75 mg, 100 mg or 125 mg.

[0595] Embodiment 63. The method of any one of Embodiments 59 to 62, wherein palbociclib is administered once daily for up to 21 consecutive days, followed by up to 7 consecutive days off treatment, wherein the cycle of treatment with palbociclib followed by off treatment is repeated one, two, three, four, five or more times.

[0596] Embodiment 64. The method according to any one of Embodiments 59 to 62, wherein the compound of Formula (Ic) is administered once daily for up to 21 consecutive days, followed by up to 7 consecutive days off treatment, wherein the cycle of treatment with the compound of Formula (Ic) followed by off treatment is repeated one, two, three, four, five or more times.

[0597] Embodiment 65. A method according to any one of embodiments 59 to 64, wherein the subject is in a fed state.

[0598] Embodiment 66. A method according to any one of embodiments 59 to 64, wherein the subject is in a fasting state.

[0599] Embodiment 67. The method of any one of Embodiments 59 to 66, wherein administration of palbociclib occurs prior to administration of the compound of formula (Ic).

[0600] Embodiment 68. The method of Embodiment 67, wherein administration of palbociclib occurs at least 30 minutes prior to administration of the compound of Formula (Ic).

[0601] Embodiment 69. The method of any one of Embodiments 59 to 66, wherein administration of palbociclib occurs after administration of the compound of formula (Ic).

[0602] Embodiment 70. The method of Embodiment 69, wherein administration of palbociclib occurs at least 30 minutes after administration of the compound of Formula (Ic).

[0603] Embodiment 71. A method for selective estrogen receptor degradation in a patient, the method comprising:

[0604] (i) orally administering a therapeutically effective amount of a compound of formula (Ic) once a day, or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative or prodrug thereof, and

[0605] (ii) palbociclib is administered orally once daily.

[0606] Embodiment 72. A method for inhibiting cyclin-dependent kinase in a subject in need thereof, the method comprising:

[0607] (i) orally administering a therapeutically effective amount of a compound of formula (Ic) once a day, or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative or prodrug thereof, and

[0608] (ii) palbociclib is administered orally once daily.

[0609] Embodiment 73. A kit comprising:

[0610] (i) a compound of formula (Ic),

[0611]

[0612] (ii) palbociclib, and

[0613] (iii) Instructions for use.

[0614] Embodiment 74. A liquid composition comprising a surfactant, a solvent and a compound of formula (Ic):

[0615]

[0616] Embodiment 75. The liquid composition of embodiment 74, wherein the surfactant is Tween 80.

[0617] Embodiment 76. A liquid composition according to embodiment 74 or 75, wherein the solvent is PEG-400.

[0618] Embodiment 77. A method for preparing a liquid composition comprising a surfactant, a solvent and a compound of formula (Ic):

[0619]

[0620] The step of adding the solvent to a pre-aliquoted volume of the surfactant is included.

[0621] Embodiment 78. The method of embodiment 77, wherein the surfactant is Tween 80.

[0622] Embodiment 79. The method of embodiment 77 or 78, wherein the solvent is PEG-400.

Claims

1. A method for treating breast cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative or prodrug thereof, wherein: Each R 1 and each R 2 Independently selected from the group consisting of halo, OR5, N(R5)(R6), NO2, CN, SO2(R5), C1-C6 alkyl and C3-C6 cycloalkyl; R3 and R4 are both hydrogen or, together with the carbon to which they are attached, form a carbonyl group; Each R5 and each R6 are independently selected from the group consisting of hydrogen, C1-C6 alkyl and C3-C6 cycloalkyl; m is 0, 1, 2, 3, 4 or 5; and n is 0, 1, 2, 3, or 4, The therapeutically effective amount of the compound of formula (I) is about 10 mg to about 1000 mg.

2. The method of claim 1, further comprising administering to the subject in need thereof a therapeutically effective amount of a CDK4 / 6 inhibitor.

3. A method of treating metastatic breast cancer in a subject in need thereof, the method comprising orally administering once daily a therapeutically effective amount of a compound of formula (I), wherein the compound of formula (I) is: Or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative or prodrug of any of the foregoing.

4. A method of treating metastatic breast cancer in a subject in need thereof, the method comprising: (i) orally administering a therapeutically effective amount of a compound of formula (Ic) once a day, or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative or prodrug thereof, and (ii) palbociclib is administered orally once daily.

5. A method of treating metastatic breast cancer in a subject in need thereof, the method comprising: (i) orally administering a therapeutically effective amount of a compound of formula (Ic) once a day, as well as (ii) palbociclib is administered orally once daily.

6. A method for selective estrogen receptor degradation in a patient, the method comprising: (i) orally administering a therapeutically effective amount of a compound of formula (Ic) once a day, or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative or prodrug thereof, and (ii) palbociclib is administered orally once daily.

7. A method for inhibiting cyclin-dependent kinase in a subject in need thereof, the method comprising: (i) orally administering a therapeutically effective amount of a compound of formula (Ic) once a day, or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative or prodrug thereof, and (ii) palbociclib is administered orally once daily.

8. A kit comprising: (i) a compound of formula (Ic), (ii) palbociclib, and (iii) Instructions for use.

9. A liquid composition comprising a surfactant, a solvent and a compound of formula (Ic):

10. A method for preparing a liquid composition comprising a surfactant, a solvent and a compound of formula (Ic): The step of adding the solvent to a pre-aliquoted volume of the surfactant is included.